[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Olympus America Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":338},{"warningLetters":4,"total":337},[5,31,54,75,94,112,127,144,168,190,211,235,253,274,295,316],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},2262,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2023-01-10T14:20:00Z\">01\u002F10\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-02T04:00:00Z\">11\u002F02\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faizu-olympus-co-ltd-643172-11022022\">Aizu Olympus Co., Ltd.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yasuo Takeuchi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aizu Olympus Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3-1 Nishi-Shinjuku 2-Chome Shinjuku-Ku\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tokyo\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>163-0914\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 2, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Yasuo Takeuchi:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Aizuwakamatsu, Fukushima, Japan, on July 5, 2022, through July 8, 2022, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm manufactures sterile and non-sterile Endoscopes and Automated Endoscope Reprocessors. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Kenji Matsuoka, President of Aizu Olympus, dated July 29, 2022, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for validating the device design to ensure that devices conform to defined user needs and intended uses and validation shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g).\u003C\u002Fp>\n\n\u003Cp>For example: Document \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “Design Rules” version 13 defines Design Validation as, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, User-Assessment Procedures for URF-V3\u002FV3R and UFR-P7\u002FP7R Validation Report Document #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated October 4, 2017, states that only the, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” of the URF-V3\u002FV3R and URF-P7\u002FP7R needed to be evaluated. The entire device design was not validated to ensure that devices conform to defined user needs under actual or simulated use conditions. For example, image quality was not validated.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm's response cannot be determined at this time. Your firm decided they would re-validate the URF-P7 to cover all user needs. Your firm will determine the due date for the validation activities after your firm completes the design validation plan (due October 14, 2022).\u003C\u002Fp>\n\n\u003Cp>You state that your firm will also revise the design controls procedure to clarify that design validation will cover the entire device under review and determine what elements are required in a justification for the use of an alternate device. Your firm will review design projects for the last two years for similar issues. Your firm plans to complete corrective actions by November 18, 2022. Your firm will train staff on revised procedures. However, the adequacy of the corrective actions cannot be determined at this time because the actions are ongoing. Please provide updates on the corrective actions as they are completed.\u003C\u002Fp>\n\n\u003Cp>2. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\u003C\u002Fp>\n\n\u003Cp>For example: the bonding\u002Fgluing processes using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> adhesives during final assembly have not been validated. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Docking Work Instruction, Document #\u003Cstrong>(b)(4)\u003C\u002Fstrong> (among others) follows the application of adhesive with “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” which cannot fully verify the application of the adhesive.\u003C\u002Fp>\n\n\u003Cp>Your firm's response is not adequate. Your firm determined the output of ‘preventing screws from loosening’ is not verifiable and you state that your firm will conduct a health hazard evaluation (HHE) by August 31, 2022 to determine the health risk from the screws loosening. Your firm will update their process validation procedures with criteria for when a process is verifiable by October 31, 2022. In addition, your firm will review all manufacturing processes at Aizu Olympus to ensure that processes whose outputs cannot be verified are validated by October 31, 2022.&nbsp;You state that your firm will train staff on revised procedures by October 31, 2022.\u003C\u002Fp>\n\n\u003Cp>Your firm did not state if there are previously distributed devices that were made with specifications that were not validated. Your firm did not provide information on addressing the lack of knowledge of previous curing times and it is unclear how these products meet validation criteria. Your firm’s HHE should address these concerns and determine if a correction or removal is necessary. Your firm should also determine through the HHE whether this issue could have any impact on device reprocessing.\u003C\u002Fp>\n\n\u003Cp>Your firm's response is not adequate because, the sample size for the adhesive process validation is unclear. Secondly, it is also unclear if there are previously distributed devices that were made with specifications that were not validated. Thirdly, how your firm will address the lack of knowledge of previous curing times and determine if products meet validation criteria. Fourthly, it is unclear if inadequate curing of the adhesive could lead to reprocessing issues (e.g. material getting stuck in and around the adhesive and making it difficult to adequately reprocess the device). Finally, your firm should assess if a correction or removal is necessary. Please provide updates on the corrective actions as they are completed.\u003C\u002Fp>\n\n\u003Cp>3.&nbsp;Failure to establish and maintain procedures to ensure that Design History Record (DHR) for each batch, lot, or unit are maintained to demonstrate that the device is manufactured accordance with the DMR and the requirements of 21 CFR 820, as required by 21 CFR 820.184.\u003C\u002Fp>\n\n\u003Cp>For example: the curing time (\u003Cstrong>(b)(4)\u003C\u002Fstrong> hours or more) for the adhesive bonding\u002Fgluing process during final assembly was not documented on all 11 URF-P7 DHRs reviewed during the inspection. Additionally, the ultrasonic cleaning process used to clean various components during final assembly was not documented on all 11 URF-P7 DHRs reviewed during the inspection.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response indicated that the curing and ultrasonic cleaning process parameters were not documented in the URF-P7 DHR. Your firm’s root cause investigation determined that there was no requirement to record these parameters. Your firm provided:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>AMS A001139W1 Device History Record (DHR) Management, rev 14\u003C\u002Fli>\n\t\u003Cli>AMS A00112W1 Preparation of Assembly Work Standards, rev 28\u003C\u002Fli>\n\t\u003Cli>AMS A05209W1 Controls of Process Parameters, rev 36\u003C\u002Fli>\n\t\u003Cli>N-OIS M22003 Cleaning Work Element Standard, Rev 11\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm is conducting an HHE of the risk for falling to document the curing time and ultrasonic cleaning parameters. Your firm plans to complete the HHE by August 31, 2022. Your firm also plans to update the DHR for the URF-P7 to include process parameters for the bonding and cleaning processes by August 3, 2022.\u003C\u002Fp>\n\n\u003Cp>Your firm also plans to review AMS A05209W1 Control of Process to determine if there are other process parameters that should be monitored and are not. This review will be completed by September 16, 2022. Your firm will update AMS A05209W1 by December 9, 2022, to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Specify the curing time be monitored\u003C\u002Fli>\n\t\u003Cli>Include the ultrasonic cleaning parameters\u003C\u002Fli>\n\t\u003Cli>Include any additional missing process parameters.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm will then review all DHRs for currently manufactured devices and remediate gaps as necessary. Your firm will complete the DHR review by January 31, 2022.\u003Cbr>\n\u003Cbr>\nThe adequacy of your firm’s corrective actions cannot be determined at this time because the actions are ongoing. Please provide updates on the corrective actions as they are completed.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm's sterile and non-sterile Endoscopes and and Automated Endoscope Reprocessors devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>4. Failure to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\u003C\u002Fp>\n\n\u003Cp>For example: during this inspection, your firm acknowledged that it had not established written MDR procedures.\u003C\u002Fp>\n\n\u003Cp>In the response, your firm developed two documents titled “CoE Global MDR: Handling US MDR Reporting for Potential Adverse Event Complaints”, GSOP-8.15-7, Rev. AD, dated 7\u002F13\u002F2022 and “Medical Device Reporting Work Instruction”, OMBS W 8.2.3_01_001, Rev. 13, dated 7\u002F26\u002F2022. The documents collectively were referenced as your firm’s MDR procedure. The document references Aizu Olympus Co. Ltd. as a Manufacturer. Your firm did not provide documentation or evidence of implementation. You state that plans for staff training and MDR reporting process realignment are still ongoing. Therefore, the adequacy of your firm's response cannot be determined at this time. Please provide updates on the corrective actions as they are completed.\u003C\u002Fp>\n\n\u003Cp>U.S. federal agencies may take your compliance history into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration - CDRH\u002FORP\u002FDRP2\u003Cbr>\nCDRH Regulatory Inspections and Audit Team, WO66-1434\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Refer to CMS case # 643172 when replying.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact: Mark Antonino at Mark.Antonino@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely Yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nLydia Sakakeeny\u003Cbr>\nGyrus ACMI Inc.\u003Cbr>\n800 West Park Drive\u003Cbr>\nWestborough, MA US 01581\u003Cbr>\nPhone: 617 7976458 Ext\u003Cbr>\nEmail: Lydia.Sakakeeny@Olympus.Com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nYasuo Takeuchi\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nAizu Olympus Co., Ltd.\n\n3-1 Nishi-Shinjuku 2-Chome Shinjuku-Ku\n\nTokyo\n\n163-0914\n\nJapan\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nNovember 2, 2022\n\nWARNING LETTER\n\nDear Yasuo Takeuchi:\n\nDuring an inspection of your firm located in Aizuwakamatsu, Fukushima, Japan, on July 5, 2022, through July 8, 2022, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm manufactures sterile and non-sterile Endoscopes and Automated Endoscope Reprocessors. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Kenji Matsuoka, President of Aizu Olympus, dated July 29, 2022, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for validating the device design to ensure that devices conform to defined user needs and intended uses and validation shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g).\n\nFor example: Document (b)(4), “Design Rules” version 13 defines Design Validation as, (b)(4).” However, User-Assessment Procedures for URF-V3\u002FV3R and UFR-P7\u002FP7R Validation Report Document #(b)(4), dated October 4, 2017, states that only the, “(b)(4)” of the URF-V3\u002FV3R and URF-P7\u002FP7R needed to be evaluated. The entire device design was not validated to ensure that devices conform to defined user needs under actual or simulated use conditions. For example, image quality was not validated.\n\nThe adequacy of your firm's response cannot be determined at this time. Your firm decided they would re-validate the URF-P7 to cover all user needs. Your firm will determine the due date for the validation activities after your firm completes the design validation plan (due October 14, 2022).\n\nYou state that your firm will also revise the design controls procedure to clarify that design validation will cover the entire device under review and determine what elements are required in a justification for the use of an alternate device. Your firm will review design projects for the last two years for similar issues. Your firm plans to complete corrective actions by November 18, 2022. Your firm will train staff on revised procedures. However, the adequacy of the corrective actions cannot be determined at this time because the actions are ongoing. Please provide updates on the corrective actions as they are completed.\n\n2. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\n\nFor example: the bonding\u002Fgluing processes using the (b)(4) and (b)(4) adhesives during final assembly have not been validated. (b)(4) Docking Work Instruction, Document #(b)(4) (among others) follows the application of adhesive with “(b)(4)” which cannot fully verify the application of the adhesive.\n\nYour firm's response is not adequate. Your firm determined the output of ‘preventing screws from loosening’ is not verifiable and you state that your firm will conduct a health hazard evaluation (HHE) by August 31, 2022 to determine the health risk from the screws loosening. Your firm will update their process validation procedures with criteria for when a process is verifiable by October 31, 2022. In addition, your firm will review all manufacturing processes at Aizu Olympus to ensure that processes whose outputs cannot be verified are validated by October 31, 2022. You state that your firm will train staff on revised procedures by October 31, 2022.\n\nYour firm did not state if there are previously distributed devices that were made with specifications that were not validated. Your firm did not provide information on addressing the lack of knowledge of previous curing times and it is unclear how these products meet validation criteria. Your firm’s HHE should address these concerns and determine if a correction or removal is necessary. Your firm should also determine through the HHE whether this issue could have any impact on device reprocessing.\n\nYour firm's response is not adequate because, the sample size for the adhesive process validation is unclear. Secondly, it is also unclear if there are previously distributed devices that were made with specifications that were not validated. Thirdly, how your firm will address the lack of knowledge of previous curing times and determine if products meet validation criteria. Fourthly, it is unclear if inadequate curing of the adhesive could lead to reprocessing issues (e.g. material getting stuck in and around the adhesive and making it difficult to adequately reprocess the device). Finally, your firm should assess if a correction or removal is necessary. Please provide updates on the corrective actions as they are completed.\n\n3. Failure to establish and maintain procedures to ensure that Design History Record (DHR) for each batch, lot, or unit are maintained to demonstrate that the device is manufactured accordance with the DMR and the requirements of 21 CFR 820, as required by 21 CFR 820.184.\n\nFor example: the curing time ((b)(4) hours or more) for the adhesive bonding\u002Fgluing process during final assembly was not documented on all 11 URF-P7 DHRs reviewed during the inspection. Additionally, the ultrasonic cleaning process used to clean various components during final assembly was not documented on all 11 URF-P7 DHRs reviewed during the inspection.\n\nYour firm’s response indicated that the curing and ultrasonic cleaning process parameters were not documented in the URF-P7 DHR. Your firm’s root cause investigation determined that there was no requirement to record these parameters. Your firm provided:\n\nAMS A001139W1 Device History Record (DHR) Management, rev 14\n\nAMS A00112W1 Preparation of Assembly Work Standards, rev 28\n\nAMS A05209W1 Controls of Process Parameters, rev 36\n\nN-OIS M22003 Cleaning Work Element Standard, Rev 11\n\nYour firm is conducting an HHE of the risk for falling to document the curing time and ultrasonic cleaning parameters. Your firm plans to complete the HHE by August 31, 2022. Your firm also plans to update the DHR for the URF-P7 to include process parameters for the bonding and cleaning processes by August 3, 2022.\n\nYour firm also plans to review AMS A05209W1 Control of Process to determine if there are other process parameters that should be monitored and are not. This review will be completed by September 16, 2022. Your firm will update AMS A05209W1 by December 9, 2022, to:\n\nSpecify the curing time be monitored\n\nInclude the ultrasonic cleaning parameters\n\nInclude any additional missing process parameters.\n\nYour firm will then review all DHRs for currently manufactured devices and remediate gaps as necessary. Your firm will complete the DHR review by January 31, 2022.\n\nThe adequacy of your firm’s corrective actions cannot be determined at this time because the actions are ongoing. Please provide updates on the corrective actions as they are completed.\n\nOur inspection also revealed that your firm's sterile and non-sterile Endoscopes and and Automated Endoscope Reprocessors devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. These violations include, but are not limited to, the following:\n\n4. Failure to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\n\nFor example: during this inspection, your firm acknowledged that it had not established written MDR procedures.\n\nIn the response, your firm developed two documents titled “CoE Global MDR: Handling US MDR Reporting for Potential Adverse Event Complaints”, GSOP-8.15-7, Rev. AD, dated 7\u002F13\u002F2022 and “Medical Device Reporting Work Instruction”, OMBS W 8.2.3_01_001, Rev. 13, dated 7\u002F26\u002F2022. The documents collectively were referenced as your firm’s MDR procedure. The document references Aizu Olympus Co. Ltd. as a Manufacturer. Your firm did not provide documentation or evidence of implementation. You state that plans for staff training and MDR reporting process realignment are still ongoing. Therefore, the adequacy of your firm's response cannot be determined at this time. Please provide updates on the corrective actions as they are completed.\n\nU.S. federal agencies may take your compliance history into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made.\n\nYour firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\n\nFood and Drug Administration - CDRH\u002FORP\u002FDRP2\n\nCDRH Regulatory Inspections and Audit Team, WO66-1434\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to CMS case # 643172 when replying.\n\nIf you have any questions about the contents of this letter, please contact: Mark Antonino at Mark.Antonino@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely Yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nDirector\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nLydia Sakakeeny\n\nGyrus ACMI Inc.\n\n800 West Park Drive\n\nWestborough, MA US 01581\n\nPhone: 617 7976458 Ext\n\nEmail: Lydia.Sakakeeny@Olympus.Com","Aizu Olympus Co., Ltd.","aizu-olympus-co-ltd-643172-11022022","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faizu-olympus-co-ltd-643172-11022022","2026-10-26T08:07:51.635711+00:00","Warning Letter","Issued","2023-01-10","643172","Medical Devices","Yasuo Takeuchi","2026-08-20T01:19:37.65+00:00","VIA UNITED PARCEL SERVICE","2022-11-02",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":52,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},139,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2026-05-26T13:20:00Z\">05\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-14T04:00:00Z\">05\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgc-america-inc-727602-05142026\">GC America, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-76\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Joseph T. Talanges\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Chief Operating Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>GC America, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3737 West 127th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alsip\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 14, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>Dear Mr. Talanges:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, GC America, Inc., FEI 1410097, at 3737 West 127th Street, Alsip, Illinois, from November 3 to 7, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your November 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC drug products, including those for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm failed to ensure components were suitable for use in manufacturing your drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>Used as a Component in Drug Products\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You did not adequately demonstrate your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, at a minimum, meets specifications in the United States Pharmacopeia (USP) \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph. For example, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system records show that you only performed \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing. However, the USP monograph requires additional testing for chemical purity and microbial quality. We also noted you failed to establish a procedure describing \u003Cstrong>(b)(4) \u003C\u002Fstrong>sampling requirements and acceptance criteria. According to your management, you manufactured approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished drug batches with inadequately tested \u003Cstrong>(b)(4)\u003C\u002Fstrong> from 2023 through 2025.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ingredients at Risk for \u003C\u002Fem>\u003Cstrong>(b)(4) \u003C\u002Fstrong>\u003Cem>Contamination\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also state in your correspondence to the agency that you do not conduct identity testing on each shipment of each lot of your incoming components at high risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination before using them to manufacture your drug products. This includes, but is not limited to, testing \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine its appropriate identity prior to use in manufacturing your drug products.\u003C\u002Fp>\u003Cp>Identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and certain other high-risk drug components includes a USP limit test to ensure the component meets the relevant safety limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong> levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cstrong>(b)(4).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In your response, you acknowledge you do not perform all testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> per USP, and you commit to sending a sample of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a third-party testing laboratory. You also commit to conducting a risk assessment of your deficient \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing on drug products released from 2023 to 2025 and to establishing a \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing SOP.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide a detailed procedure explaining how you will assess your \u003Cstrong>(b)(4)\u003C\u002Fstrong> against compendial requirements. You also lack a comprehensive review of your material system, including supplier evaluations, to ensure the quality of all materials is consistently acceptable.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to adequately sample, test, and examine drug components before use in production to assure quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fp>\u003Cp>• The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fp>\u003Cp>• A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP monograph specifications and appropriate microbial limits.\u003C\u002Fp>\u003Cp>• A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data)\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\u003C\u002Fp>\u003Cp>• Based on a thorough review, provide a summary of your systems corrective actions and preventive actions (CAPA) to remediate the vendor qualification program and prevent use of unsuitable components, containers and closures.\u003C\u002Fp>\u003Cp>• Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system qualification report.\u003C\u002Fp>\u003Cp>• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing, including high risk drug components.\u003C\u002Fp>\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificates of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the USP monograph.\u003C\u002Fp>\u003Cp>• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fp>\u003Cp>• A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\u003Cbr>• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination (including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow a written testing program designed to assess the stability characteristics of drug products and to test an adequate number of batches of each drug product to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a) and 211.166(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to establish a stability program with adequate data from long-term or accelerated storage conditions, demonstrating that drug products remain acceptable throughout the labeled expiry period. For example, the only stability data provided for \u003Cstrong>(b)(4)\u003C\u002Fstrong> consisted of a single batch tested for \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Celsius with no controlled humidity condition. Furthermore, you have no ongoing stability studies for any drugs currently manufactured.\u003C\u002Fp>\u003Cp>Without an appropriate stability program, you lack adequate scientific evidence to demonstrate your drug products meet established specifications and retain their quality attributes through your labeled expiry.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Q1A(R2) Stability Testing of New Drug Substances and Products\u003C\u002Fem> to help you meet the CGMP requirements for stability testing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71707\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you acknowledge you do not have an appropriate written testing program to assess the stability characteristics of your drugs. You also state you will test expired reserve samples and perform a risk assessment for distributing drugs without adequate stability data. You also commit to initiating ongoing stability testing and modifying your procedures to include updated stability instructions.\u003C\u002Fp>\u003Cp>Your response is inadequate. You lack analytical data to show your drugs maintain their quality attributes throughout their shelf life. You also fail to provide updated procedures and training records indicating you have implemented an adequate stability program.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o all procedures that describe these and other elements of your remediated stability program\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not adequately oversee your drug manufacturing operations. For example, your QU failed to ensure adequate control of your analytical data. Our investigator documented an uncontrolled password for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter affixed to a laptop by a sticker used for processing \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter test results. In addition, the data from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter is automatically deleted when the laptop is shutdown, so no records were available to show that your QU reviewed this data. Furthermore, you were unable to provide audit trails or an SOP describing oversight and retention requirements of electronic records. The lack of proper electronic record controls undermines the reliability and integrity of your laboratory data (21 CFR 211.68(b)).\u003C\u002Fp>\u003Cp>Your QU also failed to perform annual product reviews of your drug products since our previous inspection in 2018. Furthermore, no written procedures for this requirement were available (21 CFR 211.180(e)).\u003C\u002Fp>\u003Cp>In your response, you acknowledge you did not exercise appropriate controls to ensure authorized access to electronic records. Also, you commit to removing shared passwords, creating a data integrity policy, and implementing an annual product review procedure.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide updated procedures and training records to demonstrate you have corrected your data control deficiencies. You also lack product quality assessments.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance with Drug CGMP: Questions and Answers\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed in the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fp>\u003Cp>• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003Cbr>\u003Cbr>• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fp>\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a qualified consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003Cbr>\u003Cbr>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1410097 and ATTN: Matthew Jensen.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>Kennerly K. Chapman -S\u003Cbr>Francis Godwin\u003Cbr>Director\u003Cbr>Digitally signed by Kennerly K. Chapman -S\u003Cbr>Date: 2026.05.14 15:58:58 -04'00'\u003Cbr>Office of Manufacturing Quality Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email Return Receipt Requested\n\nReference #:\n\n320-26-76\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Joseph T. Talanges\n\nRecipient Title\n\nPresident & Chief Operating Officer\n\nGC America, Inc.\n\n3737 West 127th Street\n\nAlsip, IL 60803\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nMay 14, 2026\nWARNING LETTER\n\nDear Mr. Talanges:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, GC America, Inc., FEI 1410097, at 3737 West 127th Street, Alsip, Illinois, from November 3 to 7, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your November 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures OTC drug products, including those for (b)(4). Your firm failed to ensure components were suitable for use in manufacturing your drug products.\n(b)(4) Used as a Component in Drug Products\nYou did not adequately demonstrate your (b)(4), at a minimum, meets specifications in the United States Pharmacopeia (USP) (b)(4) monograph. For example, your (b)(4) system records show that you only performed (b)(4) testing. However, the USP monograph requires additional testing for chemical purity and microbial quality. We also noted you failed to establish a procedure describing (b)(4) sampling requirements and acceptance criteria. According to your management, you manufactured approximately (b)(4) finished drug batches with inadequately tested (b)(4) from 2023 through 2025.\nProducts Containing Ingredients at Risk for (b)(4) Contamination\nYou also state in your correspondence to the agency that you do not conduct identity testing on each shipment of each lot of your incoming components at high risk of (b)(4) contamination before using them to manufacture your drug products. This includes, but is not limited to, testing (b)(4) to determine its appropriate identity prior to use in manufacturing your drug products.\nIdentity testing for (b)(4) and certain other high-risk drug components includes a USP limit test to ensure the component meets the relevant safety limits for (b)(4) levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4).\nIn your response, you acknowledge you do not perform all testing of (b)(4) per USP, and you commit to sending a sample of your (b)(4) to a third-party testing laboratory. You also commit to conducting a risk assessment of your deficient (b)(4) testing on drug products released from 2023 to 2025 and to establishing a (b)(4) testing SOP.\nYour response is inadequate. You do not provide a detailed procedure explaining how you will assess your (b)(4) against compendial requirements. You also lack a comprehensive review of your material system, including supplier evaluations, to ensure the quality of all materials is consistently acceptable.\nWithout adequate testing, you do not have scientific evidence that components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to adequately sample, test, and examine drug components before use in production to assure quality.\nIn response to this letter, provide:\n• A procedure for your (b)(4) system monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\n• The current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) system. Ensure that the total count limits for your (b)(4) are appropriately stringent in view of the intended use of each of the products produced by your firm.\n• A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces (b)(4) that meets (b)(4) USP monograph specifications and appropriate microbial limits.\n• A comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\no an assessment of all materials to determine whether they are consistently of acceptable quality\no a review to ensure assigned expiration or retest dates are appropriate (supported by data)\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\n• Based on a thorough review, provide a summary of your systems corrective actions and preventive actions (CAPA) to remediate the vendor qualification program and prevent use of unsuitable components, containers and closures.\n• Your (b)(4) system qualification report.\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing, including high risk drug components.\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificates of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), and certain additional high-risk components we note that this includes the performance of (b)(4) of the USP monograph.\n• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n• A commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4).\n\n• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination (including, but not limited to, (b)(4)). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n2. Your firm failed to establish and follow a written testing program designed to assess the stability characteristics of drug products and to test an adequate number of batches of each drug product to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a) and 211.166(b)).\nYour firm failed to establish a stability program with adequate data from long-term or accelerated storage conditions, demonstrating that drug products remain acceptable throughout the labeled expiry period. For example, the only stability data provided for (b)(4) consisted of a single batch tested for (b)(4) at (b)(4) degrees Celsius with no controlled humidity condition. Furthermore, you have no ongoing stability studies for any drugs currently manufactured.\nWithout an appropriate stability program, you lack adequate scientific evidence to demonstrate your drug products meet established specifications and retain their quality attributes through your labeled expiry.\nSee FDA’s guidance document Q1A(R2) Stability Testing of New Drug Substances and Products to help you meet the CGMP requirements for stability testing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71707\u002Fdownload.\nIn your response, you acknowledge you do not have an appropriate written testing program to assess the stability characteristics of your drugs. You also state you will test expired reserve samples and perform a risk assessment for distributing drugs without adequate stability data. You also commit to initiating ongoing stability testing and modifying your procedures to include updated stability instructions.\nYour response is inadequate. You lack analytical data to show your drugs maintain their quality attributes throughout their shelf life. You also fail to provide updated procedures and training records indicating you have implemented an adequate stability program.\nIn response to this letter, provide:\n• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\no detailed definition of the specific attributes to be tested at each station (timepoint)\no all procedures that describe these and other elements of your remediated stability program\n3. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d)).\nYour quality unit (QU) did not adequately oversee your drug manufacturing operations. For example, your QU failed to ensure adequate control of your analytical data. Our investigator documented an uncontrolled password for the (b)(4) meter affixed to a laptop by a sticker used for processing (b)(4) meter test results. In addition, the data from the (b)(4) meter is automatically deleted when the laptop is shutdown, so no records were available to show that your QU reviewed this data. Furthermore, you were unable to provide audit trails or an SOP describing oversight and retention requirements of electronic records. The lack of proper electronic record controls undermines the reliability and integrity of your laboratory data (21 CFR 211.68(b)).\nYour QU also failed to perform annual product reviews of your drug products since our previous inspection in 2018. Furthermore, no written procedures for this requirement were available (21 CFR 211.180(e)).\nIn your response, you acknowledge you did not exercise appropriate controls to ensure authorized access to electronic records. Also, you commit to removing shared passwords, creating a data integrity policy, and implementing an annual product review procedure.\nYour response is inadequate. You do not provide updated procedures and training records to demonstrate you have corrected your data control deficiencies. You also lack product quality assessments.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance with Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed in the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a qualified consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1410097 and ATTN: Matthew Jensen.\n\nSincerely,\nKennerly K. Chapman -S\nFrancis Godwin\nDirector\nDigitally signed by Kennerly K. Chapman -S\nDate: 2026.05.14 15:58:58 -04'00'\nOffice of Manufacturing Quality Office of Compliance\nCenter for Drug Evaluation and Research","GC America, Inc.","gc-america-inc-727602-05142026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgc-america-inc-727602-05142026","2026-10-26T08:08:44.827832+00:00","2026-05-26","727602","Drugs Over-the-Counter Drugs","Mr. Joseph T. Talanges","2026-08-19T04:39:48.869+00:00","Via Email Return Receipt Requested","320-26-76","2026-05-14",{"id":55,"raw":56,"subject":38,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":70,"closeout_date":19,"issuing_office":60,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":19,"reference_number":19,"action_taken_date":74,"medical_device_id":19,"response_letter_date":19},2632,[57,58,59,60,38,13,13,13],"\u003Ctime datetime=\"2022-06-07T13:20:00Z\">06\u002F07\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-23T04:00:00Z\">05\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faire-master-america-inc-622546-05232022\">Aire-Master of America, Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations III","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Walter R. Heinle\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCOO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aire-Master of America, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1821 N. State Highway CC\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nixa\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>65714-8015\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 23, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCase #622546\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Heinle:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Aire-Master of America, Inc., FEI 3002764676, at 1821 N. State Highway CC, Nixa Missouri, from October 5 to October 19, 2021\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and are misbranded under sections 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your November 4, 2022, response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your laboratory sampling plans and testing methods were not scientifically sound. You collected non-representative samples of your water system. Water from your water system is used in the formulation of your topical over-the-counter (OTC) drug products. Specifically, your water system monitoring procedure provided during the inspection did not discuss the number, location, or frequency of samples to collect. You told our investigator that you typically take a sample from your water system \u003Cstrong>(b)(4)\u003C\u002Fstrong> from a single location near the \u003Cstrong>(b)(4)\u003C\u002Fstrong> component. The sampling frequency and locations, which did not include sampling from any point of use, were not appropriate to provide substantive data to promptly detect system variability.\u003C\u002Fp>\n\n\u003Cp>Furthermore, your microbiological testing used for water analysis was deficient. You have not shown your test methods were adequate for determining the quality of the water in view of its intended use in your drug products. Furthermore, you lacked appropriate limits, routine testing, or validated methods for detecting the presence of \u003Cem>B. cepacia\u003C\u002Fem> in your water system. Your microbiological testing is insufficient to assure that your water system is suitable for its intended use.\u003C\u002Fp>\n\n\u003Cp>Additionally, FDA analysis of samples collected from your water system recovered too-numerous-to-count results for multiple total microbial count tests.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your water system design, control, and maintenance.\u003C\u002Fli>\n\t\u003Cli>A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design consistently produces water adhering to \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\t\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\t\u003Cli>A procedure for your water system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>A diagram of your water system and its components. Include a list of all water system point-of-uses (POUs), their locations, and frequency of testing.\u003C\u002Fli>\n\t\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) failed to conduct an adequate investigation into a complaint received for a “fishy” odor in your Foaming Waterless Hand Sanitizer\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> lot #713588. Your investigation stated that you “checked inventory in the warehouse and noticed the smell that the customer complained of. Inventory was then taken out of stock.” You determined to rework some of the old product into a new batch “to lessen the smell of the product in question.”\u003C\u002Fp>\n\n\u003Cp>Our investigator collected a certificate of analysis (COA) showing “alcohol\u002Fno fragrance” as the specification for this drug product. As this complaint described a foul odor in distributed drug product, your QU should have performed a thorough investigation into this complaint as per 21 CFR 211.198. Instead, your production management performed a very limited investigation. The resolution for this complaint was to ensure employees “purge the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank before filling the vat with \u003Cstrong>(b)(4)\u003C\u002Fstrong> water.” While the investigation indicated that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water was the source of the odor, you failed to address why your formulation water had a foul odor. Additionally, your investigation lacked meaningful corrective action and preventive action (CAPA) to prevent recurrence.\u003C\u002Fp>\n\n\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to produce safe and effective products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm released finished drug products without adequate testing for critical microbial attributes (e.g., total count, absence of objectionable microorganisms). Without testing each batch prior to release, you did not have scientific evidence that all drug product batches were free of microbial contamination that is objectionable in view of its intended use.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fli>\n\t\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\n\t\u003Cli>A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to demonstrate that your cleaning and disinfection practices are adequate to remove contaminants from shared equipment used to manufacture household cleaners as well as your topical OTC drug products. Although you did not validate your equipment cleaning methods, you continued to manufacture your topical OTC drug products using the same equipment that you use to manufacture numerous cleaners in your facility, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> Bathroom Cleaner.\u003C\u002Fp>\n\n\u003Cp>This cleaner is labeled as, “CAUTION: IRRITANT” and “For Sensitive skin, please wear household rubber gloves.”\u003Cbr>\n\u003Cbr>\nIt is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture industrial-grade cleaning products. Moreover, the potential toxicity of these products increases the hazard if a cross-contamination or material mixup deviation occurs.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; segregation of pharmaceutical from non-pharmaceutical manufacturing; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated standard operating procedure (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>5. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You lacked appropriate identity testing for your incoming components used to manufacture your drug products. For example, your firm did not ensure that at least one specific identity test was conducted for each lot of your drug product components citric acid and carbomer. Additionally, your identity test methods for glycerin, and ethyl alcohol components are insufficient as they were not adequate to detect the toxic chemicals diethylene glycol and methanol, respectively.\u003C\u002Fp>\n\n\u003Cp>By not adequately analyzing each incoming lot of components for identity, you failed to ensure your incoming components are of appropriate quality to use in the manufacture of drug products.\u003C\u002Fp>\n\n\u003Cp>You manufacture multiple drugs that contain glycerin. The use of glycerin contaminated with DEG has resulted in various lethal poisoning incidents in humans worldwide.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Testing of Glycerin for Diethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing glycerin at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-diethylene-glycol\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-diethylene-glycol\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>You also manufacture multiple drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) to help you meet the CGMP requirements when manufacturing drugs containing ethanol at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fpolicy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol-including-during-public-health\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fpolicy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol-including-during-public-health\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\t\u003Cli>Results of tests for diethylene glycol (DEG) and ethylene glycol (EG) in retain samples of all glycerin lots used to manufacture your drug products.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that contain glycerin and are within expiry in the U.S. market. Take prompt corrective actions and preventive actions, and detail your future actions to ensure appropriate selection of your suppliers, ongoing scrutiny of their supply chain, and appropriate incoming lot controls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and AireMaster Foaming Hand Sanitizer with Aloe labels that provide evidence of the intended uses\u003Csup>\u003Cem>\u003Cstrong>2&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>(as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Drug Facts . . . Active Ingredient\u003C\u002Fstrong> . . . Ethanol 62% . . . \u003Cstrong>Purpose\u003C\u002Fstrong> . . . Antiseptic. . . \u003Cstrong>Uses\u003C\u002Fstrong> . . . Handwash to help reduce bacteria that potentially can cause disease. . . \u003Cstrong>Directions\u003C\u002Fstrong> . . . Dispense an adequate amount in your palm to cover all surfaces of hands completely · Rub hands together until dry · Does not require rinsing. . .” [from your Aire-Master Foaming Hand Sanitizer label]\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>Drug Facts . . . Active Ingredient\u003C\u002Fstrong> . . . Ethanol 62% . . . \u003Cstrong>Purpose\u003C\u002Fstrong> . . . Antiseptic. . . \u003Cstrong>Uses\u003C\u002Fstrong> . . . Handwash to help reduce bacteria that potentially can cause disease. . . \u003Cstrong>Directions\u003C\u002Fstrong> . . . Dispense an adequate amount in your palm to cover all surfaces of hands completely · Rub hands together until dry · Does not require rinsing. . .” [from your Aire-Master Foaming Hand Sanitizer with Aloe label]\u003C\u002Fp>\n\n\u003Cp>These topical antiseptic products are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your AireMaster Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe products are GRASE for use under the conditions suggested, recommended, or prescribed in their labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub. Additionally, OTC consumer antiseptic washes were addressed in “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Proposed Rule, 78 FR 76444 (December 17, 2013) (Consumer Antiseptic Washes Proposed Rule) and “OTC Safety and Effectiveness of Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Final Rule, 81 FR 61106 (September 6, 2016). We note that ethyl alcohol is not one of the active ingredients that was classified as Category III for use as an active ingredient in a consumer antiseptic wash. Under the Consumer Antiseptic Washes rulemaking, ethyl alcohol was determined to be ineligible for evaluation under the OTC Drug Review for use as an active ingredient in consumer antiseptic washes.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule [and the 2013 Consumer Antiseptic Washes Proposed Rule], nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>As previously noted, statements on each of the product labels for Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe suggest that these products are intended to be both consumer antiseptic washes and consumer antiseptic rubs. However, ethyl alcohol (in any concentration) is not an active ingredient permitted for use in consumer antiseptic hand washes under the 1994 TFM.\u003C\u002Fp>\n\n\u003Cp>Lastly, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe are nonprescription drug(s) subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Additionally, we note that under 21 CFR 201.61(a), “[t]he principal display panel of an over-the-counter drug in package form shall bear as one of its principal features, a statement of identity of the commodity.” Under section 505G(a)(3) of the FD&amp;C Act and the 1994 TFM, the statement of identity for health-care antiseptic drug products, a category that included consumer antiseptic rub drug products, must contain “the established name of the drug, if any” (59 FR 31442). Currently, there is no established name for consumer antiseptic rub drug products that have the active ingredient ethyl alcohol and are formulated as a gel. However, we recommend that you include the active ingredient’s name, such as “alcohol gel,” as appropriate, as part of the statement of identity that appears on the principal display panel for all of your product labels.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Objectionable Organisms\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For further information regarding the significance of \u003Cem>B. cepacia \u003C\u002Fem>complex and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice posted on July 7, 2021, at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm\">https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (622546). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Nicholas F. Lyons, Director of Compliance\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Nicholas F. Lyons, Director of Compliance at (312) 596-4220.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jeffrey D. Meng\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>__________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. A review of the formulations of the drug products indicates that such products were not prepared consistent with FDA’s temporary policy set forth in the guidance. Because Aire-Master of America’s hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer drug products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We note that your Aire-Master Foaming Hand Sanitizer Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe, drug products’ labeling contains conflicting information regarding whether they should be used as consumer antiseptic rub\u002Fconsumer antiseptic wash or consumer antiseptic rub. The term “hand sanitizer” generally refers to consumer antiseptic rubs, and the Drug Facts Label of your product both indicates that the product is to be used for handwashing (presumably with water) and suggests that it should be used without water (i.e., “[a]pply liberal amount into hand” and “rub to dryness with attention to area around nails and between fingers”). These products, however, do not conform to the requirements for either a consumer antiseptic rub or a consumer antiseptic wash, as further described below.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Walter R. Heinle\n\nRecipient Title\n\nPresident\u002FCOO\n\nAire-Master of America, Inc.\n\n1821 N. State Highway CC\n\nNixa, MO 65714-8015\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nMay 23, 2022\n\nWARNING LETTER\n\nCase #622546\n\nDear Mr. Heinle:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Aire-Master of America, Inc., FEI 3002764676, at 1821 N. State Highway CC, Nixa Missouri, from October 5 to October 19, 2021\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and are misbranded under sections 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nWe reviewed your November 4, 2022, response to our Form FDA 483 in detail.\n\nYour response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nYour laboratory sampling plans and testing methods were not scientifically sound. You collected non-representative samples of your water system. Water from your water system is used in the formulation of your topical over-the-counter (OTC) drug products. Specifically, your water system monitoring procedure provided during the inspection did not discuss the number, location, or frequency of samples to collect. You told our investigator that you typically take a sample from your water system (b)(4) from a single location near the (b)(4) component. The sampling frequency and locations, which did not include sampling from any point of use, were not appropriate to provide substantive data to promptly detect system variability.\n\nFurthermore, your microbiological testing used for water analysis was deficient. You have not shown your test methods were adequate for determining the quality of the water in view of its intended use in your drug products. Furthermore, you lacked appropriate limits, routine testing, or validated methods for detecting the presence of B. cepacia in your water system. Your microbiological testing is insufficient to assure that your water system is suitable for its intended use.\n\nAdditionally, FDA analysis of samples collected from your water system recovered too-numerous-to-count results for multiple total microbial count tests.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent assessment of your water system design, control, and maintenance.\n\nA thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design consistently produces water adhering to (b)(4) Water, USP monograph specifications and appropriate microbial limits.\n\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets (b)(4) Water, USP monograph specifications and appropriate microbial limits.\n\nA procedure for your water system monitoring that specifies routine microbial testing of (b)(4) water to ensure its acceptability for use in each batch of drug products produced by your firm.\n\nA diagram of your water system and its components. Include a list of all water system point-of-uses (POUs), their locations, and frequency of testing.\n\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) Water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm.\n\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour quality unit (QU) failed to conduct an adequate investigation into a complaint received for a “fishy” odor in your Foaming Waterless Hand Sanitizer1 lot #713588. Your investigation stated that you “checked inventory in the warehouse and noticed the smell that the customer complained of. Inventory was then taken out of stock.” You determined to rework some of the old product into a new batch “to lessen the smell of the product in question.”\n\nOur investigator collected a certificate of analysis (COA) showing “alcohol\u002Fno fragrance” as the specification for this drug product. As this complaint described a foul odor in distributed drug product, your QU should have performed a thorough investigation into this complaint as per 21 CFR 211.198. Instead, your production management performed a very limited investigation. The resolution for this complaint was to ensure employees “purge the (b)(4) tank before filling the vat with (b)(4) water.” While the investigation indicated that the (b)(4) water was the source of the odor, you failed to address why your formulation water had a foul odor. Additionally, your investigation lacked meaningful corrective action and preventive action (CAPA) to prevent recurrence.\n\nInadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to produce safe and effective products.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\n3. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\n\nYour firm released finished drug products without adequate testing for critical microbial attributes (e.g., total count, absence of objectionable microorganisms). Without testing each batch prior to release, you did not have scientific evidence that all drug product batches were free of microbial contamination that is objectionable in view of its intended use.\n\nIn response to this letter, provide the following:\n\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\n\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\nA summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n4. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\n\nYou failed to demonstrate that your cleaning and disinfection practices are adequate to remove contaminants from shared equipment used to manufacture household cleaners as well as your topical OTC drug products. Although you did not validate your equipment cleaning methods, you continued to manufacture your topical OTC drug products using the same equipment that you use to manufacture numerous cleaners in your facility, including (b)(4) Bathroom Cleaner.\n\nThis cleaner is labeled as, “CAUTION: IRRITANT” and “For Sensitive skin, please wear household rubber gloves.”\n\nIt is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture industrial-grade cleaning products. Moreover, the potential toxicity of these products increases the hazard if a cross-contamination or material mixup deviation occurs.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nA CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; segregation of pharmaceutical from non-pharmaceutical manufacturing; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no drugs with higher toxicities\n\no drugs with higher drug potencies\n\no drugs of lower solubility in their cleaning solvents\n\no drugs with characteristics that make them difficult to clean\n\no swabbing locations for areas that are most difficult to clean\n\no maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\nA summary of updated standard operating procedure (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n5. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYou lacked appropriate identity testing for your incoming components used to manufacture your drug products. For example, your firm did not ensure that at least one specific identity test was conducted for each lot of your drug product components citric acid and carbomer. Additionally, your identity test methods for glycerin, and ethyl alcohol components are insufficient as they were not adequate to detect the toxic chemicals diethylene glycol and methanol, respectively.\n\nBy not adequately analyzing each incoming lot of components for identity, you failed to ensure your incoming components are of appropriate quality to use in the manufacture of drug products.\n\nYou manufacture multiple drugs that contain glycerin. The use of glycerin contaminated with DEG has resulted in various lethal poisoning incidents in humans worldwide.\n\nSee FDA’s guidance document Testing of Glycerin for Diethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing glycerin at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-diethylene-glycol.\n\nYou also manufacture multiple drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide.\n\nSee FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fpolicy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol-including-during-public-health.\n\nIn response to this letter, provide the following:\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\nResults of tests for diethylene glycol (DEG) and ethylene glycol (EG) in retain samples of all glycerin lots used to manufacture your drug products.\n\nA full risk assessment for drug products that contain glycerin and are within expiry in the U.S. market. Take prompt corrective actions and preventive actions, and detail your future actions to ensure appropriate selection of your suppliers, ongoing scrutiny of their supply chain, and appropriate incoming lot controls.\n\nUnapproved New Drug and Misbranding Violations\n\nExamples of claims observed on the Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and AireMaster Foaming Hand Sanitizer with Aloe labels that provide evidence of the intended uses2 (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“Drug Facts . . . Active Ingredient . . . Ethanol 62% . . . Purpose . . . Antiseptic. . . Uses . . . Handwash to help reduce bacteria that potentially can cause disease. . . Directions . . . Dispense an adequate amount in your palm to cover all surfaces of hands completely · Rub hands together until dry · Does not require rinsing. . .” [from your Aire-Master Foaming Hand Sanitizer label]\n\n“Drug Facts . . . Active Ingredient . . . Ethanol 62% . . . Purpose . . . Antiseptic. . . Uses . . . Handwash to help reduce bacteria that potentially can cause disease. . . Directions . . . Dispense an adequate amount in your palm to cover all surfaces of hands completely · Rub hands together until dry · Does not require rinsing. . .” [from your Aire-Master Foaming Hand Sanitizer with Aloe label]\n\nThese topical antiseptic products are “new drugs” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your AireMaster Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe products are GRASE for use under the conditions suggested, recommended, or prescribed in their labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub. Additionally, OTC consumer antiseptic washes were addressed in “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Proposed Rule, 78 FR 76444 (December 17, 2013) (Consumer Antiseptic Washes Proposed Rule) and “OTC Safety and Effectiveness of Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Final Rule, 81 FR 61106 (September 6, 2016). We note that ethyl alcohol is not one of the active ingredients that was classified as Category III for use as an active ingredient in a consumer antiseptic wash. Under the Consumer Antiseptic Washes rulemaking, ethyl alcohol was determined to be ineligible for evaluation under the OTC Drug Review for use as an active ingredient in consumer antiseptic washes.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule [and the 2013 Consumer Antiseptic Washes Proposed Rule], nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAs previously noted, statements on each of the product labels for Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe suggest that these products are intended to be both consumer antiseptic washes and consumer antiseptic rubs. However, ethyl alcohol (in any concentration) is not an active ingredient permitted for use in consumer antiseptic hand washes under the 1994 TFM.\n\nLastly, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because Aire-Master Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe are nonprescription drug(s) subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nAdditionally, we note that under 21 CFR 201.61(a), “[t]he principal display panel of an over-the-counter drug in package form shall bear as one of its principal features, a statement of identity of the commodity.” Under section 505G(a)(3) of the FD&C Act and the 1994 TFM, the statement of identity for health-care antiseptic drug products, a category that included consumer antiseptic rub drug products, must contain “the established name of the drug, if any” (59 FR 31442). Currently, there is no established name for consumer antiseptic rub drug products that have the active ingredient ethyl alcohol and are formulated as a gel. However, we recommend that you include the active ingredient’s name, such as “alcohol gel,” as appropriate, as part of the statement of identity that appears on the principal display panel for all of your product labels.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nObjectionable Organisms\n\nFor further information regarding the significance of B. cepacia complex and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice posted on July 7, 2021, at https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to the Warning Letter Number above (622546). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Nicholas F. Lyons, Director of Compliance\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nIf you have questions regarding the contents of this letter, please contact Nicholas F. Lyons, Director of Compliance at (312) 596-4220.\n\nSincerely,\n\n\u002FS\u002F\n\nJeffrey D. Meng\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations III\n\n__________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. A review of the formulations of the drug products indicates that such products were not prepared consistent with FDA’s temporary policy set forth in the guidance. Because Aire-Master of America’s hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer drug products for violations of section 505 of the FD&C Act.\n\n2 We note that your Aire-Master Foaming Hand Sanitizer Foaming Hand Sanitizer (2 and 64 fl oz) and Aire-Master Foaming Hand Sanitizer with Aloe, drug products’ labeling contains conflicting information regarding whether they should be used as consumer antiseptic rub\u002Fconsumer antiseptic wash or consumer antiseptic rub. The term “hand sanitizer” generally refers to consumer antiseptic rubs, and the Drug Facts Label of your product both indicates that the product is to be used for handwashing (presumably with water) and suggests that it should be used without water (i.e., “[a]pply liberal amount into hand” and “rub to dryness with attention to area around nails and between fingers”). These products, however, do not conform to the requirements for either a consumer antiseptic rub or a consumer antiseptic wash, as further described below.","Aire-Master of America, Inc.","aire-master-america-inc-622546-05232022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faire-master-america-inc-622546-05232022","2026-10-26T08:07:51.568165+00:00","2022-06-07","622546","Drugs","Mr. Walter R. Heinle","2026-08-20T01:50:22.912+00:00","UPS","2022-05-23",{"id":76,"raw":77,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":86,"fei_number":19,"letter_url":87,"updated_at":88,"action_type":22,"case_status":23,"posted_date":89,"marcs_cms_no":90,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":91,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},21920,[78,79,80,11,81,13,13,13],"\u003Ctime datetime=\"2026-10-20T04:00:00Z\">10\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-07T04:00:00Z\">10\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corporation-729208-10072026\">Olympus Medical Systems Corporation\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Olympus Medical Systems Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2951 Ishikawa-machi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hachioji-shi\u003C\u002Fspan>, \u003Cspan>Tokyo\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>192-8507\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@olympus.com\"> (b)(6)@olympus.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #729208\u003C\u002Fp>\u003Cp>October 7, 2026\u003C\u002Fp>\u003Cp>Dear Mr. White:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted the following inspections of your firm’s medical device facilities:\u003C\u002Fp>\u003Cul>\u003Cli>Olympus Medical Systems Corporation, located at 2951 Ishikawa-Cho, Hachioji-Shi, Tokyo, JP 192-8507, FEI 3002807795, November 17, 2025, to November 21, 2025 (“Hachioji”)\u003C\u002Fli>\u003Cli>Aomori Olympus Co., Ltd., located at 2-248-1 Okkonoki, Kuroishi-shi, Aomori, JP, 036-0357, FEI 3003995201, from November 4, 2025, to November 7, 2025 (“Aomori”)\u003C\u002Fli>\u003Cli>Olympus Medical Systems Corp. Hinode Plant, located at 34-3 Hirai, Hinode-Machi, Nishitama-Gun, Tokyo, JP, 190-0182, FEI 3003637092, from November 17, 2025, to November 21, 2025 (“Hinode”)\u003C\u002Fli>\u003Cli>Shirakawa Olympus Co., Ltd., located at 3-1 Okamiyama, Odakura, Nishigo-Mura, Nishishirakawa-Gun, Fukushima, JP 961-8061, FEI 3002808148, November 10, 2025, to November 14, 2025 (“Shirakawa”)\u003C\u002Fli>\u003Cli>Olympus Winter &amp; IBE Gmbh, located at Kuehnstrasse 61, Hamburg, DE 22045, FEI 3002807798, from November 10, 2025, to November 21, 2025 (“Hamburg”)\u003C\u002Fli>\u003Cli>Gyrus ACMI, Inc. [dba Olympus Surgical Technologies (OSTA)], located at 9600 Louisiana Ave North, Brooklyn Park, MN 55445, FEI 3011050570, from October 6, 2025, to November 12, 2025 (“Brooklyn Park”)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During these inspections, our investigators determined that your firm manufactures a variety of surgical and endotherapy devices, including but not limited to, hemostatic metal clips, sphincterotomes, cystoscopes, bronchoscopes, endoscopic distal covers, valves, and insufflators. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The above-referenced inspections revealed that the devices manufactured at the Hachioji, Aomori, Hinode, Shirakawa, Hamburg, and Brooklyn Park facilities are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. This nonconformity includes issues across the referenced inspected facilities, resulting in the distribution of nonconforming devices and significant risks to patients.\u003C\u002Fp>\u003Cp>A Form FDA 483 (FDA 483), List of Inspectional Observations, was issued to the Aomori facility on November 7, 2025, the Brooklyn Park facility on November 12, 2025, the Shirakawa facility on November 14, 2025, the Hachioji facility on November 21, 2025, the Hinode facility on November 21, 2025, and the Hamburg facility on November 21, 2025. We received responses concerning our investigator’s observations noted on these FDA 483s from Robert A. Fryc, Director, Global Quality Compliance, External Regulatory Communications, Olympus Corporation of the Americas, dated December 22, 2025, February 13, 2026, March 30, 2026, May 28, 2026, and July 31, 2026. We address these responses (collectively referred to as “your firm’s response”) below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Design Control Violations – Shirakawa, Aomori, Hamburg, and Hachioji facilities\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for validating the device design to ensure that devices conform to defined user needs and intended uses and validation shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g). For example,\u003C\u002Fp>\u003Cp>a. At the Shirakawa facility, your firm failed to identify and control known catastrophic hazards in your risk management documentation and failed to validate the device design under actual or simulated use conditions for the UHI-4 insufflator. Catastrophic hazards, including air embolism, arrhythmia, and patient death, were identified through Health Hazard Assessments and complaint investigations associated with CAPA-201353; however, your \u003Cem>Risk Management Report\u003C\u002Fem> (DC00067142, dated November 6, 2025) did not reflect these hazards or ensure implementation of appropriate risk control measures, even after a confirmed patient death and Class I recall of UHI-4 units in 2023. Further, your design validation did not simulate actual or worst-case use conditions related to pressure sensor failure or inaccurate pressure measurements to ensure that the device would operate safely. As a result, devices distributed had design deficiencies that contributed to overpressure events during clinical use.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined. Your response states that design-related deficiencies are being addressed through global CAPAs, including CAPA-204150 (design control) and CAPA-203525 (risk management), and that a traceability matrix for the UHI-4 will be developed to evaluate design requirements, verification, and validation. You also indicate that additional design verification and\u002For validation testing will be performed as needed and that potential design changes will be assessed by the design owner (Olympus Hachioji). However, these activities remain ongoing, and you have not provided objective evidence demonstrating that design validation deficiencies have been corrected or that revised validation activities adequately address identified risks, including overpressure conditions. Additionally, corrective actions have been deferred to global CAPAs and another facility, and no documentation has been provided demonstrating completion or effectiveness of these actions.\u003C\u002Fp>\u003Cp>b. At the Aomori facility, your firm failed to identify and assess known hazards in the risk management documentation and failed to establish risk control measures for manufacturing processes for the Sphincterotome. In your risk management report (E_V-KD_\u003Cem>Risk Management Report\u003C\u002Fem>_Rev.27), the corresponding risk line ID (KD-G158-00) identifies the potential patient harm as “Delay in Treatment” for complaints of deformed wires but fails to include the higher risk identified through analysis of Medical Device Reports of unintended cutting of blood vessels leading to patient bleeding. It also fails to identify any risk control measures for the manufacture of the wire for the Sphincterotome. Additionally, the risk management report (DC00609260_20250910) does not include the known hazard of failure of the Automated Optical Inspection system to detect nonconforming Sphincterotome products (KD-V400 Series) with burrs and flakes and does not include risk control measures for this hazard, which can lead to tissue damage and procedural complications.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm has not provided an updated \u003Cem>Risk Management Report\u003C\u002Fem> (DC00609260_20250910) to address the hazard and implement risk control measures for failure of the Automated Optical Inspection system to detect nonconforming Sphincterotome products (KD-V400 Series) with burrs and flakes. Additionally, your firm has not provided an updated risk management report (E_V-KD_\u003Cem>Risk Management Report\u003C\u002Fem>) to address the risk of unintended cutting of blood vessels leading to patient bleeding and risk control measures for manufacture of the wire.\u003C\u002Fp>\u003Cp>c. At the Hamburg facility, your firm distributed the Continuous Flow Cystoscope (model WA22810A) with instructions for use (IFU) that claimed compatibility with the GreenLight PV ADDstat laser fiber component without conducting design validation testing to ensure compatibility under use conditions. This resulted in two recalls, RES 95584 and RES 98300, due to a risk of damage and\u002For overheating to the tip of the sheath when used together. Unrecognized sheath damage can result in tissue injury or parts of the sheath breaking off into the patient.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response should include a retrospective review of similar devices with IFU compatibility claims to ensure that they are supported by design validation activities to ensure compatibility under use conditions.\u003C\u002Fp>\u003Cp>d. At the Hachioji facility:\u003C\u002Fp>\u003Cp>i. Your firm distributed the BF-1TH190 bronchoscope with instructions for use (IFU) claiming compatibility with CO\u003Csub>2\u003C\u002Fsub> lasers without conducting design validation testing to ensure compatibility under use conditions. This resulted in a class I recall (RES 93052), due to a risk of endobronchial combustion if high-frequency cauterization is performed while supplying oxygen and\u002For the electrode section of the electrosurgical accessory is too close to the distal end of the endoscope. If endobronchial combustion occurs, the patient may suffer adverse events, including internal burns in their airway or lungs. The related CAPA did not evaluate compatibility claims for all endoscopes and lasers.\u003C\u002Fp>\u003Cp>ii. Design validation activities were not conducted with an understanding of the actual operating conditions for the Evis Exera Video Imaging System, used with your firm’s endoscopes for processing images. For example, design validation did not consider the conductivity of the electrolyte when it contained dust and moisture, nor did it consider the impact over time of water entering the scope during cleaning. This caused signal transmission problems and resulted in a significant number of complaints and MDRs for image erasure, image transition problems, and poor-quality images.\u003C\u002Fp>\u003Cp>iii. Your firm failed to complete design verification testing after implementing a change to the 0.2 μm Water Filter (Part MAJ-2318) to demonstrate that the device meets established design requirements and acceptance criteria. This water filter is used in your OER-Elite and OER-Mini Reprocessors for cleaning and high-level disinfection of your flexible endoscopes, their accessories, and endoscope reprocessor accessories. Your firm’s design change control procedure, OMBS_S_7.3.9_01_001, requires design verification or validation for all changes. However, ECR ER00006389 (dated December 11, 2024) shows verification testing was incomplete. Document MAJ-318_DC00429244 establishes the requirements and acceptance criteria for the product, including a filter service life of at least one month; however, design verification and validation records did not demonstrate that the filter has a service life of at least one month.\u003C\u002Fp>\u003Cp>iv. Your firm’s design change control procedure, OMBS_S_7.3.9_01_001, and \u003Cem>Traceability Activities\u003C\u002Fem> (OMBS W_7.3.3_03_002) require documentation of design traceability matrices. However, you have not implemented design traceability matrices for the following products: Evis Exera III Bronchovideoscopes, Evis Exera III Video System Center, Evis X1 Video System Center, Single Use Reloadable Clip Applicator, Endoscope Reprocessor, Evis Exera III Duodenovideoscopes. Without design traceability matrices there is no documentation demonstrating that all design requirements, including safety requirements, were properly verified and validated.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response for (i) through (iv) above cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Nonconforming Product Violations – Brooklyn Park and Hinode facilities:\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm reworked and distributed nonconforming Vizishot 2 FLEX (19G) devices without adequate justification that the rework addressed the cause of the nonconformance. NCR-00038111 was opened on July 30, 2025, to disposition nonconforming material subject to recall (RES 97303) for the detachment of the Vizishot 2 Flex 19G needle [laser cut hypotube (LCH)] after reported complaints and MDRs, including where the device may have contributed to a patient death during explant surgery to recover the detached needle. Your firm reworked product under NCR-00038111 and dispositioned passing products using an automated vision system for release, stating this minimized impact on any product safety, efficacy, or performance of the product\u002Fmaterial. However, the primary CAPA for the LCH ejection issues had not identified a root cause, and there were two additional CAPAs open related to the observed complaints (pebax material degradation and sheath snap lock not engaging), indicating other potential contributing factors to nonconformances. Additionally, your firm circumvented the ship hold in place under the NCR by changing the manufacturing date during rework, which allowed the release of those units.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203864 was opened and determined that the issue was linked to global processes GSOP‑00022 \u003Cem>Global NC Management\u003C\u002Fem> and GSOP‑00023 \u003Cem>Global CAPA Management\u003C\u002Fem>. The process related aspects of this observation are being addressed separately under Global CAPAs, CAPA-203799 and CAPA-204047. Your response acknowledged in CAPA 203864 that the eleven lots of product noted in NCR-00038111 underwent rework outside of your procedures. You reinstated the ship hold and quarantined all Vizishot 2 FLEX product. You executed product removal activities separately for Vizishot 2 FLEX (19G) devices, including a global removal decision made on December 11, 2025, with a corresponding 806 report submitted to FDA. Your firm’s corrective actions are ongoing under CAPA-203864, CAPA-203799 and CAPA-204047.\u003C\u002Fp>\u003Cp>ii. Your firm failed to control all nonconforming Shockpulse Lithotripsy generators that were subject to recall due to a miswired component (RES 98360). NCR-00000670 was opened on June 1, 2022, to scope the units affected under recall FY23-OSTA-05, for the miswiring of the Shockpulse generator. This NCR did not include a scope of all affected devices, including 2 lots containing 21 and 25 sub-assemblies, 9 finished units, and 2 service units. NCR-00046008 was opened to address the scoping nonconformance.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203777 was opened and the root cause identified the need to evaluate process gaps in \u003Cem>Global Nonconformance Management\u003C\u002Fem> GSOP-00022, specifically related to scoping methodology, alignment with HHA\u002FFCA teams, and decision-making during NCR and Stop Ship activities. A Global Ship Hold for miswired ShockPulse generator units was initiated on November 12, 2025, and the recall scope was expanded on December 9, 2025, with an 806 report submitted to FDA. Your firm’s corrective actions are ongoing under CAPA-203777 and CAPA-204047.\u003C\u002Fp>\u003Cp>b. At the Hinode facility,\u003C\u002Fp>\u003Cp>i. Your firm failed to control nonconforming MAJ 210 single-use biopsy valves when devices failed durability testing during the investigation of CAPA 203270. This CAPA was initiated after receiving multiple complaints reporting fractures of the device, including MDR reportable events. Although devices failed testing during the complaint investigation, your firm did not initiate a nonconformance for these out-of-specification device failures. Your firm eventually initiated NCR-00030581 for the complaint trend, but not for the identified testing failures.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your firm has initiated actions to address the MAJ-210 failures, including a shipping hold on the device, a plan to modify the device design, and an investigation into the complaint trend. Your response does not address why a nonconformance was not initiated when testing showed the product\u002Ffailed the durability specification per GSOP-00029 \u003Cem>Global Complaint Investigation\u003C\u002Fem> and was only later opened for the complaint trend. It is unclear if you plan to evaluate whether similar issues occurred for other devices and how you will ensure that complaint investigations result in CAPAs when appropriate.\u003C\u002Fp>\u003Cp>ii. Your firm failed to control nonconforming devices with sterile barrier seal overlap defects that were found to impact seal integrity. A nonconformance (NCR-00025684) was initiated in March 2025 in response to observed defects in sterile seals from September 2024- January 2025. NCR-00025684 identified overlaps as a novel defect that was not included in your visual inspection procedures. CAPA-202690 concluded that because seal overlaps are a large wrinkle, inspectors trained to visually identify wrinkles would identify seal overlap defects. However, wrinkles and seal overlaps represent distinct sterile barrier defects. CAPA-203907 included a retrospective evaluation to demonstrate that existing visual inspection procedures were likely to identify seal overlaps, based on a blind test of engineers. However, this evaluation does not demonstrate that overlaps were identified at the time of the nonconformances.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. You state that you are conducting an investigation and root cause analysis as part of your CAPA; however, this is in progress and the details of this investigation and corrective actions are not clear, and you have not yet provided objective evidence demonstrating completion or effectiveness.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Production and Process Controls Violations – Brooklyn Park, Hinode, Aomori, and Shirakawa facilities\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>3. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm failed to validate the heat sealing process for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tray Sealer. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tray Sealer (P4001467-001 Gyrus ACMI SN:01) Operational Qualification using Universal tray sealing nests, documented in \u003Cem>Operational Qualification (OQ) Report\u003C\u002Fem> D8201348-002 Rev AB, does not contain passing results for the challenge conditions at the high and low setpoints. The validation was intended to cover low setpoints of 200°F, 100 PSI, and 2.0 seconds and high setpoints of 265°F, 125 PSI, and 7.0 seconds. However, visual results showed all failures at the lower setpoints and all failures at the high setpoints for the Universal and PKS Omni products. Only the nominal settings (232°F, 115 PSI, 4.5 seconds) showed passing results, which do not match your current production setpoints (253°F, 118 PSI, 4 seconds).\u003C\u002Fp>\u003Cp>During the inspection, you re-executed the validation (D8201348-002, Revision AC). While this validation passed seal integrity and seal strength requirements at high and low challenge conditions, the deviation section notes that trays sealed at low settings had spottiness in the seal and trays from high settings had warp that would cause rejection during 100% visual inspection, demonstrating that the process is not capable of consistently producing conforming product throughout the acceptable setpoint ranges.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. You are in the process of implementing CAPA-203841 to address the root cause of inadequate process for assessing procedure revisions that resulted in earlier validations (Operational Qualifications) not being updated to meet regulatory requirements. Specifically, you plan to transition from \u003Cem>Process Validation\u003C\u002Fem> GSOP-7.5-1 to \u003Cem>Global Process Validation\u003C\u002Fem> GSOP-00002. Your response indicates that the retrospective re-validation of the heat sealers is complete except for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealer for the Universal Tray products and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealer for the Powerseal vessel sealing product line. You are currently assessing the risks associated with products manufactured and distributed using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tray Sealer, which failed the retrospective re-validation. Regarding the retrospective revalidation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> heat sealer used for the Powerseal product line you have noted the OQ failed to meet seal width acceptance criteria as detailed in the protocol, however, the OQ\u002FPQ testing will not be repeated at the current process settings (temperature, time, pressure). You have indicated that you will communicate with FDA regarding any actions taken based on the outcome of the completed HHA for distributed product and failed retrospective revalidation.\u003C\u002Fp>\u003Cp>ii. Your firm failed to validate the heat sealing process for tray material PN0003356 (45cm PETG Tray line) on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealer SN01. The \u003Cem>OQ Report for \u003Cstrong>(b)(4)\u003C\u002Fstrong> BM3025-E2W2 for 45cm packaging\u003C\u002Fem> (DN0010012) and \u003Cem>PQ Report for BP \u003Cstrong>(b)(4)\u003C\u002Fstrong> BM3025-E2W2 for 45cm packaging\u003C\u002Fem> (DN0010301) for this material and setpoints is for sealer \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which was decommissioned and removed from use in 2023. Your firm did not provide documentation showing this material was validated on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealer or justification for equipment equivalency.\u003C\u002Fp>\u003Cp>In addition, your procedure \u003Cem>Process Confirmation for Sterile Barrier Sealing\u003C\u002Fem> GWI-0704-07 Rev AE dated April 4, 2024, allows for abbreviated validation runs for \"equivalent or duplicate equipment.\" This procedure allows for equipment with the same manufacturer and model number to be considered equivalent, regardless of the year purchased or any other modifications made to the sealers. There is no additional justification or testing required to establish equivalency of the equipment.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. You are in the process of implementing CAPA-203842 to address GWI-0704-07 REV AE, \u003Cem>Process Confirmation for Sterile Barrier Sealing\u003C\u002Fem>, and FM-7.4-3 REV AC, \u003Cem>Sterile Barrier Sealing Confirmation\u003C\u002Fem>, not aligning with GSOP-00002 REV AD, \u003Cem>Validation Program\u003C\u002Fem>, nor GSOP-7.5-1 REV BA, Process Validation. In addition, your response confirmed that the work instructions and form lacked objective evidence to justify equipment equivalency. You are in the process of completing a Health Hazard Assessment (HHA- FY26-071-A) to evaluate any risks associated with sterile barriers for distributed products.\u003C\u002Fp>\u003Cp>iii. Your firm failed to operate your heat sealers at the validated setpoints used for the Powerseal vessel sealing products. Heat sealer numbers 19-11821 and 23-70915 are only calibrated for time at 5 seconds and 10 seconds, but the nominal setpoint is 3 seconds according to your procedure \u003Cem>POWERSEAL MP: Tray Sealer Setup and Peel Test\u003C\u002Fem> DN0044870 Rev AE. There is no documented justification on why this calibration is acceptable to demonstrate accuracy at the validated setpoint, or potential impact on packaging seal quality and sterile barrier integrity for the Powerseal products.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. For example, GSOP-7.18-1 REV AT, \u003Cem>Control of Inspection, Measuring, and Test Equipment\u003C\u002Fem>, does not ensure consistent implementation of calibration across the intended use range. Additionally, the supporting work instruction, GWI-0718-03 Rev AB \u003Cem>Completing a Calibration Request Form\u003C\u002Fem>, lacked sufficient clarity to implement the requirements of GSOP-7.18-1. Your firm plans to revise GWI-0718-03 to improve clarity, include a requirement to notify external calibration vendors of specification changes, and ensure calibration point selection is documented with clear rationale. The calibration request form (FM 7.18-1) will also be updated to provide traceability, reference the revised work instruction, and ensure alignment with validated set points. GSOP-7.18-1 will be updated to explicitly require calibration points to cover validated set points, document rationale for selected calibration points, and mandate re-evaluation of calibration points when validation parameters or process conditions change.\u003C\u002Fp>\u003Cp>b. At the Hinode facility, your firm failed to adequately validate critical process parameters of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the heat sealing process. An Operational Qualification (OQ) for the heat sealing process for the MAJ-210 Single Use Biopsy valve was conducted in July 2024, after \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the heat sealing packaging process to address seal wrinkle defects; however, the process parameters and validation are inadequate. The process parameter range shown in the Operational Qualification lists a lower set value of \u003Cstrong>(b)(4)\u003C\u002Fstrong> liters\u002Fminute and a higher set value of \u003Cstrong>(b)(4)\u003C\u002Fstrong> liters\u002Fminute, which is flawed because the \"lower\" limit exceeds the \"higher\" limit. The OQ documentation does not detail how the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm completed an investigation and root cause analysis under CAPA-203908, and as a result, updated GSOP-00002 to provide instruction for how to identify process parameters that require control in a validated process. Your firm is also planning to conduct a review of all validated manufacturing processes in place at the facility to confirm that process parameters are adequately controlled.\u003C\u002Fp>\u003Cp>c. At the Aomori facility, your firm failed to validate the cleaning process for metal components used in the production of the HX-610 EZ Clip (hemostasis clip) made according to procedure DC00736661 to remove dirt or other particles. For example, the procedure doesn’t include defining and validating all critical process parameters with acceptable ranges including cleaning solution (type, concentration, temperature), immersion time, drying parameters, and visual inspection criteria.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm initiated a Global Ship Hold (ID.530) and CAPA 203781 as part of your corrective actions.\u003C\u002Fp>\u003Cp>d. At the Shirakawa facility, your firm did not adequately validate the testing process used in the production of UHI-4 Insufflation Unit where the results could not be fully verified by subsequent inspection and testing. For example, the software-driven functional testing process used to evaluate device performance was not adequately validated to ensure that it consistently produced devices meeting specifications in that it did not include appropriate test cases to demonstrate user requirements met acceptance criteria.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined. Your response states that process validation deficiencies are being addressed through ongoing remediation activities and global CAPA efforts, and that validation activities are planned or underway to ensure processes consistently produce conforming devices. You have not provided objective evidence demonstrating that process validation activities have been completed or that affected processes have been validated, including validation protocols, reports, or data demonstrating that processes consistently produce conforming devices.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility, your firm failed to establish adequate process monitoring to ensure validated sealing processes for the heat sealers used for the Powerseal vessel sealing and Miscellaneous Urology products continue to meet specifications throughout production. Per procedure \u003Cem>Peel Strength Test Method for Trays and Pouches\u003C\u002Fem> D5100327-001 Rev AL, the heat sealer for Powerseal products requires peel strength testing to be completed at the beginning and the end of a lot. The process monitoring does not demonstrate that the heat sealing meets specification throughout the manufacturing operations, nor does the process monitoring demonstrate the machine was fully set up and operational when heat sealing process for a lot occurs over multiple days. The DHR for Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> notes that the sealing took place over two days. However, the process monitoring was conducted according to the procedure and only had a single tray sealing sample for testing at the start of the lot on June 20, 2025, and at shutdown on June 23, 2025. Your firm’s procedure for set-up, “\u003Cem>POWERSEAL MP: Tray Sealer Setup and Peel Test\u003C\u002Fem>” DN0044870 Rev AE states in \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the temperature to stabilize prior to use; however, there is no indication that this was done at the start of the second production day. This step is identified as critical, according to your firm’s Symbol Index in DN0044870. Additionally, the sealing procedure, D5100327-001, is also used for the Miscellaneous Urology line and the Cutting Forceps line and requires the pull strength testing be performed at the beginning and end of every day. Your firm has not assessed whether critical parameters remain in control during all production activities, including after equipment set up on subsequent production days and when processing multiple products with different configurations on the same day. Finally, your procedure \u003Cem>Process Monitoring - Packaging Data Review\u003C\u002Fem> D0300188-001 Rev AK states in section 4, step 2 that a process control analysis should include an evaluation of lower and upper control limits. However, these limits are not currently calculated by your firm, and the upper and lower bound specifications are used instead. There is no documented statistical rationale for this decision.\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened CAPA-203867 to capture corrective actions such as the retraining of employees on process monitoring requirements to include peel testing at the beginning and end of each lot for the affected product lines. You note that you will revise FM-7.5-10, Control Plan requirements with risk assessments to define and align appropriate sample sizes and frequency monitoring. Ongoing actions as part of CAPA-203867 include defining, establishing, and implementing risk-based requirements in Process Controls, GSOP-7.5-4, for ongoing validated process monitoring. You have not performed an assessment of potentially affected units in the field and any ongoing post market monitoring to assess any risks of commercially distributed product. Your firm plans to review all process monitoring plans subject to D0300188-001 Rev AK, to ensure that such plans include justified control limits as well as specification limits. Your firm has not implemented calculated control limits.\u003C\u002Fp>\u003Cp>5. Failure to ensure that when changes or process deviations occur, the manufacturer shall review and evaluate the process and perform revalidation where appropriate, as required by 21 CFR 820.75(c). For example,\u003C\u002Fp>\u003Cp>a. At the Hinode facility, your firm failed to revalidate the heat sealing process after implementing process changes in response to seal defects in the MAJ-1555. CAPA-202690 identified the cause of the overlap defects as a misalignment of the bag surfaces when the bag enters the sealing operation to create the sterile barrier. To address this issue, your firm added a sensor to control opening and closing of the extraction arm and receiving arm, which impacts bag surface alignment during sealing. Operational qualification or performance qualification was not performed after these changes to validate that the modified process continued to meet specifications and quality attributes.\u003C\u002Fp>\u003Cp>This is a repeat violation from our 2023 Warning Letter issued to the Hinode facility.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Following an investigation and root cause analysis under CAPA-203919, your firm revised GSOP-00002 to provide additional instruction on how to assess whether a manufacturing change triggers revalidation of the manufacturing process, and your firm established the guidance document GREF-00197 to provide revalidation guidelines. The verification of effectiveness of these actions is not yet complete, and it is unclear whether concerns with process validation have been adequately addressed for other products subject to sealing at your facility. Your response stated that all seals are subject to visual inspection and, therefore, any nonconforming seals would be detected prior to release; however, visual inspection is not a substitute for adequate process validation.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Corrective and Preventive Action Violations – Brooklyn Park, Shirakawa, Hinode, Hachioji, Hamburg, and Aomori facilities:\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>6. Failure to identify the action(s) needed to correct and prevent the recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3). Specifically,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm failed to identify corrective actions that address the full scope of multiple Line Clearance Control nonconformances on the Miscellaneous Urology Production Line. CAPA-201354 was opened on August 31, 2023, and included automated verification steps and automated inspections on the lines. However, the CAPA only included implementing the automated verifications for the Soltive laser fibers and did not address corrections for any of the other products made on the Miscellaneous Urology production line, including nonconformances associated with missing syringes in the Irri-Flow line or incorrectly labeled RB Electrodes, as listed in the CAPA Initiation Information.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened and is developing an action plan for CAPA-203705, which revealed that the Miscellaneous Urology product line lacks sufficient process controls and robust automation and further noted that this technical gap creates a potential for the recurrence of nonconformances. While a quality plan was developed per GSOP-5.5-1 Rev AB \u003Cem>Quality Plans\u003C\u002Fem> to address the remaining implementation requirements for this line, the execution of these corrective actions occurred outside of the formal CAPA framework and did not include verification of effectiveness.\u003C\u002Fp>\u003Cp>ii. Your firm failed to identify corrective actions to address ongoing Supplier Quality Performance rate failures for Vizishot endoscopic aspiration needle slider components. CAPA-202086 was opened on August 15, 2024, to address the Supplier Quality Performance rate (SQ3) not meeting the KPI objective for more than three months in a row. The investigation identified root causes related to supplier capability gaps, including inadequate manufacturing processes, insufficient purchase order review, and delayed drawing revisions. A separate NCR-00028865 due to a SQ2 KPI signal (Part Failure Rate) was escalated to CAPA-202086 on May 20, 2025. CAPA-202086 was closed on October 16, 2025, with no corrective or preventive actions taken, and the SQ3 KPI was eliminated without addressing the underlying quality problems or providing a rationale for no action taken.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203869 confirmed that the early closure of CAPA-202086 occurred because GSOP-00023, Rev AF \u003Cem>Global Corrective Action and Preventive Action Management\u003C\u002Fem> and GWI-00014, Rev AB \u003Cem>CAPA Management Work Instruction\u003C\u002Fem> – Agile did not clearly define requirements for early closure rationale or verification of linked records. An action plan is being developed but has not yet been implemented for CAPA-203869.\u003C\u002Fp>\u003Cp>iii. Your firm identified a root cause for the blue ring on the Powerseal vessel sealing device detaching from the rotation knob during use (operator error during assembly) but failed to implement corrective actions consistent with that root cause. CAPA-200547 was opened on July 22, 2022, for the detachment, which resulted in a recall (RES 90788). The CAPA found the root cause was an operator error during assembly and not the out of specification supplier component originally documented in the HHA FY23-OSTA-07. However, the scope of corrections for the recall were based on supplier component lots and the scope was not expanded to include all devices assembled during the period when the operator error occurred, allowing potentially defective devices to remain in distribution.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened CAPA-203868 and noted that the Health Hazard Assessment (HHA) and Field Corrective Action (FCA) for CAPA-200547 were not reassessed after the identified root cause changed, as procedure GSOP-00023 Rev AF \u003Cem>Global Corrective Action and Preventive Action Management\u003C\u002Fem> did not define requirements for re-evaluation when new investigation findings modify the identified failure mode. Your firm indicated that since the process is shared among sites, the process related aspects of this observation are being addressed separately under Global CAPA-203799. An action plan is being developed but has not yet been implemented for CAPA-203868.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm failed to identify corrective actions needed to correct and prevent the recurrence of known quality problems associated with the UHI-4 insufflation system. CAPA-200872 identified pressure sensor failures as the root cause of front panel display issues; however, you relied on prior corrective actions (SCAR-Shirakawa-152-06) and concluded that the risk remained acceptable despite 325 complaints. Your firm failed to implement adequate corrective actions to address supplier control failures, complaint trending deficiencies, and design and risk management process gaps that allowed these repeated failures. As a result, your supplier control processes failed to prevent defective components from entering production and your quality system failed to detect and escalate recurring defects.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response noted planned corrective actions, including reliance on global CAPA procedures (GSOP00023) and proposed improvements to complaint trending, supplier controls, and risk management processes. You indicated that CAPA deficiencies continue to be addressed through ongoing local and global CAPAs and that you have initiated additional CAPAs (e.g., CAPA-203879, CAPA-203856, CAPA-203877).\u003C\u002Fp>\u003Cp>c. At the Hinode facility, your firm’s CAPA procedures failed to ensure that corrective actions addressed the root causes and prevented recurrence. Between October 2022 and September 2025, three CAPAs (CAPA-200736, CAPA-201399, CAPA-203398) were opened for wrinkle defects in sterile barrier seals across five products (MAJ-2315, MAJ-1555, MAJ-209, MAJ-210, MAJ-287). Each CAPA identified inadequate process validation as a contributing factor, yet none implemented corrective actions to address the underlying validation methodology deficiency that allowed critical process parameters to be missed. For example, CAPA-203398 identified the root cause as \"Method Inadequate validation\" but did not implement corrective actions to address the validation failure. CAPA-201399 identified wrinkles across multiple products but concluded that inspection would remove nonconforming product, without implementing corrective actions to the validated processes producing defects. CAPA-200736 \u003Cstrong>(b)(4)\u003C\u002Fstrong> to address wrinkles but did not investigate why \u003Cstrong>(b)(4)\u003C\u002Fstrong> identified in initial validations. Wrinkle defects may create channels for microbial contamination.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm characterized the pattern of recurring CAPAs for seal defects as representative of continuous improvement, citing decreases in defect rates, and your firm characterized the sealing processes as “under control”. However, ongoing nonconformances were initiated for wrinkles even after CAPAs were initiated. Your responses do not appear to address why your CAPA process allowed the same problem to require three separate CAPAs over three years without implementing corrections to the validation methodology.\u003C\u002Fp>\u003Cp>d. At the Hachioji facility, your firm failed to identify corrective actions for CAPA 201212, initiated June 20, 2023, in response to an FDA Additional Information request related to a patient death following use of the Evis Exera III Bronchovideoscope. Your CAPA documented that your firm failed to conduct design verification for use conditions and accessory compatibility claims in your IFU; however, no corrective actions were taken to address these design control deficiencies and the suspension of shipping was lifted on July 28, 2023. Your investigation revealed that your firm received 210 similar complaints and your investigation was not completed until November 14, 2025, over two years after CAPA initiation and your decision to continue shipping the devices.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\u003C\u002Fp>\u003Cp>7. Failure to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm implemented actions to address root causes of a Vizishot II component mix-up without classifying them as corrective actions and verifying their effectiveness. CAPA-203041 was opened on June 30, 2025, for the use of the 21G slider components instead of the 22G on the Vizishot II NA-U401SX-4022 line. The Early Closure memo states that “operators were retrained on the line clearance procedure GWI-0705-16 and \u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was modified to restrict access to the sides…”. Neither of these actions were considered a corrective action, nor was a verification of effectiveness conducted to ensure these actions prevented recurrence of the component mix-up.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203041 was prematurely closed because actions taken under the NCR were misclassified as corrections, even though they addressed root-cause-level factors that required corrective actions and verification of effectiveness (VOE). GSOP-00023 Rev AF \u003Cem>Global Corrective Action and Preventive Action Management\u003C\u002Fem> did not explicitly distinguish correction from corrective action within the CAPA workflow, which contributed to the omission of VOE. Your firm also indicated an action plan is being developed but has not yet been implemented for CAPA-203705.\u003C\u002Fp>\u003Cp>ii. Your procedures, \u003Cem>Quality Planning\u003C\u002Fem> QSP-5.5 Rev AL and \u003Cem>Quality Plans\u003C\u002Fem> GSOP-5.5-1 Rev AB, have not adequately defined when quality plans contain corrective or preventive actions and should contain a verification that changes are effective and do not adversely affect devices. These procedures do not adequately define the difference between a quality plan and a corrective or preventive action. Additionally, during the inspection your firm had 54 quality plans open, including multiple plans intended to address backlogs in the complaint system and late MDRs. These quality plans directly address deficiencies in your quality system and are also being referenced within and in conjunction with CAPAs addressing the same issues.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203836 determined that the current procedures lack defined criteria for determining when a Quality Plan is not appropriate and a CAPA is required and does not require oversight to ensure appropriate use and completion tracking of Quality Plans. The \u003Cem>Quality Management Review Presentation Template\u003C\u002Fem> GTMP-00077 was revised to require that quality plans be reviewed as part of the Quality Management Review process. The scope of affected quality plans that lacked VOE was not provided. An action plan is being developed but has not yet been implemented for CAPA-203836.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm failed to verify that corrective actions implemented for overpressure events for the UHI-4 Insufflator were effective in preventing recurrence. For example, CAPA-200872 (opened February 2023) relied on prior corrective actions related to pressure sensor failures and concluded that these actions were effective without demonstrating that they prevented recurrence of similar defects or adequately mitigated risk in distributed devices. CAPA-201353 (opened August 2023) was subsequently opened to address overpressure events associated with the UHI-4 insufflation system only after significant adverse events occurred, including cardiac arrest and possible gas embolism, and resulted in a Class I recall (RES 92932). Your CAPA activities did not demonstrate that corrective actions were verified or validated to ensure effectiveness in preventing recurrence of overpressure-related failures.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Several CAPAs remain open, and you have not demonstrated that corrective actions have been verified or validated to ensure effectiveness or to prevent recurrence of similar defects, including overpressure-related failures.\u003C\u002Fp>\u003Cp>8. Failure to analyze processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility, your firm is using statistical methods for complaint trending without a documented rationale for the appropriateness of those methods. \u003Cem>Complaint Trending Attributes, Statistical Method, and Trending Rules\u003C\u002Fem> GREF-00157 Rev AA defines your complaint quality data analysis method of using median values and recalculating control limits each month. During the inspection your employees noted the calculations used were originally chosen in 2020, due to COVID-related data irregularities. However, you acknowledged that your firm does not still see these data irregularities and confirmed your firm has not documented a re-assessment or other justification for why this analysis method is still appropriate. The use of median values and monthly recalculation of control limits (that may not be appropriate for post-COVID data) may mask trends or delay detection of increasing complaint rates, potentially allowing serious device problems to persist undetected.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203873 determined that Olympus lacks a global procedure or guidance for statistical techniques, resulting in the absence of defined expectations for the consistent implementation of statistical methods. An action plan is being developed but has not yet been implemented for CAPA-203873.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm did not adequately analyze quality data, including complaints and adverse event information, to identify causes of quality problems. For example, you received a high volume of complaints related to pressure sensor defects and front panel failures associated with the UHI-4 insufflation system (including 325 complaints between November 2020 and October 2022), yet you did not appropriately trend or escalate these data to identify a cause or initiate CAPA in a timely manner. Additionally, you were aware of pressure sensor defects as early as 2018–2021 but did not reassess risk or investigate the increased occurrence of these defects in distributed devices. A CAPA was not initiated until FDA inquiry, indicating that your quality system did not effectively analyze available data sources, including complaints, supplier information, and risk management records.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your response states that CAPA deficiencies are being addressed through a combination of local and global CAPAs, including local CAPA-203879, CAPA-203856, CAPA-203850, and global CAPA-203789, CAPA-203525, and CAPA-204150. You indicate that updates to procedures, including GSOP-00023 (CAPA), GSOP-00033 (complaint trending), GSOP-00069 (supplier quality agreement), and GSOP-00079 (supplier corrective action), have been implemented or are in progress. You also state that retrospective reviews of complaint data and supplier corrective action requests have been conducted. Several CAPAs remain open and root cause investigations and corrective actions are ongoing. Additionally, you indicate that certain local CAPAs will be closed early and that corrective actions will be addressed under global CAPAs, which limits the ability to assess whether site-specific deficiencies have been adequately addressed. Your response further confirms that complaint trend signals were not adequately identified and that supplier-related defects were not appropriately evaluated for field impact at the time they were identified. You have not provided sufficient objective evidence demonstrating implementation or effectiveness of corrective actions, including completion of investigations, verification of corrective actions, or sustained improvements to your CAPA system.\u003C\u002Fp>\u003Cp>c. At the Hamburg facility, your firm’s complaint trending failed to include all complaints as required by your procedure. \u003Cem>Trending Attributes, Statistical Method, and Trending Rules\u003C\u002Fem> GREF-00157 Rev AA, section 4.4.2 states “trending will be based on the value of monthly data (i.e. actual number of open complaints per month).” However, trend signal information (TS-1224-WA50042A) for your video telescope (model WA50042A) only includes the trending of MDR reportable complaints and does not include non-reportable complaints.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your response did not include an assessment of how the lack of trending of non-reportable complaints may impact already distributed product. For example, if the complaints reveal quality problems that may require correction or removal to address.\u003C\u002Fp>\u003Cp>d. At the Aomori facility,\u003C\u002Fp>\u003Cp>i. Your firm failed to adequately analyze quality data to identify causes of nonconforming product. CAPA-201434, which was initiated to address reports of deformed wires for the Single Use 3-Lumen Sphincterotome, incorrectly identified the root cause as “shortcomings in work procedures” during outsourcing, failing to recognize inadequate design transfer to production specification as the actual cause. Per the CAPA scope, the corrective actions only applied to products distributed to the Japanese market and were not implemented for devices distributed to the U.S. market. It was noted during the inspection that the CAPA task (Task 10012651) assigned to correct the manufacturing process for products destined for the U.S. was cancelled because the products are subject to FDA 510(k) and it would have taken longer to implement the changes which would “prolong the period until the CAPA closes.” Your firm received over 1000 complaints for this device failure, including 24 MDR reportable events.\u003C\u002Fp>\u003Cp>ii. Your firm failed to conduct a timely and adequate analysis of complaint data related to potential causes of nonconforming product for the Thunderbeat 5 mm Front-actuated Grip Type S. Your firm received over 1900 complaints between September 2021 and September 2024, including 1583 that were MDR reportable. CAPA-201438 was initiated on October 18, 2023, but no action was taken as the Health Hazard Evaluation was canceled on January 31, 2024, because it was deemed not necessary based on complaint incident rates and without considering the potential harm to patients. A recall (RES 95950) was initiated on November 25, 2024, over a year later.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response for (i) and (ii) above cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Acceptance Activities Violations – Brooklyn Park and Shirakawa facilities:\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>9. Failure to establish and maintain procedures for acceptance of incoming product, as required by 21 CFR 820.80(b). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility, your firm failed to conduct statistical calculations required to demonstrate lot acceptability in accordance with your procedure. \u003Cem>Receiving Acceptance\u003C\u002Fem> GSOP-7.11-1 Rev AT uses a variable sampling plan for receiving inspection of part number 0000315-TAB, according to \u003Cem>Inspection Procedure for 0000315-TAB JAW ASSEMBLY, MACHINED, INNER, POWERSEAL CURVED JAW B\u003C\u002Fem> DN0040655 Rev AE. However, your receiving inspection for each length of this part (PN 0000315-001, 0000315-002 and 0000315-003) does not include calculation of your standard deviation, kLSL, and kUSL as required by GSOP-7.11-1. Additionally, your acceptance procedure for Powerseal Curved Jaw B only includes a specification for sample calculation for dimension 9 but does not document a calculation of the maximum standard deviation (MSD) for any other dimension as required. Finally, your Supplier D also uses the sampling plan, but does not provide you with their standard deviation, kLSL and kUSL calculations. The calculations for standard deviation, lower controls limits and upper control limits are part of the variable sampling plan that demonstrate the acceptability of the lot.\u003C\u002Fp>\u003Cp>Your inspection procedure also allows for CMM measurements to be re-tested by another inspector if they do not pass initially. This was done for 8 of the 10 samples in the \u003Cem>FAI Inspection Request\u003C\u002Fem> for part number 0000315-002, dated March 20, 2025. The only rationale recorded was \"Believed fixture incorrect.\" Our inspection also found that retesting had occurred on all of the most recent receiving records for all sizes of the 000315-TAB. Part Number 0000315-001 was inspected on October 23, 2025, and the record includes failing CMM results for 5 of the 10 parts, as well as the retested data, but the parts were accepted into inventory. When our investigator communicated this to your employee, it was noted that this lot was accepted by mistake and NCR-00048701 was opened to contain the nonconforming material.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203866 was opened to capture corrective actions and noted that GSOP 7.11-1 Rev. AU, \u003Cem>Receiving Acceptance\u003C\u002Fem>, and the inspection procedures did not define the statistical requirements, resulting in incomplete evaluation of incoming product and acceptance of parts without proper statistical justification. Your response noted that you have updated the inspection procedures for all parts subject to ANSI\u002FASQ Z1.9 to require inclusion of sample size rationale for critical dimensions and to ensure that data is provided by their suppliers. Your firm plans to conduct a retrospective review of inspection records from the past 2 years for failed dimensions without a record of appropriate retest or passing results. Based on the results of the review you will take appropriate action; however, it is not clear what those actions would include, nor if the actions will include a risk assessment for product that has been distributed.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm failed to identify defective components used in the UHI-4 insufflation system during acceptance activities. For example, defective pressure sensor components were not identified through incoming inspection or acceptance testing prior to use in manufacturing. As a result, nonconforming components were incorporated into finished devices, contributing to reports of device malfunctions and adverse events received by your firm.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response states that improvements to incoming acceptance activities will be implemented as part of broader corrective actions, including updates to ensure that purchased materials meet specifications. However, you have not provided sufficient detail demonstrating that revised acceptance activities have been implemented or are effective in detecting nonconforming components.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Purchasing Controls Violations – Brooklyn Park, Shirakawa and Hamburg facilities:\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>10. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product, and services conform to specified requirements, as required by 21 CFR 820.50. For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm’s supplier controls procedure (GQS-00013) does not ensure that supplied product that cannot be fully verified by subsequent inspection and test is validated with a high degree of assurance and conforms to specified requirements. On December 4, 2023, your firm issued SCR-0000649 for an increased rate of complaints for broken welds in the ESG PK Cutting Forceps (model PK-CF0533), occurring in the supplied bottom and top jaw assemblies (part numbers P5700259-001 and P5700260-001, respectively). Supplier A determined the cause of the weld breaking was a sub-supplier, Supplier B. In SCR-0000649, Supplier A documented that Supplier B stated the welding process \"could not be controlled or validated.\" Your firm established increased inspection rather than requiring validation or changing suppliers. This complaint trend resulted in a recall (RES 93842) in December 2023. This unvalidated welding process has resulted in weld failures during patient use, creating risk of foreign bodies in patients assessed at Critical (S4) severity and High (S5) probability. Similar welds are also performed by Supplier B for your Halo and Cutting Forceps. Approximately 4,600 units with similar unvalidated welds have been distributed. During the inspection, your firm initiated an NCR and a Global Ship Hold.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203871 was opened to address the failure to ensure welding performed by the supplier was validated. The CAPA root cause investigation identified that the QAA template used to finalize the Supplier Agreement back in 2014 did not incorporate process validation requirements for suppliers and their Sub-Tier suppliers. Moreover, the Global QAA templates GTMP-00021 Rev AB \u003Cem>QAA Template for Component Suppliers\u003C\u002Fem> and GTMP-00022 Rev AB \u003Cem>QAA\u003C\u002Fem> \u003Cem>Template for Finished Device Suppliers\u003C\u002Fem> lack specificity on sub-tier control for process validation. All impacted product remains on Global Ship Hold (ID 476), and you have halted the manufacture of affected product. The FCA board reviewed and decided to conduct a removal of the impacted products. Your response stated you would submit a Correction and Removal report in compliance with 21 CFR Part 806 requirements. Although an expansion of the recall is being performed, it has been over 2 years between awareness (December 4, 2023) and recall decision (February 3, 2026). Your firm has not explained the delay or assessed patient harm during this period.\u003C\u002Fp>\u003Cp>ii. Your firm accepted failing process capability data after components were remeasured without justification. SCR-0000166 was issued to Supplier C for out of specification components. The investigation led to two design changes to the mating parts used in the Powerseal vessel sealing device: the blue ring (part PN0013810) and the overmolded rotation knob (part PN0013804) and resulted in a class II recall (RES 90788). You accepted first article inspection that included Supplier C “Validation Documents Submission” where parts were remeasured with passing results, “Ppk’s for Cav 2 on PQ1 was right at 1.39 and PQ2 was 1.36 failing the Ppk requirement per protocol of 1.39. 2 parts were remeasured and Ppk came into requirement.” There is no justification for why these remeasurements were considered appropriate.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203872 is ongoing, and the root cause investigation identified that the supplier procedure permitted data remeasurement without documented justification and did not define requirements for documenting the rationale or controls associated with remeasurement activities. In addition, GSOP-00086 Rev AA \u003Cem>Global External Product Qualification\u003C\u002Fem> lacked requirements for justification of remeasurement. Your firm’s response notes that you have planned the process to requalify Supplier C against new global procedure requirements by March 27, 2026, including a new Quality Agreement. The impact on released product has not been evaluated since this will involve the remeasurement at incoming testing after you have updated GSOP-00086 that governs the conditions and permissibility for remeasurement. Your firm has not provided interim results or identified how many additional components may be affected. Your response should also include a retrospective review of similar supplier processes that pose a potential for patient safety risk.\u003C\u002Fp>\u003Cp>iii. Section 3.5 of \u003Cem>First Article Inspection\u003C\u002Fem> GSOP-7.11-2 Rev AG, allows suppliers on risk improvement plans with documented quality concerns to conduct first article inspections without additional verification by your firm. For example, Supplier D has been on a risk improvement plan since January 21, 2025, but a \"Supplier conducted FAI\" for part number 0000315-002, delivered on or before March 5, 2025, and used in the Powerseal vessel sealing device. The process is currently controlled by the two procedures \u003Cem>Global Supplier Risk Improvement \u003C\u002Fem>GSOP-00045 Rev AB and \u003Cem>Global Supplier Risk Improvement with Action Plan\u003C\u002Fem> GWI-00002 Rev AB. Despite the supplier providing out-of-specification components and being on a supplier risk improvement plan, your firm failed to consider the appropriateness of the supplier performing first article inspection measurements following a design change or when implementing a new component.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203866 identified that GSOP-00045 Rev AB \u003Cem>Global Supplier Risk Improvement\u003C\u002Fem> does not require evaluation of internal inspection plans when supplier risk improvement plans are issued or revised in response to changes in part failure rate. Additionally, the procedure lacks defined linkage between supplier risk improvement plans and corresponding receiving inspection requirements. It is not clear from your response whether there is nonconforming product in the field associated with suppliers who are on a heightened inspection status or risk improvement plan and who conducted their own supplier first article inspections.\u003C\u002Fp>\u003Cp>iv. Supplier A has not adequately validated their \u003Cem>Performance Qualification Report\u003C\u002Fem> PQR-10774 Rev A for part number P5700138-001, used to support the weld tensile strength in your legacy Cutting Forceps. According to your firm’s Engineer, the worst-case weld is considered the shortest weld of the group, as the welds all have to meet a minimum weld pull strength of 30 lbs. However, part P5700138-001 has a weld length specification of 0.10 ± 0.02 inches, while parts P5700211-002 and P5700210-002 have a shorter weld length specification of 0.081 ± 0.02 inches.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203871 was opened and a Health Hazard Assessment (HHA) FY26-062 was conducted to evaluate potential field action. On February 3, 2026, the FCA board reviewed and decided to conduct a removal of the impacted products in the Cutting Forceps product line (RES 98454). Olympus completed the review of validations for Supplier A to determine conformance with Global GSOP-00002 Rev AD \u003Cem>Validation Program\u003C\u002Fem> and GWI-00112 Rev AA \u003Cem>Global Standards for External Product Qualification\u003C\u002Fem> for worst-case trials with documented rationale. The review determined that three (3) components manufactured by Supplier A require additional process validation. The review, however, was limited to products with an active production schedule. Products that have reached end-of-life and are in the process to be discontinued were excluded from the scope (jaw assemblies, ESG Cutting Forceps, Halo, Everest 5mm Cutting Forceps, and PKS Cutting Forceps). It is not clear from your response whether there is product within expiry date that is still in commercial distribution. Your firm will complete a review of applicable supplier-manufactured components documentation, through collaboration with suppliers to identify potential validation gaps.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm did not adequately control suppliers to ensure that components used in the UHI-4 insufflation system met specified requirements. For example, pressure sensor defects associated with supplier-provided components were identified; however, your supplier control processes did not prevent nonconforming components from being incorporated into finished devices. Your CAPA investigations did not adequately evaluate why supplier controls were ineffective or ensure that appropriate corrective actions were implemented to prevent recurrence of similar supplier-related defects. Root cause analysis identified gaps in supplier change control procedures and audit processes, including lack of mechanisms to verify supplier changes against specifications.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined. Your response states that supplier control deficiencies are being addressed through local and global CAPAs, including CAPA-203856 and CAPA-203789, and that supplier oversight processes will be enhanced through updated supplier quality agreements and risk-based supplier requalification activities. You also indicate that procedures, including GSOP-00079, have been updated to require assessment of field impact for supplier-related defects. However, investigations into supplier-related root causes remain ongoing, and corrective actions have not been fully implemented. Additionally, you indicate that certain local CAPAs will be closed early and that corrective actions will be addressed under global CAPAs, which limits the ability to assess whether site-specific supplier control deficiencies have been adequately addressed. You have not provided objective evidence demonstrating that revised supplier controls are effective in preventing recurrence of nonconforming components.\u003C\u002Fp>\u003Cp>c. At the Hamburg facility, your firm failed to ensure that purchased services conform to specified requirements. Your firm hired HCL Technologies as part of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to reduce the backlog of complaint investigation and closures; however, your firm did not evaluate HCL Technologies on the basis of their ability to provide contract services to meet specified quality requirements, including their ability to provide qualified staff to perform quality assurance responsibilities. Your firm’s contract services included approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> temporary personnel to investigate and close complaint files. Your firm was unable to demonstrate that the contract personnel received product specific training.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your firm initiated CAPA-204033 and CAPA-204034. Your firm indicated that your root cause investigation determined that there was no central governance defining shared services requirements within the Quality Management System (QMS) and that as a result, roles and responsibilities between Legal Manufacturers, Global QMS functions, and shared service owners were not consistently defined or understood, leading to fragmented accountability for end-to-end oversight. Your firm is developing a corrective action plan; however, you have not provided corrective actions demonstrating how you will ensure contract personnel are qualified and trained in the services they will perform.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Records Violations – Brooklyn Park and Shirakawa facilities:\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>11. Failure to review, evaluate and investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, as required by 21 CFR 820.198(c). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility, your firm's procedure, \u003Cem>Complaint Investigation Tiers and Investigation Activities\u003C\u002Fem> GWI-0809-10 Rev BB, does not require investigations to be completed on complaints in investigation Tier 3. For example, complaints C22097460, C22184070, C22248777, C22249599, C22259835, C22279317, C22332770, and C22387391 all state in the investigation summary that the complaints are “non-PAE, Tier 3 codes. No investigation is required,” in the “Evaluation Result” section (PAE stands for potential adverse event). There is no documentation of a complaint investigation or reference to where an investigation for this failure has previously been investigated or other similar rationale for why this investigation is not required. Lack of investigation only allows trending on this subset of complaints based on date of receipt and device model. After transitioning to your current Trackwise system in November 2024, you indicate you no longer use a tier system; however, your trending is based on 24 months of historical data which is still limited by the lack of investigation results on potential device performance issues.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your response does not address the failure to investigate complaints.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm failed to adequately investigate complaints involving serious adverse events to determine whether device malfunction contributed to the reported outcomes. For example, complaints associated with UHI-4 insufflation systems, including reports of overpressure events and serious adverse outcomes such as cardiac arrest and possible gas embolism, were not fully evaluated to determine whether device malfunction contributed to the reported events. Your complaint investigations did not consistently incorporate available device performance data to determine whether the device met specifications during use. For example, complaint CN-249953 reported a death due to gas embolism during use and included the device event log retrieved by the Field Service Engineer; however, this log was not reviewed as part of the investigation.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. You state that complaint handling and trending processes have been improved through implementation of GSOP-00033 and that retrospective reviews of complaint data have been conducted to assess whether complaint signals were appropriately escalated. You also indicate that CAPA-203879 was initiated to address missed complaint trend signals. However, CAPA-203879 and related investigations remain ongoing, and you have not provided sufficient objective evidence demonstrating that complaint investigations are comprehensive or that systemic issues are consistently identified and escalated.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection at your Hamburg facility also revealed that your firm’s resection sets are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>12. Failure to report the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that the firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that the firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\u003Cp>For example, the information included in Complaints CN-182867 and CN-184790 reasonably suggests that your firm’s resection set malfunctioned (e.g., broken ceramic insulation) while in use. A serious injury MDR 2951238-2019-00404, submitted by your firm on February 1, 2019, documents a serious injury resulting from the same malfunction involving the same device. That malfunction would be likely to cause or contribute to a death or serious injury if it were to recur, as evidenced by the serious injury MDR 2951238-2019-00404. Accordingly, the referenced adverse events represent MDR-reportable malfunctions as defined under 21 CFR 803.3. Your firm became aware of complaint CN-182867 on February 13, 2025, and submitted the corresponding MDR 9610773-2025-06509 on October 20, 2025; and became aware of CN-184790 on February 12, 2025, and submitted the corresponding MDR 9610773-2025-04016 on June 16, 2025. These two MDRs were submitted beyond the required 30-calendar-day reporting timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. The response states that your firm initiated CAPA-204035 to address late reporting, including revising procedures to correctly document event dates and the dates your firm became aware of the events. However, supporting evidence demonstrating completion of these corrective actions was not provided because the corrective actions are still ongoing.\u003C\u002Fp>\u003Cp>Failure to address any violations of the FD&amp;C Act may result in the FDA refusing admission of the devices manufactured by your firm into the United States under section 801(a) of the FD&amp;C Act, 21 U.S.C. § 381(a). Devices under this authority that appear to be adulterated may be detained or refused admission.\u003C\u002Fp>\u003Cp>Your firm should provide a written response to this Warning Letter as described below and address the violations described in this letter. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facilities to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspections conducted between October 2025 and December 2025 were conducted pursuant to the QS Regulation, which was in effect at the time of the inspections. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>In addition, we also note the following comments:\u003C\u002Fp>\u003Cp>1. In response to three prior warning letters issued to your firm in 2022 and 2023 (including the Hachioji and Hinode facilities), your firm implemented new global procedures, including complaint handling, MDR, and CAPA procedures. Review of these procedures found the roles and responsibilities of manufacturing sites versus your global remote corporate entity have not been clearly defined, including, for example, how your firm will assess that site specific quality issues have been resolved, and how your global CAPA process will provide oversight and ensure correction and prevention of repetitive quality issues within and across your global facilities that follow these procedures.\u003C\u002Fp>\u003Cp>2. Regarding the inspection of Olympus Corporation of the Americas, located at 3500 Corporate Pkwy, Center Valley, PA 18034, FEI 2429304, from November 18, 2025, to December 16, 2025: Multiple complaint files reviewed during the inspection were found to contain insufficient documentation of complaint intake, evaluation, and investigation conclusions. Complete complaint files provide your firm with critical information to detect and trend medical device failures and to make reportability decisions.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to \u003Cstrong>Kristina Donohue\u003C\u002Fstrong> at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “\u003Cstrong>CMS #729208\u003C\u002Fstrong>” when replying. If you have any questions about the contents of this letter, please contact: \u003Cstrong>Beckilyn Dorsey\u003C\u002Fstrong> at \u003Cstrong>Rebecca.dorsey@fda.hhs.gov.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F&nbsp;\u003Cbr>Michael J. Hoffmann&nbsp;&nbsp;\u003Cbr>Director&nbsp;&nbsp;\u003Cbr>Office of Health Technologies 3 - Gastrorenal, ObGyn,\u003Cbr>General Hospital, and Urology Devices\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Todd Brill, US Agent, Gyrus ACMI, Inc., \u003Cstrong>(b)(6)\u003C\u002Fstrong>@Olympus.com\u003Cbr>Daniel S. Sampson, Senior Director of Operations, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Richard Reynolds, President, Olympus Corporation of the Americas, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Hiroaki Hosoi, President, Aomori Olympus, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Kota Ishibiki, President, Olympus Medical Systems Corporation \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Shinji Egami, Senior Director, Olympus Medical Systems Corporation, Hinode, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Seiji Morishita, President, Shirakawa Olympus Co., Ltd., \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Carl A. Yallop, Vice President OSTE, SIS Operations &amp; ISC and Managing Director, EMEA, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nOlympus Medical Systems Corporation\n\n2951 Ishikawa-machi\n\nHachioji-shi, Tokyo\n\n192-8507\n\nJapan\n\n(b)(6)@olympus.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nCMS #729208\nOctober 7, 2026\nDear Mr. White:\nThe United States Food and Drug Administration (FDA) conducted the following inspections of your firm’s medical device facilities:\nOlympus Medical Systems Corporation, located at 2951 Ishikawa-Cho, Hachioji-Shi, Tokyo, JP 192-8507, FEI 3002807795, November 17, 2025, to November 21, 2025 (“Hachioji”)\nAomori Olympus Co., Ltd., located at 2-248-1 Okkonoki, Kuroishi-shi, Aomori, JP, 036-0357, FEI 3003995201, from November 4, 2025, to November 7, 2025 (“Aomori”)\nOlympus Medical Systems Corp. Hinode Plant, located at 34-3 Hirai, Hinode-Machi, Nishitama-Gun, Tokyo, JP, 190-0182, FEI 3003637092, from November 17, 2025, to November 21, 2025 (“Hinode”)\nShirakawa Olympus Co., Ltd., located at 3-1 Okamiyama, Odakura, Nishigo-Mura, Nishishirakawa-Gun, Fukushima, JP 961-8061, FEI 3002808148, November 10, 2025, to November 14, 2025 (“Shirakawa”)\nOlympus Winter & IBE Gmbh, located at Kuehnstrasse 61, Hamburg, DE 22045, FEI 3002807798, from November 10, 2025, to November 21, 2025 (“Hamburg”)\nGyrus ACMI, Inc. [dba Olympus Surgical Technologies (OSTA)], located at 9600 Louisiana Ave North, Brooklyn Park, MN 55445, FEI 3011050570, from October 6, 2025, to November 12, 2025 (“Brooklyn Park”)\nDuring these inspections, our investigators determined that your firm manufactures a variety of surgical and endotherapy devices, including but not limited to, hemostatic metal clips, sphincterotomes, cystoscopes, bronchoscopes, endoscopic distal covers, valves, and insufflators. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nQuality System Regulation Violations\nThe above-referenced inspections revealed that the devices manufactured at the Hachioji, Aomori, Hinode, Shirakawa, Hamburg, and Brooklyn Park facilities are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. This nonconformity includes issues across the referenced inspected facilities, resulting in the distribution of nonconforming devices and significant risks to patients.\nA Form FDA 483 (FDA 483), List of Inspectional Observations, was issued to the Aomori facility on November 7, 2025, the Brooklyn Park facility on November 12, 2025, the Shirakawa facility on November 14, 2025, the Hachioji facility on November 21, 2025, the Hinode facility on November 21, 2025, and the Hamburg facility on November 21, 2025. We received responses concerning our investigator’s observations noted on these FDA 483s from Robert A. Fryc, Director, Global Quality Compliance, External Regulatory Communications, Olympus Corporation of the Americas, dated December 22, 2025, February 13, 2026, March 30, 2026, May 28, 2026, and July 31, 2026. We address these responses (collectively referred to as “your firm’s response”) below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\nDesign Control Violations – Shirakawa, Aomori, Hamburg, and Hachioji facilities\n1. Failure to establish and maintain procedures for validating the device design to ensure that devices conform to defined user needs and intended uses and validation shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g). For example,\na. At the Shirakawa facility, your firm failed to identify and control known catastrophic hazards in your risk management documentation and failed to validate the device design under actual or simulated use conditions for the UHI-4 insufflator. Catastrophic hazards, including air embolism, arrhythmia, and patient death, were identified through Health Hazard Assessments and complaint investigations associated with CAPA-201353; however, your Risk Management Report (DC00067142, dated November 6, 2025) did not reflect these hazards or ensure implementation of appropriate risk control measures, even after a confirmed patient death and Class I recall of UHI-4 units in 2023. Further, your design validation did not simulate actual or worst-case use conditions related to pressure sensor failure or inaccurate pressure measurements to ensure that the device would operate safely. As a result, devices distributed had design deficiencies that contributed to overpressure events during clinical use.\nThe adequacy of your firm’s response cannot be determined. Your response states that design-related deficiencies are being addressed through global CAPAs, including CAPA-204150 (design control) and CAPA-203525 (risk management), and that a traceability matrix for the UHI-4 will be developed to evaluate design requirements, verification, and validation. You also indicate that additional design verification and\u002For validation testing will be performed as needed and that potential design changes will be assessed by the design owner (Olympus Hachioji). However, these activities remain ongoing, and you have not provided objective evidence demonstrating that design validation deficiencies have been corrected or that revised validation activities adequately address identified risks, including overpressure conditions. Additionally, corrective actions have been deferred to global CAPAs and another facility, and no documentation has been provided demonstrating completion or effectiveness of these actions.\nb. At the Aomori facility, your firm failed to identify and assess known hazards in the risk management documentation and failed to establish risk control measures for manufacturing processes for the Sphincterotome. In your risk management report (E_V-KD_Risk Management Report_Rev.27), the corresponding risk line ID (KD-G158-00) identifies the potential patient harm as “Delay in Treatment” for complaints of deformed wires but fails to include the higher risk identified through analysis of Medical Device Reports of unintended cutting of blood vessels leading to patient bleeding. It also fails to identify any risk control measures for the manufacture of the wire for the Sphincterotome. Additionally, the risk management report (DC00609260_20250910) does not include the known hazard of failure of the Automated Optical Inspection system to detect nonconforming Sphincterotome products (KD-V400 Series) with burrs and flakes and does not include risk control measures for this hazard, which can lead to tissue damage and procedural complications.\nThe adequacy of your firm’s response cannot be determined at this time. Your firm has not provided an updated Risk Management Report (DC00609260_20250910) to address the hazard and implement risk control measures for failure of the Automated Optical Inspection system to detect nonconforming Sphincterotome products (KD-V400 Series) with burrs and flakes. Additionally, your firm has not provided an updated risk management report (E_V-KD_Risk Management Report) to address the risk of unintended cutting of blood vessels leading to patient bleeding and risk control measures for manufacture of the wire.\nc. At the Hamburg facility, your firm distributed the Continuous Flow Cystoscope (model WA22810A) with instructions for use (IFU) that claimed compatibility with the GreenLight PV ADDstat laser fiber component without conducting design validation testing to ensure compatibility under use conditions. This resulted in two recalls, RES 95584 and RES 98300, due to a risk of damage and\u002For overheating to the tip of the sheath when used together. Unrecognized sheath damage can result in tissue injury or parts of the sheath breaking off into the patient.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response should include a retrospective review of similar devices with IFU compatibility claims to ensure that they are supported by design validation activities to ensure compatibility under use conditions.\nd. At the Hachioji facility:\ni. Your firm distributed the BF-1TH190 bronchoscope with instructions for use (IFU) claiming compatibility with CO2 lasers without conducting design validation testing to ensure compatibility under use conditions. This resulted in a class I recall (RES 93052), due to a risk of endobronchial combustion if high-frequency cauterization is performed while supplying oxygen and\u002For the electrode section of the electrosurgical accessory is too close to the distal end of the endoscope. If endobronchial combustion occurs, the patient may suffer adverse events, including internal burns in their airway or lungs. The related CAPA did not evaluate compatibility claims for all endoscopes and lasers.\nii. Design validation activities were not conducted with an understanding of the actual operating conditions for the Evis Exera Video Imaging System, used with your firm’s endoscopes for processing images. For example, design validation did not consider the conductivity of the electrolyte when it contained dust and moisture, nor did it consider the impact over time of water entering the scope during cleaning. This caused signal transmission problems and resulted in a significant number of complaints and MDRs for image erasure, image transition problems, and poor-quality images.\niii. Your firm failed to complete design verification testing after implementing a change to the 0.2 μm Water Filter (Part MAJ-2318) to demonstrate that the device meets established design requirements and acceptance criteria. This water filter is used in your OER-Elite and OER-Mini Reprocessors for cleaning and high-level disinfection of your flexible endoscopes, their accessories, and endoscope reprocessor accessories. Your firm’s design change control procedure, OMBS_S_7.3.9_01_001, requires design verification or validation for all changes. However, ECR ER00006389 (dated December 11, 2024) shows verification testing was incomplete. Document MAJ-318_DC00429244 establishes the requirements and acceptance criteria for the product, including a filter service life of at least one month; however, design verification and validation records did not demonstrate that the filter has a service life of at least one month.\niv. Your firm’s design change control procedure, OMBS_S_7.3.9_01_001, and Traceability Activities (OMBS W_7.3.3_03_002) require documentation of design traceability matrices. However, you have not implemented design traceability matrices for the following products: Evis Exera III Bronchovideoscopes, Evis Exera III Video System Center, Evis X1 Video System Center, Single Use Reloadable Clip Applicator, Endoscope Reprocessor, Evis Exera III Duodenovideoscopes. Without design traceability matrices there is no documentation demonstrating that all design requirements, including safety requirements, were properly verified and validated.\nThe adequacy of your firm’s response for (i) through (iv) above cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\nNonconforming Product Violations – Brooklyn Park and Hinode facilities:\n2. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). For example,\na. At the Brooklyn Park facility,\ni. Your firm reworked and distributed nonconforming Vizishot 2 FLEX (19G) devices without adequate justification that the rework addressed the cause of the nonconformance. NCR-00038111 was opened on July 30, 2025, to disposition nonconforming material subject to recall (RES 97303) for the detachment of the Vizishot 2 Flex 19G needle [laser cut hypotube (LCH)] after reported complaints and MDRs, including where the device may have contributed to a patient death during explant surgery to recover the detached needle. Your firm reworked product under NCR-00038111 and dispositioned passing products using an automated vision system for release, stating this minimized impact on any product safety, efficacy, or performance of the product\u002Fmaterial. However, the primary CAPA for the LCH ejection issues had not identified a root cause, and there were two additional CAPAs open related to the observed complaints (pebax material degradation and sheath snap lock not engaging), indicating other potential contributing factors to nonconformances. Additionally, your firm circumvented the ship hold in place under the NCR by changing the manufacturing date during rework, which allowed the release of those units.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203864 was opened and determined that the issue was linked to global processes GSOP‑00022 Global NC Management and GSOP‑00023 Global CAPA Management. The process related aspects of this observation are being addressed separately under Global CAPAs, CAPA-203799 and CAPA-204047. Your response acknowledged in CAPA 203864 that the eleven lots of product noted in NCR-00038111 underwent rework outside of your procedures. You reinstated the ship hold and quarantined all Vizishot 2 FLEX product. You executed product removal activities separately for Vizishot 2 FLEX (19G) devices, including a global removal decision made on December 11, 2025, with a corresponding 806 report submitted to FDA. Your firm’s corrective actions are ongoing under CAPA-203864, CAPA-203799 and CAPA-204047.\nii. Your firm failed to control all nonconforming Shockpulse Lithotripsy generators that were subject to recall due to a miswired component (RES 98360). NCR-00000670 was opened on June 1, 2022, to scope the units affected under recall FY23-OSTA-05, for the miswiring of the Shockpulse generator. This NCR did not include a scope of all affected devices, including 2 lots containing 21 and 25 sub-assemblies, 9 finished units, and 2 service units. NCR-00046008 was opened to address the scoping nonconformance.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203777 was opened and the root cause identified the need to evaluate process gaps in Global Nonconformance Management GSOP-00022, specifically related to scoping methodology, alignment with HHA\u002FFCA teams, and decision-making during NCR and Stop Ship activities. A Global Ship Hold for miswired ShockPulse generator units was initiated on November 12, 2025, and the recall scope was expanded on December 9, 2025, with an 806 report submitted to FDA. Your firm’s corrective actions are ongoing under CAPA-203777 and CAPA-204047.\nb. At the Hinode facility,\ni. Your firm failed to control nonconforming MAJ 210 single-use biopsy valves when devices failed durability testing during the investigation of CAPA 203270. This CAPA was initiated after receiving multiple complaints reporting fractures of the device, including MDR reportable events. Although devices failed testing during the complaint investigation, your firm did not initiate a nonconformance for these out-of-specification device failures. Your firm eventually initiated NCR-00030581 for the complaint trend, but not for the identified testing failures.\nWe reviewed your firm’s response and determined that it is not adequate. Your firm has initiated actions to address the MAJ-210 failures, including a shipping hold on the device, a plan to modify the device design, and an investigation into the complaint trend. Your response does not address why a nonconformance was not initiated when testing showed the product\u002Ffailed the durability specification per GSOP-00029 Global Complaint Investigation and was only later opened for the complaint trend. It is unclear if you plan to evaluate whether similar issues occurred for other devices and how you will ensure that complaint investigations result in CAPAs when appropriate.\nii. Your firm failed to control nonconforming devices with sterile barrier seal overlap defects that were found to impact seal integrity. A nonconformance (NCR-00025684) was initiated in March 2025 in response to observed defects in sterile seals from September 2024- January 2025. NCR-00025684 identified overlaps as a novel defect that was not included in your visual inspection procedures. CAPA-202690 concluded that because seal overlaps are a large wrinkle, inspectors trained to visually identify wrinkles would identify seal overlap defects. However, wrinkles and seal overlaps represent distinct sterile barrier defects. CAPA-203907 included a retrospective evaluation to demonstrate that existing visual inspection procedures were likely to identify seal overlaps, based on a blind test of engineers. However, this evaluation does not demonstrate that overlaps were identified at the time of the nonconformances.\nWe reviewed your firm’s response and determined that it is not adequate. You state that you are conducting an investigation and root cause analysis as part of your CAPA; however, this is in progress and the details of this investigation and corrective actions are not clear, and you have not yet provided objective evidence demonstrating completion or effectiveness.\nProduction and Process Controls Violations – Brooklyn Park, Hinode, Aomori, and Shirakawa facilities\n3. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). For example,\na. At the Brooklyn Park facility,\ni. Your firm failed to validate the heat sealing process for the (b)(4) Tray Sealer. The (b)(4) Tray Sealer (P4001467-001 Gyrus ACMI SN:01) Operational Qualification using Universal tray sealing nests, documented in Operational Qualification (OQ) Report D8201348-002 Rev AB, does not contain passing results for the challenge conditions at the high and low setpoints. The validation was intended to cover low setpoints of 200°F, 100 PSI, and 2.0 seconds and high setpoints of 265°F, 125 PSI, and 7.0 seconds. However, visual results showed all failures at the lower setpoints and all failures at the high setpoints for the Universal and PKS Omni products. Only the nominal settings (232°F, 115 PSI, 4.5 seconds) showed passing results, which do not match your current production setpoints (253°F, 118 PSI, 4 seconds).\nDuring the inspection, you re-executed the validation (D8201348-002, Revision AC). While this validation passed seal integrity and seal strength requirements at high and low challenge conditions, the deviation section notes that trays sealed at low settings had spottiness in the seal and trays from high settings had warp that would cause rejection during 100% visual inspection, demonstrating that the process is not capable of consistently producing conforming product throughout the acceptable setpoint ranges.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. You are in the process of implementing CAPA-203841 to address the root cause of inadequate process for assessing procedure revisions that resulted in earlier validations (Operational Qualifications) not being updated to meet regulatory requirements. Specifically, you plan to transition from Process Validation GSOP-7.5-1 to Global Process Validation GSOP-00002. Your response indicates that the retrospective re-validation of the heat sealers is complete except for the (b)(4) sealer for the Universal Tray products and the (b)(4) sealer for the Powerseal vessel sealing product line. You are currently assessing the risks associated with products manufactured and distributed using the (b)(4) Tray Sealer, which failed the retrospective re-validation. Regarding the retrospective revalidation of the (b)(4) heat sealer used for the Powerseal product line you have noted the OQ failed to meet seal width acceptance criteria as detailed in the protocol, however, the OQ\u002FPQ testing will not be repeated at the current process settings (temperature, time, pressure). You have indicated that you will communicate with FDA regarding any actions taken based on the outcome of the completed HHA for distributed product and failed retrospective revalidation.\nii. Your firm failed to validate the heat sealing process for tray material PN0003356 (45cm PETG Tray line) on the (b)(4) sealer SN01. The OQ Report for (b)(4) BM3025-E2W2 for 45cm packaging (DN0010012) and PQ Report for BP (b)(4) BM3025-E2W2 for 45cm packaging (DN0010301) for this material and setpoints is for sealer (b)(4), which was decommissioned and removed from use in 2023. Your firm did not provide documentation showing this material was validated on the (b)(4) sealer or justification for equipment equivalency.\nIn addition, your procedure Process Confirmation for Sterile Barrier Sealing GWI-0704-07 Rev AE dated April 4, 2024, allows for abbreviated validation runs for \"equivalent or duplicate equipment.\" This procedure allows for equipment with the same manufacturer and model number to be considered equivalent, regardless of the year purchased or any other modifications made to the sealers. There is no additional justification or testing required to establish equivalency of the equipment.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. You are in the process of implementing CAPA-203842 to address GWI-0704-07 REV AE, Process Confirmation for Sterile Barrier Sealing, and FM-7.4-3 REV AC, Sterile Barrier Sealing Confirmation, not aligning with GSOP-00002 REV AD, Validation Program, nor GSOP-7.5-1 REV BA, Process Validation. In addition, your response confirmed that the work instructions and form lacked objective evidence to justify equipment equivalency. You are in the process of completing a Health Hazard Assessment (HHA- FY26-071-A) to evaluate any risks associated with sterile barriers for distributed products.\niii. Your firm failed to operate your heat sealers at the validated setpoints used for the Powerseal vessel sealing products. Heat sealer numbers 19-11821 and 23-70915 are only calibrated for time at 5 seconds and 10 seconds, but the nominal setpoint is 3 seconds according to your procedure POWERSEAL MP: Tray Sealer Setup and Peel Test DN0044870 Rev AE. There is no documented justification on why this calibration is acceptable to demonstrate accuracy at the validated setpoint, or potential impact on packaging seal quality and sterile barrier integrity for the Powerseal products.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. For example, GSOP-7.18-1 REV AT, Control of Inspection, Measuring, and Test Equipment, does not ensure consistent implementation of calibration across the intended use range. Additionally, the supporting work instruction, GWI-0718-03 Rev AB Completing a Calibration Request Form, lacked sufficient clarity to implement the requirements of GSOP-7.18-1. Your firm plans to revise GWI-0718-03 to improve clarity, include a requirement to notify external calibration vendors of specification changes, and ensure calibration point selection is documented with clear rationale. The calibration request form (FM 7.18-1) will also be updated to provide traceability, reference the revised work instruction, and ensure alignment with validated set points. GSOP-7.18-1 will be updated to explicitly require calibration points to cover validated set points, document rationale for selected calibration points, and mandate re-evaluation of calibration points when validation parameters or process conditions change.\nb. At the Hinode facility, your firm failed to adequately validate critical process parameters of the (b)(4) to the heat sealing process. An Operational Qualification (OQ) for the heat sealing process for the MAJ-210 Single Use Biopsy valve was conducted in July 2024, after (b)(4) to the heat sealing packaging process to address seal wrinkle defects; however, the process parameters and validation are inadequate. The process parameter range shown in the Operational Qualification lists a lower set value of (b)(4) liters\u002Fminute and a higher set value of (b)(4) liters\u002Fminute, which is flawed because the \"lower\" limit exceeds the \"higher\" limit. The OQ documentation does not detail how the (b)(4).\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm completed an investigation and root cause analysis under CAPA-203908, and as a result, updated GSOP-00002 to provide instruction for how to identify process parameters that require control in a validated process. Your firm is also planning to conduct a review of all validated manufacturing processes in place at the facility to confirm that process parameters are adequately controlled.\nc. At the Aomori facility, your firm failed to validate the cleaning process for metal components used in the production of the HX-610 EZ Clip (hemostasis clip) made according to procedure DC00736661 to remove dirt or other particles. For example, the procedure doesn’t include defining and validating all critical process parameters with acceptable ranges including cleaning solution (type, concentration, temperature), immersion time, drying parameters, and visual inspection criteria.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm initiated a Global Ship Hold (ID.530) and CAPA 203781 as part of your corrective actions.\nd. At the Shirakawa facility, your firm did not adequately validate the testing process used in the production of UHI-4 Insufflation Unit where the results could not be fully verified by subsequent inspection and testing. For example, the software-driven functional testing process used to evaluate device performance was not adequately validated to ensure that it consistently produced devices meeting specifications in that it did not include appropriate test cases to demonstrate user requirements met acceptance criteria.\nThe adequacy of your firm’s response cannot be determined. Your response states that process validation deficiencies are being addressed through ongoing remediation activities and global CAPA efforts, and that validation activities are planned or underway to ensure processes consistently produce conforming devices. You have not provided objective evidence demonstrating that process validation activities have been completed or that affected processes have been validated, including validation protocols, reports, or data demonstrating that processes consistently produce conforming devices.\n4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b). For example,\na. At the Brooklyn Park facility, your firm failed to establish adequate process monitoring to ensure validated sealing processes for the heat sealers used for the Powerseal vessel sealing and Miscellaneous Urology products continue to meet specifications throughout production. Per procedure Peel Strength Test Method for Trays and Pouches D5100327-001 Rev AL, the heat sealer for Powerseal products requires peel strength testing to be completed at the beginning and the end of a lot. The process monitoring does not demonstrate that the heat sealing meets specification throughout the manufacturing operations, nor does the process monitoring demonstrate the machine was fully set up and operational when heat sealing process for a lot occurs over multiple days. The DHR for Lot (b)(4) notes that the sealing took place over two days. However, the process monitoring was conducted according to the procedure and only had a single tray sealing sample for testing at the start of the lot on June 20, 2025, and at shutdown on June 23, 2025. Your firm’s procedure for set-up, “POWERSEAL MP: Tray Sealer Setup and Peel Test” DN0044870 Rev AE states in (b)(4) for the temperature to stabilize prior to use; however, there is no indication that this was done at the start of the second production day. This step is identified as critical, according to your firm’s Symbol Index in DN0044870. Additionally, the sealing procedure, D5100327-001, is also used for the Miscellaneous Urology line and the Cutting Forceps line and requires the pull strength testing be performed at the beginning and end of every day. Your firm has not assessed whether critical parameters remain in control during all production activities, including after equipment set up on subsequent production days and when processing multiple products with different configurations on the same day. Finally, your procedure Process Monitoring - Packaging Data Review D0300188-001 Rev AK states in section 4, step 2 that a process control analysis should include an evaluation of lower and upper control limits. However, these limits are not currently calculated by your firm, and the upper and lower bound specifications are used instead. There is no documented statistical rationale for this decision.\nThe adequacy of your response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened CAPA-203867 to capture corrective actions such as the retraining of employees on process monitoring requirements to include peel testing at the beginning and end of each lot for the affected product lines. You note that you will revise FM-7.5-10, Control Plan requirements with risk assessments to define and align appropriate sample sizes and frequency monitoring. Ongoing actions as part of CAPA-203867 include defining, establishing, and implementing risk-based requirements in Process Controls, GSOP-7.5-4, for ongoing validated process monitoring. You have not performed an assessment of potentially affected units in the field and any ongoing post market monitoring to assess any risks of commercially distributed product. Your firm plans to review all process monitoring plans subject to D0300188-001 Rev AK, to ensure that such plans include justified control limits as well as specification limits. Your firm has not implemented calculated control limits.\n5. Failure to ensure that when changes or process deviations occur, the manufacturer shall review and evaluate the process and perform revalidation where appropriate, as required by 21 CFR 820.75(c). For example,\na. At the Hinode facility, your firm failed to revalidate the heat sealing process after implementing process changes in response to seal defects in the MAJ-1555. CAPA-202690 identified the cause of the overlap defects as a misalignment of the bag surfaces when the bag enters the sealing operation to create the sterile barrier. To address this issue, your firm added a sensor to control opening and closing of the extraction arm and receiving arm, which impacts bag surface alignment during sealing. Operational qualification or performance qualification was not performed after these changes to validate that the modified process continued to meet specifications and quality attributes.\nThis is a repeat violation from our 2023 Warning Letter issued to the Hinode facility.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Following an investigation and root cause analysis under CAPA-203919, your firm revised GSOP-00002 to provide additional instruction on how to assess whether a manufacturing change triggers revalidation of the manufacturing process, and your firm established the guidance document GREF-00197 to provide revalidation guidelines. The verification of effectiveness of these actions is not yet complete, and it is unclear whether concerns with process validation have been adequately addressed for other products subject to sealing at your facility. Your response stated that all seals are subject to visual inspection and, therefore, any nonconforming seals would be detected prior to release; however, visual inspection is not a substitute for adequate process validation.\nCorrective and Preventive Action Violations – Brooklyn Park, Shirakawa, Hinode, Hachioji, Hamburg, and Aomori facilities:\n6. Failure to identify the action(s) needed to correct and prevent the recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3). Specifically,\na. At the Brooklyn Park facility,\ni. Your firm failed to identify corrective actions that address the full scope of multiple Line Clearance Control nonconformances on the Miscellaneous Urology Production Line. CAPA-201354 was opened on August 31, 2023, and included automated verification steps and automated inspections on the lines. However, the CAPA only included implementing the automated verifications for the Soltive laser fibers and did not address corrections for any of the other products made on the Miscellaneous Urology production line, including nonconformances associated with missing syringes in the Irri-Flow line or incorrectly labeled RB Electrodes, as listed in the CAPA Initiation Information.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened and is developing an action plan for CAPA-203705, which revealed that the Miscellaneous Urology product line lacks sufficient process controls and robust automation and further noted that this technical gap creates a potential for the recurrence of nonconformances. While a quality plan was developed per GSOP-5.5-1 Rev AB Quality Plans to address the remaining implementation requirements for this line, the execution of these corrective actions occurred outside of the formal CAPA framework and did not include verification of effectiveness.\nii. Your firm failed to identify corrective actions to address ongoing Supplier Quality Performance rate failures for Vizishot endoscopic aspiration needle slider components. CAPA-202086 was opened on August 15, 2024, to address the Supplier Quality Performance rate (SQ3) not meeting the KPI objective for more than three months in a row. The investigation identified root causes related to supplier capability gaps, including inadequate manufacturing processes, insufficient purchase order review, and delayed drawing revisions. A separate NCR-00028865 due to a SQ2 KPI signal (Part Failure Rate) was escalated to CAPA-202086 on May 20, 2025. CAPA-202086 was closed on October 16, 2025, with no corrective or preventive actions taken, and the SQ3 KPI was eliminated without addressing the underlying quality problems or providing a rationale for no action taken.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203869 confirmed that the early closure of CAPA-202086 occurred because GSOP-00023, Rev AF Global Corrective Action and Preventive Action Management and GWI-00014, Rev AB CAPA Management Work Instruction – Agile did not clearly define requirements for early closure rationale or verification of linked records. An action plan is being developed but has not yet been implemented for CAPA-203869.\niii. Your firm identified a root cause for the blue ring on the Powerseal vessel sealing device detaching from the rotation knob during use (operator error during assembly) but failed to implement corrective actions consistent with that root cause. CAPA-200547 was opened on July 22, 2022, for the detachment, which resulted in a recall (RES 90788). The CAPA found the root cause was an operator error during assembly and not the out of specification supplier component originally documented in the HHA FY23-OSTA-07. However, the scope of corrections for the recall were based on supplier component lots and the scope was not expanded to include all devices assembled during the period when the operator error occurred, allowing potentially defective devices to remain in distribution.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened CAPA-203868 and noted that the Health Hazard Assessment (HHA) and Field Corrective Action (FCA) for CAPA-200547 were not reassessed after the identified root cause changed, as procedure GSOP-00023 Rev AF Global Corrective Action and Preventive Action Management did not define requirements for re-evaluation when new investigation findings modify the identified failure mode. Your firm indicated that since the process is shared among sites, the process related aspects of this observation are being addressed separately under Global CAPA-203799. An action plan is being developed but has not yet been implemented for CAPA-203868.\nb. At the Shirakawa facility, your firm failed to identify corrective actions needed to correct and prevent the recurrence of known quality problems associated with the UHI-4 insufflation system. CAPA-200872 identified pressure sensor failures as the root cause of front panel display issues; however, you relied on prior corrective actions (SCAR-Shirakawa-152-06) and concluded that the risk remained acceptable despite 325 complaints. Your firm failed to implement adequate corrective actions to address supplier control failures, complaint trending deficiencies, and design and risk management process gaps that allowed these repeated failures. As a result, your supplier control processes failed to prevent defective components from entering production and your quality system failed to detect and escalate recurring defects.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response noted planned corrective actions, including reliance on global CAPA procedures (GSOP00023) and proposed improvements to complaint trending, supplier controls, and risk management processes. You indicated that CAPA deficiencies continue to be addressed through ongoing local and global CAPAs and that you have initiated additional CAPAs (e.g., CAPA-203879, CAPA-203856, CAPA-203877).\nc. At the Hinode facility, your firm’s CAPA procedures failed to ensure that corrective actions addressed the root causes and prevented recurrence. Between October 2022 and September 2025, three CAPAs (CAPA-200736, CAPA-201399, CAPA-203398) were opened for wrinkle defects in sterile barrier seals across five products (MAJ-2315, MAJ-1555, MAJ-209, MAJ-210, MAJ-287). Each CAPA identified inadequate process validation as a contributing factor, yet none implemented corrective actions to address the underlying validation methodology deficiency that allowed critical process parameters to be missed. For example, CAPA-203398 identified the root cause as \"Method Inadequate validation\" but did not implement corrective actions to address the validation failure. CAPA-201399 identified wrinkles across multiple products but concluded that inspection would remove nonconforming product, without implementing corrective actions to the validated processes producing defects. CAPA-200736 (b)(4) to address wrinkles but did not investigate why (b)(4) identified in initial validations. Wrinkle defects may create channels for microbial contamination.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm characterized the pattern of recurring CAPAs for seal defects as representative of continuous improvement, citing decreases in defect rates, and your firm characterized the sealing processes as “under control”. However, ongoing nonconformances were initiated for wrinkles even after CAPAs were initiated. Your responses do not appear to address why your CAPA process allowed the same problem to require three separate CAPAs over three years without implementing corrections to the validation methodology.\nd. At the Hachioji facility, your firm failed to identify corrective actions for CAPA 201212, initiated June 20, 2023, in response to an FDA Additional Information request related to a patient death following use of the Evis Exera III Bronchovideoscope. Your CAPA documented that your firm failed to conduct design verification for use conditions and accessory compatibility claims in your IFU; however, no corrective actions were taken to address these design control deficiencies and the suspension of shipping was lifted on July 28, 2023. Your investigation revealed that your firm received 210 similar complaints and your investigation was not completed until November 14, 2025, over two years after CAPA initiation and your decision to continue shipping the devices.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\n7. Failure to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). For example,\na. At the Brooklyn Park facility,\ni. Your firm implemented actions to address root causes of a Vizishot II component mix-up without classifying them as corrective actions and verifying their effectiveness. CAPA-203041 was opened on June 30, 2025, for the use of the 21G slider components instead of the 22G on the Vizishot II NA-U401SX-4022 line. The Early Closure memo states that “operators were retrained on the line clearance procedure GWI-0705-16 and (b)(4)” and “the (b)(4) was modified to restrict access to the sides…”. Neither of these actions were considered a corrective action, nor was a verification of effectiveness conducted to ensure these actions prevented recurrence of the component mix-up.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203041 was prematurely closed because actions taken under the NCR were misclassified as corrections, even though they addressed root-cause-level factors that required corrective actions and verification of effectiveness (VOE). GSOP-00023 Rev AF Global Corrective Action and Preventive Action Management did not explicitly distinguish correction from corrective action within the CAPA workflow, which contributed to the omission of VOE. Your firm also indicated an action plan is being developed but has not yet been implemented for CAPA-203705.\nii. Your procedures, Quality Planning QSP-5.5 Rev AL and Quality Plans GSOP-5.5-1 Rev AB, have not adequately defined when quality plans contain corrective or preventive actions and should contain a verification that changes are effective and do not adversely affect devices. These procedures do not adequately define the difference between a quality plan and a corrective or preventive action. Additionally, during the inspection your firm had 54 quality plans open, including multiple plans intended to address backlogs in the complaint system and late MDRs. These quality plans directly address deficiencies in your quality system and are also being referenced within and in conjunction with CAPAs addressing the same issues.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203836 determined that the current procedures lack defined criteria for determining when a Quality Plan is not appropriate and a CAPA is required and does not require oversight to ensure appropriate use and completion tracking of Quality Plans. The Quality Management Review Presentation Template GTMP-00077 was revised to require that quality plans be reviewed as part of the Quality Management Review process. The scope of affected quality plans that lacked VOE was not provided. An action plan is being developed but has not yet been implemented for CAPA-203836.\nb. At the Shirakawa facility, your firm failed to verify that corrective actions implemented for overpressure events for the UHI-4 Insufflator were effective in preventing recurrence. For example, CAPA-200872 (opened February 2023) relied on prior corrective actions related to pressure sensor failures and concluded that these actions were effective without demonstrating that they prevented recurrence of similar defects or adequately mitigated risk in distributed devices. CAPA-201353 (opened August 2023) was subsequently opened to address overpressure events associated with the UHI-4 insufflation system only after significant adverse events occurred, including cardiac arrest and possible gas embolism, and resulted in a Class I recall (RES 92932). Your CAPA activities did not demonstrate that corrective actions were verified or validated to ensure effectiveness in preventing recurrence of overpressure-related failures.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Several CAPAs remain open, and you have not demonstrated that corrective actions have been verified or validated to ensure effectiveness or to prevent recurrence of similar defects, including overpressure-related failures.\n8. Failure to analyze processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example,\na. At the Brooklyn Park facility, your firm is using statistical methods for complaint trending without a documented rationale for the appropriateness of those methods. Complaint Trending Attributes, Statistical Method, and Trending Rules GREF-00157 Rev AA defines your complaint quality data analysis method of using median values and recalculating control limits each month. During the inspection your employees noted the calculations used were originally chosen in 2020, due to COVID-related data irregularities. However, you acknowledged that your firm does not still see these data irregularities and confirmed your firm has not documented a re-assessment or other justification for why this analysis method is still appropriate. The use of median values and monthly recalculation of control limits (that may not be appropriate for post-COVID data) may mask trends or delay detection of increasing complaint rates, potentially allowing serious device problems to persist undetected.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203873 determined that Olympus lacks a global procedure or guidance for statistical techniques, resulting in the absence of defined expectations for the consistent implementation of statistical methods. An action plan is being developed but has not yet been implemented for CAPA-203873.\nb. At the Shirakawa facility, your firm did not adequately analyze quality data, including complaints and adverse event information, to identify causes of quality problems. For example, you received a high volume of complaints related to pressure sensor defects and front panel failures associated with the UHI-4 insufflation system (including 325 complaints between November 2020 and October 2022), yet you did not appropriately trend or escalate these data to identify a cause or initiate CAPA in a timely manner. Additionally, you were aware of pressure sensor defects as early as 2018–2021 but did not reassess risk or investigate the increased occurrence of these defects in distributed devices. A CAPA was not initiated until FDA inquiry, indicating that your quality system did not effectively analyze available data sources, including complaints, supplier information, and risk management records.\nWe reviewed your firm’s response and determined that it is not adequate. Your response states that CAPA deficiencies are being addressed through a combination of local and global CAPAs, including local CAPA-203879, CAPA-203856, CAPA-203850, and global CAPA-203789, CAPA-203525, and CAPA-204150. You indicate that updates to procedures, including GSOP-00023 (CAPA), GSOP-00033 (complaint trending), GSOP-00069 (supplier quality agreement), and GSOP-00079 (supplier corrective action), have been implemented or are in progress. You also state that retrospective reviews of complaint data and supplier corrective action requests have been conducted. Several CAPAs remain open and root cause investigations and corrective actions are ongoing. Additionally, you indicate that certain local CAPAs will be closed early and that corrective actions will be addressed under global CAPAs, which limits the ability to assess whether site-specific deficiencies have been adequately addressed. Your response further confirms that complaint trend signals were not adequately identified and that supplier-related defects were not appropriately evaluated for field impact at the time they were identified. You have not provided sufficient objective evidence demonstrating implementation or effectiveness of corrective actions, including completion of investigations, verification of corrective actions, or sustained improvements to your CAPA system.\nc. At the Hamburg facility, your firm’s complaint trending failed to include all complaints as required by your procedure. Trending Attributes, Statistical Method, and Trending Rules GREF-00157 Rev AA, section 4.4.2 states “trending will be based on the value of monthly data (i.e. actual number of open complaints per month).” However, trend signal information (TS-1224-WA50042A) for your video telescope (model WA50042A) only includes the trending of MDR reportable complaints and does not include non-reportable complaints.\nWe reviewed your firm’s response and determined that it is not adequate. Your response did not include an assessment of how the lack of trending of non-reportable complaints may impact already distributed product. For example, if the complaints reveal quality problems that may require correction or removal to address.\nd. At the Aomori facility,\ni. Your firm failed to adequately analyze quality data to identify causes of nonconforming product. CAPA-201434, which was initiated to address reports of deformed wires for the Single Use 3-Lumen Sphincterotome, incorrectly identified the root cause as “shortcomings in work procedures” during outsourcing, failing to recognize inadequate design transfer to production specification as the actual cause. Per the CAPA scope, the corrective actions only applied to products distributed to the Japanese market and were not implemented for devices distributed to the U.S. market. It was noted during the inspection that the CAPA task (Task 10012651) assigned to correct the manufacturing process for products destined for the U.S. was cancelled because the products are subject to FDA 510(k) and it would have taken longer to implement the changes which would “prolong the period until the CAPA closes.” Your firm received over 1000 complaints for this device failure, including 24 MDR reportable events.\nii. Your firm failed to conduct a timely and adequate analysis of complaint data related to potential causes of nonconforming product for the Thunderbeat 5 mm Front-actuated Grip Type S. Your firm received over 1900 complaints between September 2021 and September 2024, including 1583 that were MDR reportable. CAPA-201438 was initiated on October 18, 2023, but no action was taken as the Health Hazard Evaluation was canceled on January 31, 2024, because it was deemed not necessary based on complaint incident rates and without considering the potential harm to patients. A recall (RES 95950) was initiated on November 25, 2024, over a year later.\nThe adequacy of your firm’s response for (i) and (ii) above cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\nAcceptance Activities Violations – Brooklyn Park and Shirakawa facilities:\n9. Failure to establish and maintain procedures for acceptance of incoming product, as required by 21 CFR 820.80(b). For example,\na. At the Brooklyn Park facility, your firm failed to conduct statistical calculations required to demonstrate lot acceptability in accordance with your procedure. Receiving Acceptance GSOP-7.11-1 Rev AT uses a variable sampling plan for receiving inspection of part number 0000315-TAB, according to Inspection Procedure for 0000315-TAB JAW ASSEMBLY, MACHINED, INNER, POWERSEAL CURVED JAW B DN0040655 Rev AE. However, your receiving inspection for each length of this part (PN 0000315-001, 0000315-002 and 0000315-003) does not include calculation of your standard deviation, kLSL, and kUSL as required by GSOP-7.11-1. Additionally, your acceptance procedure for Powerseal Curved Jaw B only includes a specification for sample calculation for dimension 9 but does not document a calculation of the maximum standard deviation (MSD) for any other dimension as required. Finally, your Supplier D also uses the sampling plan, but does not provide you with their standard deviation, kLSL and kUSL calculations. The calculations for standard deviation, lower controls limits and upper control limits are part of the variable sampling plan that demonstrate the acceptability of the lot.\nYour inspection procedure also allows for CMM measurements to be re-tested by another inspector if they do not pass initially. This was done for 8 of the 10 samples in the FAI Inspection Request for part number 0000315-002, dated March 20, 2025. The only rationale recorded was \"Believed fixture incorrect.\" Our inspection also found that retesting had occurred on all of the most recent receiving records for all sizes of the 000315-TAB. Part Number 0000315-001 was inspected on October 23, 2025, and the record includes failing CMM results for 5 of the 10 parts, as well as the retested data, but the parts were accepted into inventory. When our investigator communicated this to your employee, it was noted that this lot was accepted by mistake and NCR-00048701 was opened to contain the nonconforming material.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203866 was opened to capture corrective actions and noted that GSOP 7.11-1 Rev. AU, Receiving Acceptance, and the inspection procedures did not define the statistical requirements, resulting in incomplete evaluation of incoming product and acceptance of parts without proper statistical justification. Your response noted that you have updated the inspection procedures for all parts subject to ANSI\u002FASQ Z1.9 to require inclusion of sample size rationale for critical dimensions and to ensure that data is provided by their suppliers. Your firm plans to conduct a retrospective review of inspection records from the past 2 years for failed dimensions without a record of appropriate retest or passing results. Based on the results of the review you will take appropriate action; however, it is not clear what those actions would include, nor if the actions will include a risk assessment for product that has been distributed.\nb. At the Shirakawa facility, your firm failed to identify defective components used in the UHI-4 insufflation system during acceptance activities. For example, defective pressure sensor components were not identified through incoming inspection or acceptance testing prior to use in manufacturing. As a result, nonconforming components were incorporated into finished devices, contributing to reports of device malfunctions and adverse events received by your firm.\nThe adequacy of your firm’s response cannot be determined. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response states that improvements to incoming acceptance activities will be implemented as part of broader corrective actions, including updates to ensure that purchased materials meet specifications. However, you have not provided sufficient detail demonstrating that revised acceptance activities have been implemented or are effective in detecting nonconforming components.\nPurchasing Controls Violations – Brooklyn Park, Shirakawa and Hamburg facilities:\n10. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product, and services conform to specified requirements, as required by 21 CFR 820.50. For example,\na. At the Brooklyn Park facility,\ni. Your firm’s supplier controls procedure (GQS-00013) does not ensure that supplied product that cannot be fully verified by subsequent inspection and test is validated with a high degree of assurance and conforms to specified requirements. On December 4, 2023, your firm issued SCR-0000649 for an increased rate of complaints for broken welds in the ESG PK Cutting Forceps (model PK-CF0533), occurring in the supplied bottom and top jaw assemblies (part numbers P5700259-001 and P5700260-001, respectively). Supplier A determined the cause of the weld breaking was a sub-supplier, Supplier B. In SCR-0000649, Supplier A documented that Supplier B stated the welding process \"could not be controlled or validated.\" Your firm established increased inspection rather than requiring validation or changing suppliers. This complaint trend resulted in a recall (RES 93842) in December 2023. This unvalidated welding process has resulted in weld failures during patient use, creating risk of foreign bodies in patients assessed at Critical (S4) severity and High (S5) probability. Similar welds are also performed by Supplier B for your Halo and Cutting Forceps. Approximately 4,600 units with similar unvalidated welds have been distributed. During the inspection, your firm initiated an NCR and a Global Ship Hold.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203871 was opened to address the failure to ensure welding performed by the supplier was validated. The CAPA root cause investigation identified that the QAA template used to finalize the Supplier Agreement back in 2014 did not incorporate process validation requirements for suppliers and their Sub-Tier suppliers. Moreover, the Global QAA templates GTMP-00021 Rev AB QAA Template for Component Suppliers and GTMP-00022 Rev AB QAA Template for Finished Device Suppliers lack specificity on sub-tier control for process validation. All impacted product remains on Global Ship Hold (ID 476), and you have halted the manufacture of affected product. The FCA board reviewed and decided to conduct a removal of the impacted products. Your response stated you would submit a Correction and Removal report in compliance with 21 CFR Part 806 requirements. Although an expansion of the recall is being performed, it has been over 2 years between awareness (December 4, 2023) and recall decision (February 3, 2026). Your firm has not explained the delay or assessed patient harm during this period.\nii. Your firm accepted failing process capability data after components were remeasured without justification. SCR-0000166 was issued to Supplier C for out of specification components. The investigation led to two design changes to the mating parts used in the Powerseal vessel sealing device: the blue ring (part PN0013810) and the overmolded rotation knob (part PN0013804) and resulted in a class II recall (RES 90788). You accepted first article inspection that included Supplier C “Validation Documents Submission” where parts were remeasured with passing results, “Ppk’s for Cav 2 on PQ1 was right at 1.39 and PQ2 was 1.36 failing the Ppk requirement per protocol of 1.39. 2 parts were remeasured and Ppk came into requirement.” There is no justification for why these remeasurements were considered appropriate.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203872 is ongoing, and the root cause investigation identified that the supplier procedure permitted data remeasurement without documented justification and did not define requirements for documenting the rationale or controls associated with remeasurement activities. In addition, GSOP-00086 Rev AA Global External Product Qualification lacked requirements for justification of remeasurement. Your firm’s response notes that you have planned the process to requalify Supplier C against new global procedure requirements by March 27, 2026, including a new Quality Agreement. The impact on released product has not been evaluated since this will involve the remeasurement at incoming testing after you have updated GSOP-00086 that governs the conditions and permissibility for remeasurement. Your firm has not provided interim results or identified how many additional components may be affected. Your response should also include a retrospective review of similar supplier processes that pose a potential for patient safety risk.\niii. Section 3.5 of First Article Inspection GSOP-7.11-2 Rev AG, allows suppliers on risk improvement plans with documented quality concerns to conduct first article inspections without additional verification by your firm. For example, Supplier D has been on a risk improvement plan since January 21, 2025, but a \"Supplier conducted FAI\" for part number 0000315-002, delivered on or before March 5, 2025, and used in the Powerseal vessel sealing device. The process is currently controlled by the two procedures Global Supplier Risk Improvement GSOP-00045 Rev AB and Global Supplier Risk Improvement with Action Plan GWI-00002 Rev AB. Despite the supplier providing out-of-specification components and being on a supplier risk improvement plan, your firm failed to consider the appropriateness of the supplier performing first article inspection measurements following a design change or when implementing a new component.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203866 identified that GSOP-00045 Rev AB Global Supplier Risk Improvement does not require evaluation of internal inspection plans when supplier risk improvement plans are issued or revised in response to changes in part failure rate. Additionally, the procedure lacks defined linkage between supplier risk improvement plans and corresponding receiving inspection requirements. It is not clear from your response whether there is nonconforming product in the field associated with suppliers who are on a heightened inspection status or risk improvement plan and who conducted their own supplier first article inspections.\niv. Supplier A has not adequately validated their Performance Qualification Report PQR-10774 Rev A for part number P5700138-001, used to support the weld tensile strength in your legacy Cutting Forceps. According to your firm’s Engineer, the worst-case weld is considered the shortest weld of the group, as the welds all have to meet a minimum weld pull strength of 30 lbs. However, part P5700138-001 has a weld length specification of 0.10 ± 0.02 inches, while parts P5700211-002 and P5700210-002 have a shorter weld length specification of 0.081 ± 0.02 inches.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203871 was opened and a Health Hazard Assessment (HHA) FY26-062 was conducted to evaluate potential field action. On February 3, 2026, the FCA board reviewed and decided to conduct a removal of the impacted products in the Cutting Forceps product line (RES 98454). Olympus completed the review of validations for Supplier A to determine conformance with Global GSOP-00002 Rev AD Validation Program and GWI-00112 Rev AA Global Standards for External Product Qualification for worst-case trials with documented rationale. The review determined that three (3) components manufactured by Supplier A require additional process validation. The review, however, was limited to products with an active production schedule. Products that have reached end-of-life and are in the process to be discontinued were excluded from the scope (jaw assemblies, ESG Cutting Forceps, Halo, Everest 5mm Cutting Forceps, and PKS Cutting Forceps). It is not clear from your response whether there is product within expiry date that is still in commercial distribution. Your firm will complete a review of applicable supplier-manufactured components documentation, through collaboration with suppliers to identify potential validation gaps.\nb. At the Shirakawa facility, your firm did not adequately control suppliers to ensure that components used in the UHI-4 insufflation system met specified requirements. For example, pressure sensor defects associated with supplier-provided components were identified; however, your supplier control processes did not prevent nonconforming components from being incorporated into finished devices. Your CAPA investigations did not adequately evaluate why supplier controls were ineffective or ensure that appropriate corrective actions were implemented to prevent recurrence of similar supplier-related defects. Root cause analysis identified gaps in supplier change control procedures and audit processes, including lack of mechanisms to verify supplier changes against specifications.\nThe adequacy of your firm’s response cannot be determined. Your response states that supplier control deficiencies are being addressed through local and global CAPAs, including CAPA-203856 and CAPA-203789, and that supplier oversight processes will be enhanced through updated supplier quality agreements and risk-based supplier requalification activities. You also indicate that procedures, including GSOP-00079, have been updated to require assessment of field impact for supplier-related defects. However, investigations into supplier-related root causes remain ongoing, and corrective actions have not been fully implemented. Additionally, you indicate that certain local CAPAs will be closed early and that corrective actions will be addressed under global CAPAs, which limits the ability to assess whether site-specific supplier control deficiencies have been adequately addressed. You have not provided objective evidence demonstrating that revised supplier controls are effective in preventing recurrence of nonconforming components.\nc. At the Hamburg facility, your firm failed to ensure that purchased services conform to specified requirements. Your firm hired HCL Technologies as part of “(b)(4)” to reduce the backlog of complaint investigation and closures; however, your firm did not evaluate HCL Technologies on the basis of their ability to provide contract services to meet specified quality requirements, including their ability to provide qualified staff to perform quality assurance responsibilities. Your firm’s contract services included approximately (b)(4) temporary personnel to investigate and close complaint files. Your firm was unable to demonstrate that the contract personnel received product specific training.\nWe reviewed your firm’s response and determined that it is not adequate. Your firm initiated CAPA-204033 and CAPA-204034. Your firm indicated that your root cause investigation determined that there was no central governance defining shared services requirements within the Quality Management System (QMS) and that as a result, roles and responsibilities between Legal Manufacturers, Global QMS functions, and shared service owners were not consistently defined or understood, leading to fragmented accountability for end-to-end oversight. Your firm is developing a corrective action plan; however, you have not provided corrective actions demonstrating how you will ensure contract personnel are qualified and trained in the services they will perform.\nRecords Violations – Brooklyn Park and Shirakawa facilities:\n11. Failure to review, evaluate and investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, as required by 21 CFR 820.198(c). For example,\na. At the Brooklyn Park facility, your firm's procedure, Complaint Investigation Tiers and Investigation Activities GWI-0809-10 Rev BB, does not require investigations to be completed on complaints in investigation Tier 3. For example, complaints C22097460, C22184070, C22248777, C22249599, C22259835, C22279317, C22332770, and C22387391 all state in the investigation summary that the complaints are “non-PAE, Tier 3 codes. No investigation is required,” in the “Evaluation Result” section (PAE stands for potential adverse event). There is no documentation of a complaint investigation or reference to where an investigation for this failure has previously been investigated or other similar rationale for why this investigation is not required. Lack of investigation only allows trending on this subset of complaints based on date of receipt and device model. After transitioning to your current Trackwise system in November 2024, you indicate you no longer use a tier system; however, your trending is based on 24 months of historical data which is still limited by the lack of investigation results on potential device performance issues.\nWe reviewed your firm’s response and determined that it is not adequate. Your response does not address the failure to investigate complaints.\nb. At the Shirakawa facility, your firm failed to adequately investigate complaints involving serious adverse events to determine whether device malfunction contributed to the reported outcomes. For example, complaints associated with UHI-4 insufflation systems, including reports of overpressure events and serious adverse outcomes such as cardiac arrest and possible gas embolism, were not fully evaluated to determine whether device malfunction contributed to the reported events. Your complaint investigations did not consistently incorporate available device performance data to determine whether the device met specifications during use. For example, complaint CN-249953 reported a death due to gas embolism during use and included the device event log retrieved by the Field Service Engineer; however, this log was not reviewed as part of the investigation.\nWe reviewed your firm’s response and determined that it is not adequate. You state that complaint handling and trending processes have been improved through implementation of GSOP-00033 and that retrospective reviews of complaint data have been conducted to assess whether complaint signals were appropriately escalated. You also indicate that CAPA-203879 was initiated to address missed complaint trend signals. However, CAPA-203879 and related investigations remain ongoing, and you have not provided sufficient objective evidence demonstrating that complaint investigations are comprehensive or that systemic issues are consistently identified and escalated.\nMedical Device Reporting (MDR) Violations\nOur inspection at your Hamburg facility also revealed that your firm’s resection sets are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n12. Failure to report the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that the firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that the firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nFor example, the information included in Complaints CN-182867 and CN-184790 reasonably suggests that your firm’s resection set malfunctioned (e.g., broken ceramic insulation) while in use. A serious injury MDR 2951238-2019-00404, submitted by your firm on February 1, 2019, documents a serious injury resulting from the same malfunction involving the same device. That malfunction would be likely to cause or contribute to a death or serious injury if it were to recur, as evidenced by the serious injury MDR 2951238-2019-00404. Accordingly, the referenced adverse events represent MDR-reportable malfunctions as defined under 21 CFR 803.3. Your firm became aware of complaint CN-182867 on February 13, 2025, and submitted the corresponding MDR 9610773-2025-06509 on October 20, 2025; and became aware of CN-184790 on February 12, 2025, and submitted the corresponding MDR 9610773-2025-04016 on June 16, 2025. These two MDRs were submitted beyond the required 30-calendar-day reporting timeframe.\nThe adequacy of your firm’s response cannot be determined at this time. The response states that your firm initiated CAPA-204035 to address late reporting, including revising procedures to correctly document event dates and the dates your firm became aware of the events. However, supporting evidence demonstrating completion of these corrective actions was not provided because the corrective actions are still ongoing.\nFailure to address any violations of the FD&C Act may result in the FDA refusing admission of the devices manufactured by your firm into the United States under section 801(a) of the FD&C Act, 21 U.S.C. § 381(a). Devices under this authority that appear to be adulterated may be detained or refused admission.\nYour firm should provide a written response to this Warning Letter as described below and address the violations described in this letter. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facilities to verify that the appropriate corrections and\u002For corrective actions have been made.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspections conducted between October 2025 and December 2025 were conducted pursuant to the QS Regulation, which was in effect at the time of the inspections. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nIn addition, we also note the following comments:\n1. In response to three prior warning letters issued to your firm in 2022 and 2023 (including the Hachioji and Hinode facilities), your firm implemented new global procedures, including complaint handling, MDR, and CAPA procedures. Review of these procedures found the roles and responsibilities of manufacturing sites versus your global remote corporate entity have not been clearly defined, including, for example, how your firm will assess that site specific quality issues have been resolved, and how your global CAPA process will provide oversight and ensure correction and prevention of repetitive quality issues within and across your global facilities that follow these procedures.\n2. Regarding the inspection of Olympus Corporation of the Americas, located at 3500 Corporate Pkwy, Center Valley, PA 18034, FEI 2429304, from November 18, 2025, to December 16, 2025: Multiple complaint files reviewed during the inspection were found to contain insufficient documentation of complaint intake, evaluation, and investigation conclusions. Complete complaint files provide your firm with critical information to detect and trend medical device failures and to make reportability decisions.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Kristina Donohue at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS #729208” when replying. If you have any questions about the contents of this letter, please contact: Beckilyn Dorsey at Rebecca.dorsey@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMichael J. Hoffmann\nDirector\nOffice of Health Technologies 3 - Gastrorenal, ObGyn,\nGeneral Hospital, and Urology Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nTodd Brill, US Agent, Gyrus ACMI, Inc., (b)(6)@Olympus.com\nDaniel S. Sampson, Senior Director of Operations, (b)(6)@olympus.com\nRichard Reynolds, President, Olympus Corporation of the Americas, (b)(6)@olympus.com\nHiroaki Hosoi, President, Aomori Olympus, (b)(6)@olympus.com\nKota Ishibiki, President, Olympus Medical Systems Corporation (b)(6)@olympus.com\nShinji Egami, Senior Director, Olympus Medical Systems Corporation, Hinode, (b)(6)@olympus.com\nSeiji Morishita, President, Shirakawa Olympus Co., Ltd., (b)(6)@olympus.com\nCarl A. Yallop, Vice President OSTE, SIS Operations & ISC and Managing Director, EMEA, (b)(6)@olympus.com","Olympus Medical Systems Corporation","olympus-medical-systems-corporation-729208-10072026","2026-10-27T01:18:54.544251+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corporation-729208-10072026","2026-11-17T01:02:03.701861+00:00","2026-10-20","729208","2026-10-27T01:19:05.406+00:00","VIA Electronic Mail","2026-10-07",{"id":95,"raw":96,"subject":100,"body_html":101,"body_text":102,"firm_name":103,"letter_id":104,"created_at":18,"fei_number":19,"letter_url":105,"updated_at":106,"action_type":22,"case_status":23,"posted_date":107,"marcs_cms_no":108,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":109,"body_fetched_at":110,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":111,"medical_device_id":19,"response_letter_date":19},2160,[97,98,99,11,100,13,13,13],"\u003Ctime datetime=\"2023-03-17T15:00:00Z\">03\u002F17\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-15T04:00:00Z\">03\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corp-654013-03152023\">Olympus Medical Systems Corp.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Seiji Morishita\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Olympus Medical Systems Corp.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>34-3 Hirai Hinode-machi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nishitama-gun\u003C\u002Fspan>, \u003Cspan>Tokyo\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>190-0182\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 15, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Morishita:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Tokyo, Japan on November 7, 2022, through November 10, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures endoscopes and endoscope accessories including, Single-Use Distal Covers for Duodenoscopes and Single-Use Suction Valve Accessories for Bronchoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are accessories intended to be used with endoscopes for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received responses from Mr. Seiji Morishita, Director of Olympus Medical Systems Corp, Hinode dated December 5, 2022, January 10, 2023, and February 13, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, including analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example:\u003C\u002Fp>\n\n\u003Cp>A. Since November 2020, Olympus Medical has received approximately 160 complaints describing the “distal end cover” model number MAJ-2315 has “dropped out.” Your firm performed trending and identified that number of complaints was above the expected numbers for that type of complaint. However, your firm did not consider this increasing trend of complaints to be a quality data input to initiate a corrective and preventive action.\u003C\u002Fp>\n\n\u003Cp>B. The process flow diagram of Procedure for Complaint Handling\u002FOMBS \u003Cstrong>(b)(4)\u003C\u002Fstrong> describes that complaint investigations that would require evaluation for reportability would not be considered for Corrective and Preventive Action. Complaints are specifically required to be analyzed for inclusion into the CAPA subsystem and complaints that are deemed reportable are of the highest risk complaints and therefore especially important to be considered for corrective and preventive action implementation.\u003C\u002Fp>\n\n\u003Cp>C. Non-Conformances \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were opened for observed wrinkles in the package seal of Distal End Cap\u002FMAJ-2315 between October 13 to October 23, 2022. Your firm stated that yield control may be appropriate for some low risk nonconformances instead of using its Nonconforming Product procedure. Yield control allows for an acceptable level of package seal defects, even though there is no assurance that visually observed seal defects would not compromise the sterile barrier. Package sealing is a validated process, which results cannot be verified when the validated requirements of the seal are not met. A potential breach of sterility in the packaging seal would not be considered a low risk nonconformance. Because yield control was inappropriately applied to the package seal defect, the nonconformances were not considered as nonconforming product and not included as quality data for the corrective and preventive actions.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses and concluded that they are not adequate. Your firm initiated CAPA-200735 to investigate complaints of MAJ-2315 “dropped out” and after conducting a Health Hazard Analysis (HHA), concluded that no additional action is required and they will continue to monitor complaints for the distal cap falling off in the patient. However, FDA does not agree that the risk to the patient is of a low enough risk to not warrant further action at this time. The HHA conducted does not discuss how\u002Fwhy the risk to the patient is not increased by exposure to the uncovered endoscope during the procedure as it is removed. The HHA does not consider the risk of tissue injury from navigating the gastrointestinal tract with an uncovered scope tip. Further, your firm’s documentation concludes that the distal cap is unlikely to fall off if the user has applied it correctly. CAPA-200735 does not consider whether the device actually meets user needs as required by 21 CFR 820.30(g), including the ability to recognize imperfections in the cap and attach it to the scope correctly without damaging it. While your firm did initiate a systemic corrective and preventive action to determine why this complaint trend was not escalated to a CAPA, the investigation into the issue itself, the cap falling off the scope in the patient, appears to be inadequate.\u003C\u002Fp>\n\n\u003Cp>2. Failure to ensure that when changes or process deviations occur, the manufacturer shall review and evaluate the process and perform revalidation where appropriate, as required by 21 CFR 820.75(c). For example, Nonconformance \u003Cstrong>(b)(4)\u003C\u002Fstrong> was opened due to wrinkles and air bubbles in the package seal of MAJ-210\u002FLot H2410 a sterile product. Your firm made a modification to the manufacturing equipment to increase the cooling rate of the package after sealing. While some testing was performed to demonstrate seal integrity, no re-validation of the process was made. Because sterility of the product is a critical requirement and the process cannot be fully verified by subsequent inspection and test, the process must be validated and re-validated when a modification such as this is made.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses and concluded that they are not adequate. Your firm identified its plan to perform revalidation for MAJ-201 sealing operation by January 31, 2023. Also, your firm stated that it will revise \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Process Validation and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Conduct of Process Validation by February 23, 2023, to clarify when revalidation is necessary and to specify who is necessary to review and approve changes to ensure revalidation decisions are appropriately made; and revise \u003Cstrong>(b)(4)\u003C\u002Fstrong> Assembly\u002FProcessing Equipment Control by February 28, 2023, to ensure that the change control process is followed when process or equipment changes are made.\u003C\u002Fp>\n\n\u003Cp>Your firm reviewed complaints and MDRs from the last two years associated with all products distributed to the US to determine if any signals exist to suggest sterility was compromised as a result of the modification made to the sealing process. It is not clear whether your firm evaluated devices shipped to other markets as well that would have the same concern or could possibly be imported into the US by a third party. Your firm should clarify this. Your firm performed a retrospective review of all changes for all products marketed in the US since each product’s last full validation to determine if any other changes have been made to any products marketed in the US that should have prompted a full or partial revalidation and opened several nonconformances for changes without adequate documentation of necessity for revalidation to investigate impact to product and revalidation requirements. Your firm completed its revalidation of MAJ-210 sealing process on January 31, 2023. Your firm has additional corrective actions planned, including revising its Process Validation procedures to clarify when revalidation is necessary and to specify who is necessary to review and approve changes to ensure revalidation decisions are appropriately made. Your firm also plans to implement a change to its Assembly\u002FProcessing Equipment Control procedure to ensure that the change control process is followed when process or equipment changes are made. However, your firm did not mention a plan to train its personnel on these new procedures, nor did it clarify that the retrospective reviews that were done were in line with the new requirements of its procedures. Your firm should provide clarification to these two points and provide documentation of implementation.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198.\u003C\u002Fp>\n\n\u003Cp>For example, Complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> was received by Olympus Medical on November 21, 2020. The complaint described that \"a patient sustained esophageal trauma\" and \"tissue from the esophagus was caught up in the distal tip of the device.\" The complaint also stated that the \"customer attributes these events to cracked caps\" and that they noticed a \"few already cracked when coming out of the packaging.\" Your firm’s complaint handling procedure, OMBS \u003Cstrong>(b)(4)\u003C\u002Fstrong> requires investigations of complaints to be made within 30 days. The investigation of the complaint was not made until 2022.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses and concluded that they are not adequate. Your firm initiated CAPA-200739 to determine the root cause of Observation 4a of the FDA-483. It appears your firm identified the root cause to be related to be a lack of linkage between the scopes and the caps within their system. Your firm completed a retrospective review of all complaints associated with MAJ-2315, expanding the search to other scopes that use the distal cap in addition to TJF-Q190V. Your firm found that there were 98 complaints not initiated according to their procedure during this retrospective review. Your firm stated that it will conduct the necessary investigation and submit MDRs as needed by February 28, 2023.\u003C\u002Fp>\n\n\u003Cp>Your firm revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> Complaint Handling, which included instructions for ensuring individual complaints are opened for all related\u002Fconcomitant devices. Your firm revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> Complaint Investigation Work Instruction, which included detailed instruction for ensuring individual complaints are opened for all related\u002Fconcomitant devices while performing complaint investigation. Your firm confirmed in its plan that personnel have been trained on the new procedures.\u003C\u002Fp>\n\n\u003Cp>Your firm plans to do a retrospective review of complaint records in the past two years related to the issue of cracked caps coming out of the packaging by February 28, 2023.\u003C\u002Fp>\n\n\u003Cp>However, it is not clear based on your firm’s CAPA and documentation whether they have investigated why the investigation into the complaint did not occur for two years, while your firm’s procedure requires it to be made within 30 days.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s Single-Use Distal Cover (MAJ-2315) devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a).\u003C\u002Fp>\n\n\u003Cp>For example, during the inspection, your firm identified the document titled “Medical Device Reporting Work Instruction”, OMBS \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated 10\u002F26\u002F2022, as its MDR procedure. After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cp>A. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure includes definitions from 21 CFR 803.3 for the terms “become aware”, “malfunction”, “MDR reportable event”, and the definition of the term “reasonably suggest” found in 803.20(c)(1). However, the procedure omits definitions of the terms “caused or contributed” and “serious injury” from the 21 CFR Part 803.3. The exclusion of the definitions for those terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\n\n\u003Cp>B. The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2).\u003C\u002Fp>\n\n\u003Cp>a. For example, there are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\u003Cbr>\nb. The MDR Decision Tree in your firm’s MDR procedure does not reference a process for investigating events identified as MDRs to ensure that MDRs are submitted to FDA within the required reporting timeframes, as required under 21 CFR 803.17(a)(1).\u003C\u002Fp>\n\n\u003Cp>C. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\u003C\u002Fp>\n\n\u003Cp>a. Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>\nb. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review, and archive in accordance with 21 CFR 803.12(a).\u003Cbr>\nc. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within the firm.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response did not address the procedural deficiencies noted above, as they were not identified in the FDA-483.\u003C\u002Fp>\n\n\u003Cp>2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\n\n\u003Cp>For example, the information included for Complaints \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and \u003Cstrong>(b)(4)\u003C\u002Fstrong> reasonably suggests your firm’s duodenovideoscope with a distal cover MAJ-2315 malfunctioned (e.g., cracked cap) while in use, leading to potential mucosal tissue damage. Your firm initiated recall Z-1292-2021 for the referenced malfunction. Per the Preamble, in Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (December 11, 1995), Comment 12, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the act as a result of the malfunction of the device or other similar devices. There is no information included for the complaints that rules out that the referenced device malfunction would not be likely to cause or contribute to a death or serious injury if it were to recur. Although your firm submitted the MDRs (MDR# 8010047-2021-03794, 8010047-2022-02861, 8010047-2021-03786, 8010047-2022-02867, 8010047-2021-03796, 8010047-2022-02865) corresponding to each of the referenced events, the MDRs were not received by FDA within the required 30 calendar day timeframe.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your firm initiated a series of CAPAs to investigate the root cause of the cracked cap problem and have plans to address it accordingly. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including a retrospective review for reportability, as these actions are still ongoing.\u003C\u002Fp>\n\n\u003Cp>Your firm is in the process of completing CAPAs to address the referenced malfunction and updating the complaint handling process. Additionally, your firm conducted a retrospective review of all complaints associated with MAJ-2315 and complaints for the endoscopes (TJF-Q190V, TJF-Q290V, TJF-Q170V), which are used in conjunction with MAJ-2315. As a result, 98 complaints were identified for further investigation and your firm is evaluating them for reportability. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including a retrospective review for reportability, as these actions are still ongoing.\u003C\u002Fp>\n\n\u003Cp>Your firm completed the update of its complaint handling procedures and is evaluating newly identified events related to cracked caps for reportability. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including the submission of newly identified reportable events, as these actions are still ongoing.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review.\u003C\u002Fp>\n\n\u003Cp>We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #654013 when replying. If you have any questions about the contents of this letter, please contact: Shanil Haugen, Ph.D., at Shanil.Haugen@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT 3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nTodd Brill\u003Cbr>\nGyrus ACMI Inc.\u003Cbr>\n800 West Park Drive\u003Cbr>\nWestborough, MA US 01581\u003Cbr>\nPhone: 508 8042600 Ext\u003Cbr>\nEmail: Todd.Brill@Olympus.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Seiji Morishita\n\nRecipient Title\n\nDirector\n\nOlympus Medical Systems Corp.\n\n34-3 Hirai Hinode-machi\n\nNishitama-gun, Tokyo\n\n190-0182\n\nJapan\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nMarch 15, 2023\n\nWARNING LETTER\n\nDear Mr. Morishita:\n\nDuring an inspection of your firm located in Tokyo, Japan on November 7, 2022, through November 10, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures endoscopes and endoscope accessories including, Single-Use Distal Covers for Duodenoscopes and Single-Use Suction Valve Accessories for Bronchoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are accessories intended to be used with endoscopes for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received responses from Mr. Seiji Morishita, Director of Olympus Medical Systems Corp, Hinode dated December 5, 2022, January 10, 2023, and February 13, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, including analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example:\n\nA. Since November 2020, Olympus Medical has received approximately 160 complaints describing the “distal end cover” model number MAJ-2315 has “dropped out.” Your firm performed trending and identified that number of complaints was above the expected numbers for that type of complaint. However, your firm did not consider this increasing trend of complaints to be a quality data input to initiate a corrective and preventive action.\n\nB. The process flow diagram of Procedure for Complaint Handling\u002FOMBS (b)(4) describes that complaint investigations that would require evaluation for reportability would not be considered for Corrective and Preventive Action. Complaints are specifically required to be analyzed for inclusion into the CAPA subsystem and complaints that are deemed reportable are of the highest risk complaints and therefore especially important to be considered for corrective and preventive action implementation.\n\nC. Non-Conformances (b)(4) and (b)(4) were opened for observed wrinkles in the package seal of Distal End Cap\u002FMAJ-2315 between October 13 to October 23, 2022. Your firm stated that yield control may be appropriate for some low risk nonconformances instead of using its Nonconforming Product procedure. Yield control allows for an acceptable level of package seal defects, even though there is no assurance that visually observed seal defects would not compromise the sterile barrier. Package sealing is a validated process, which results cannot be verified when the validated requirements of the seal are not met. A potential breach of sterility in the packaging seal would not be considered a low risk nonconformance. Because yield control was inappropriately applied to the package seal defect, the nonconformances were not considered as nonconforming product and not included as quality data for the corrective and preventive actions.\n\nWe reviewed your firm’s responses and concluded that they are not adequate. Your firm initiated CAPA-200735 to investigate complaints of MAJ-2315 “dropped out” and after conducting a Health Hazard Analysis (HHA), concluded that no additional action is required and they will continue to monitor complaints for the distal cap falling off in the patient. However, FDA does not agree that the risk to the patient is of a low enough risk to not warrant further action at this time. The HHA conducted does not discuss how\u002Fwhy the risk to the patient is not increased by exposure to the uncovered endoscope during the procedure as it is removed. The HHA does not consider the risk of tissue injury from navigating the gastrointestinal tract with an uncovered scope tip. Further, your firm’s documentation concludes that the distal cap is unlikely to fall off if the user has applied it correctly. CAPA-200735 does not consider whether the device actually meets user needs as required by 21 CFR 820.30(g), including the ability to recognize imperfections in the cap and attach it to the scope correctly without damaging it. While your firm did initiate a systemic corrective and preventive action to determine why this complaint trend was not escalated to a CAPA, the investigation into the issue itself, the cap falling off the scope in the patient, appears to be inadequate.\n\n2. Failure to ensure that when changes or process deviations occur, the manufacturer shall review and evaluate the process and perform revalidation where appropriate, as required by 21 CFR 820.75(c). For example, Nonconformance (b)(4) was opened due to wrinkles and air bubbles in the package seal of MAJ-210\u002FLot H2410 a sterile product. Your firm made a modification to the manufacturing equipment to increase the cooling rate of the package after sealing. While some testing was performed to demonstrate seal integrity, no re-validation of the process was made. Because sterility of the product is a critical requirement and the process cannot be fully verified by subsequent inspection and test, the process must be validated and re-validated when a modification such as this is made.\n\nWe reviewed your firm’s responses and concluded that they are not adequate. Your firm identified its plan to perform revalidation for MAJ-201 sealing operation by January 31, 2023. Also, your firm stated that it will revise (b)(4), Process Validation and (b)(4), Conduct of Process Validation by February 23, 2023, to clarify when revalidation is necessary and to specify who is necessary to review and approve changes to ensure revalidation decisions are appropriately made; and revise (b)(4) Assembly\u002FProcessing Equipment Control by February 28, 2023, to ensure that the change control process is followed when process or equipment changes are made.\n\nYour firm reviewed complaints and MDRs from the last two years associated with all products distributed to the US to determine if any signals exist to suggest sterility was compromised as a result of the modification made to the sealing process. It is not clear whether your firm evaluated devices shipped to other markets as well that would have the same concern or could possibly be imported into the US by a third party. Your firm should clarify this. Your firm performed a retrospective review of all changes for all products marketed in the US since each product’s last full validation to determine if any other changes have been made to any products marketed in the US that should have prompted a full or partial revalidation and opened several nonconformances for changes without adequate documentation of necessity for revalidation to investigate impact to product and revalidation requirements. Your firm completed its revalidation of MAJ-210 sealing process on January 31, 2023. Your firm has additional corrective actions planned, including revising its Process Validation procedures to clarify when revalidation is necessary and to specify who is necessary to review and approve changes to ensure revalidation decisions are appropriately made. Your firm also plans to implement a change to its Assembly\u002FProcessing Equipment Control procedure to ensure that the change control process is followed when process or equipment changes are made. However, your firm did not mention a plan to train its personnel on these new procedures, nor did it clarify that the retrospective reviews that were done were in line with the new requirements of its procedures. Your firm should provide clarification to these two points and provide documentation of implementation.\n\n3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198.\n\nFor example, Complaint (b)(4) was received by Olympus Medical on November 21, 2020. The complaint described that \"a patient sustained esophageal trauma\" and \"tissue from the esophagus was caught up in the distal tip of the device.\" The complaint also stated that the \"customer attributes these events to cracked caps\" and that they noticed a \"few already cracked when coming out of the packaging.\" Your firm’s complaint handling procedure, OMBS (b)(4) requires investigations of complaints to be made within 30 days. The investigation of the complaint was not made until 2022.\n\nWe reviewed your firm’s responses and concluded that they are not adequate. Your firm initiated CAPA-200739 to determine the root cause of Observation 4a of the FDA-483. It appears your firm identified the root cause to be related to be a lack of linkage between the scopes and the caps within their system. Your firm completed a retrospective review of all complaints associated with MAJ-2315, expanding the search to other scopes that use the distal cap in addition to TJF-Q190V. Your firm found that there were 98 complaints not initiated according to their procedure during this retrospective review. Your firm stated that it will conduct the necessary investigation and submit MDRs as needed by February 28, 2023.\n\nYour firm revised (b)(4) Complaint Handling, which included instructions for ensuring individual complaints are opened for all related\u002Fconcomitant devices. Your firm revised (b)(4) Complaint Investigation Work Instruction, which included detailed instruction for ensuring individual complaints are opened for all related\u002Fconcomitant devices while performing complaint investigation. Your firm confirmed in its plan that personnel have been trained on the new procedures.\n\nYour firm plans to do a retrospective review of complaint records in the past two years related to the issue of cracked caps coming out of the packaging by February 28, 2023.\n\nHowever, it is not clear based on your firm’s CAPA and documentation whether they have investigated why the investigation into the complaint did not occur for two years, while your firm’s procedure requires it to be made within 30 days.\n\nOur inspection also revealed that your firm’s Single-Use Distal Cover (MAJ-2315) devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\n1. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a).\n\nFor example, during the inspection, your firm identified the document titled “Medical Device Reporting Work Instruction”, OMBS (b)(4), dated 10\u002F26\u002F2022, as its MDR procedure. After reviewing the procedure, the following deficiencies were noted:\n\nA. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure includes definitions from 21 CFR 803.3 for the terms “become aware”, “malfunction”, “MDR reportable event”, and the definition of the term “reasonably suggest” found in 803.20(c)(1). However, the procedure omits definitions of the terms “caused or contributed” and “serious injury” from the 21 CFR Part 803.3. The exclusion of the definitions for those terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nB. The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2).\n\na. For example, there are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\n\nb. The MDR Decision Tree in your firm’s MDR procedure does not reference a process for investigating events identified as MDRs to ensure that MDRs are submitted to FDA within the required reporting timeframes, as required under 21 CFR 803.17(a)(1).\n\nC. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\n\na. Instructions for how to obtain and complete the FDA 3500A form.\n\nb. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review, and archive in accordance with 21 CFR 803.12(a).\n\nc. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within the firm.\n\nYour firm’s response did not address the procedural deficiencies noted above, as they were not identified in the FDA-483.\n\n2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\n\nFor example, the information included for Complaints (b)(4) and (b)(4) reasonably suggests your firm’s duodenovideoscope with a distal cover MAJ-2315 malfunctioned (e.g., cracked cap) while in use, leading to potential mucosal tissue damage. Your firm initiated recall Z-1292-2021 for the referenced malfunction. Per the Preamble, in Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (December 11, 1995), Comment 12, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the act as a result of the malfunction of the device or other similar devices. There is no information included for the complaints that rules out that the referenced device malfunction would not be likely to cause or contribute to a death or serious injury if it were to recur. Although your firm submitted the MDRs (MDR# 8010047-2021-03794, 8010047-2022-02861, 8010047-2021-03786, 8010047-2022-02867, 8010047-2021-03796, 8010047-2022-02865) corresponding to each of the referenced events, the MDRs were not received by FDA within the required 30 calendar day timeframe.\n\nThe adequacy of your firm’s responses cannot be determined at this time. Your firm initiated a series of CAPAs to investigate the root cause of the cracked cap problem and have plans to address it accordingly. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including a retrospective review for reportability, as these actions are still ongoing.\n\nYour firm is in the process of completing CAPAs to address the referenced malfunction and updating the complaint handling process. Additionally, your firm conducted a retrospective review of all complaints associated with MAJ-2315 and complaints for the endoscopes (TJF-Q190V, TJF-Q290V, TJF-Q170V), which are used in conjunction with MAJ-2315. As a result, 98 complaints were identified for further investigation and your firm is evaluating them for reportability. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including a retrospective review for reportability, as these actions are still ongoing.\n\nYour firm completed the update of its complaint handling procedures and is evaluating newly identified events related to cracked caps for reportability. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including the submission of newly identified reportable events, as these actions are still ongoing.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review.\n\nWe will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #654013 when replying. If you have any questions about the contents of this letter, please contact: Shanil Haugen, Ph.D., at Shanil.Haugen@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nDirector\n\nOHT 3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\ncc:\n\nTodd Brill\n\nGyrus ACMI Inc.\n\n800 West Park Drive\n\nWestborough, MA US 01581\n\nPhone: 508 8042600 Ext\n\nEmail: Todd.Brill@Olympus.com","Olympus Medical Systems Corp.","olympus-medical-systems-corp-654013-03152023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corp-654013-03152023","2026-10-26T08:09:37.557484+00:00","2023-03-17","654013","Mr. Seiji Morishita","2026-08-20T01:11:43.772+00:00","2023-03-15",{"id":113,"raw":114,"subject":117,"body_html":118,"body_text":119,"firm_name":84,"letter_id":120,"created_at":18,"fei_number":19,"letter_url":121,"updated_at":122,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":123,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":124,"body_fetched_at":125,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":126,"medical_device_id":19,"response_letter_date":19},2263,[8,115,116,11,117,13,13,13],"\u003Ctime datetime=\"2022-12-12T05:00:00Z\">12\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corporation-649726-12122022\">Olympus Medical Systems Corporation\u003C\u002Fa>","Medical Device Reporting\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tomohisa Sakurai\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Olympus Medical Systems Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2951, Ishikawa-cho\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hachioji-shi\u003C\u002Fspan>, \u003Cspan>Tokyo\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>192-8507\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 12, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Tomohisa Sakurai:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Hachioji-shi, Tokyo, Japan, on September 6, 2022, through September 9, 2022, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm manufactures gastrointestinal and surgical endoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm's gastrointestinal and surgical endoscopes are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. We received a response from your firm, dated September 30, 2022, to the Form FDA 483 (FDA 483). We address this response below, in relation to each of the noted violation(s). These violation(s) include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\n\n\u003Cp>For example, the information in complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> (MDR# 8010047-2021-02641), complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> (MDR# 8010047-2021-07387), complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> (MDR# 8010047-2021-11050), and complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> (MDR# 8010047-2021-09059), reasonably suggests that your firm’s Uretero-Reno Fiberscope and Uretero-Reno Videoscope malfunctioned (e.g., device breakage or rupture) while in use. Your firm failed to submit an MDR for each of the referenced complaints within the required 30-calendar day timeframe. As a result of these complaints, your firm conducted recall Z-2518-2018, for the Uretero-reno fiberscope URF-P6, where it was established that such events could result in potential perforation of a patient’s organs. Per 21 CFR 803.3, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the Act as a result of the malfunction of the device or other similar devices. As such, each of the referenced complaints represents an MDR-reportable malfunction, as defined in 21 CFR 803.3.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated September 30, 2022, cannot be determined at this time as the response notes that your firm is continuing to implement its systemic corrective actions, including optimizing the MDR reporting process and staff training. However, the adequacy of your firm’s response cannot be determined because your firm’s actions are presently ongoing. When your firm’s corrective actions are completed, please provide documentation or evidence of the systemic corrective actions, including a copy of your revised MDR procedure and a retrospective review of complaints for reportability.\u003C\u002Fp>\n\n\u003Cp>U.S. federal agencies may take your compliance history into account when considering the award of contracts.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violation, as well as an explanation of how your firm plans to prevent the violation, or similar violation, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address all violation included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration - CDRH\u002FORP\u002FDRP2\u003Cbr>\nCDRH Regulatory Inspections and Audit Team, WO66-1434\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Refer to CMS case # 478315\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact: Mark Antonino at Mark.Antonino@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violation at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA.\u003C\u002Fp>\n\n\u003Cp>Sincerely Yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nOffice Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nTodd Brill\u003Cbr>\nGyrus ACMI Inc.\u003Cbr>\n800 West Park Drive\u003Cbr>\nWestborough, MA US 01581\u003Cbr>\nPhone: 508 8042600 Ext\u003Cbr>\nEmail: Todd.Brill@Olympus.Com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nTomohisa Sakurai\n\nRecipient Title\n\nPresident\n\nOlympus Medical Systems Corporation\n\n2951, Ishikawa-cho\n\nHachioji-shi, Tokyo\n\n192-8507\n\nJapan\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nDecember 12, 2022\n\nDear Tomohisa Sakurai:\n\nDuring an inspection of your firm located in Hachioji-shi, Tokyo, Japan, on September 6, 2022, through September 9, 2022, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm manufactures gastrointestinal and surgical endoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nOur inspection revealed that your firm's gastrointestinal and surgical endoscopes are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. We received a response from your firm, dated September 30, 2022, to the Form FDA 483 (FDA 483). We address this response below, in relation to each of the noted violation(s). These violation(s) include, but are not limited to, the following:\n\n1. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\n\nFor example, the information in complaint (b)(4) (MDR# 8010047-2021-02641), complaint (b)(4) (MDR# 8010047-2021-07387), complaint (b)(4) (MDR# 8010047-2021-11050), and complaint (b)(4) (MDR# 8010047-2021-09059), reasonably suggests that your firm’s Uretero-Reno Fiberscope and Uretero-Reno Videoscope malfunctioned (e.g., device breakage or rupture) while in use. Your firm failed to submit an MDR for each of the referenced complaints within the required 30-calendar day timeframe. As a result of these complaints, your firm conducted recall Z-2518-2018, for the Uretero-reno fiberscope URF-P6, where it was established that such events could result in potential perforation of a patient’s organs. Per 21 CFR 803.3, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the Act as a result of the malfunction of the device or other similar devices. As such, each of the referenced complaints represents an MDR-reportable malfunction, as defined in 21 CFR 803.3.\n\nThe adequacy of your firm’s response dated September 30, 2022, cannot be determined at this time as the response notes that your firm is continuing to implement its systemic corrective actions, including optimizing the MDR reporting process and staff training. However, the adequacy of your firm’s response cannot be determined because your firm’s actions are presently ongoing. When your firm’s corrective actions are completed, please provide documentation or evidence of the systemic corrective actions, including a copy of your revised MDR procedure and a retrospective review of complaints for reportability.\n\nU.S. federal agencies may take your compliance history into account when considering the award of contracts.\n\nPlease notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violation, as well as an explanation of how your firm plans to prevent the violation, or similar violation, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address all violation included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made.\n\nYour firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\n\nFood and Drug Administration - CDRH\u002FORP\u002FDRP2\n\nCDRH Regulatory Inspections and Audit Team, WO66-1434\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to CMS case # 478315\n\nIf you have any questions about the contents of this letter, please contact: Mark Antonino at Mark.Antonino@fda.hhs.gov\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violation at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA.\n\nSincerely Yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nOffice Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nTodd Brill\n\nGyrus ACMI Inc.\n\n800 West Park Drive\n\nWestborough, MA US 01581\n\nPhone: 508 8042600 Ext\n\nEmail: Todd.Brill@Olympus.Com","olympus-medical-systems-corporation-649726-12122022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corporation-649726-12122022","2026-10-26T08:09:37.595173+00:00","649726","Tomohisa Sakurai","2026-08-20T01:19:56.315+00:00","2022-12-12",{"id":128,"raw":129,"subject":81,"body_html":133,"body_text":134,"firm_name":135,"letter_id":136,"created_at":43,"fei_number":19,"letter_url":137,"updated_at":138,"action_type":22,"case_status":23,"posted_date":139,"marcs_cms_no":140,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":141,"body_fetched_at":142,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":143,"medical_device_id":19,"response_letter_date":19},352,[130,131,132,11,81,13,13,13],"\u003Ctime datetime=\"2026-02-03T05:00:00Z\">02\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-27T05:00:00Z\">01\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fflextronics-america-llc-722180-01272026\">Flextronics America LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Vincent Madhavan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u002FSr. Director of Quality \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Flextronics America LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>12455 Research Blvd, Bldg. G\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Austin\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78759\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@flex.com\"> (b)(6)@flex.com    \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS 722180\u003C\u002Fp>\u003Cp>1\u002F27\u002F2026\u003C\u002Fp>\u003Cp>Dear Mr. Madhavan,\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Austin, TX from October 20 through October 30, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm contract manufactures the Freestyle Libre 3 Continuous Glucose Monitor (CGM). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from you dated 11\u002F20\u002F2025 and 12\u002F19\u002F2025 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For example: During puck assembly of the Freestyle Libre 3 sensor, \u003Cstrong>(b)(4)\u003C\u002Fstrong> are used load PCBAs onto the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These \u003Cstrong>(b)(4)\u003C\u002Fstrong> must move the PCBA along all \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) to make this transfer. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> determines the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the part and therefore has potential affect (in part) on both the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm’s employees observed sensor damage after this transfer and provided evidence they often had to make \u003Cstrong>(b)(4)\u003C\u002Fstrong> adjustments. Review of the assembly process validation on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines used in the manufacture of the sensor pucks found no defined setting or acceptable range for the equipment used to \u003Cstrong>(b)(4)\u003C\u002Fstrong> set or change the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>As described, uncontrolled \u003Cstrong>(b)(4)\u003C\u002Fstrong> can result in damaged and nonconforming product. Therefore, this parameter must be controlled as part of your process validation. The Installation Qualification Protocol and associated reports for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Puck Assembly machines do not define any specifications or set up activities for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> puck \u003Cstrong>(b)(4)\u003C\u002Fstrong>, or related acceptance criteria.\u003C\u002Fp>\u003Cp>Over four years of Libre 3 manufacturing, \u003Cstrong>(b)(4)\u003C\u002Fstrong> have caused damage or failed to pick up parts, requiring corrective maintenance to adjust \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA investigators observed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> corrective maintenance activities for puck \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> since 2021. Records describe parts being damaged or not picked up, with adjustments made without established specifications or controls. For example, REQ-1204527 documents turning \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>,\" then running cycles until \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" before resuming manufacturing.\u003C\u002Fp>\u003Cp>Therefore, associated process validation for the puck assembly process does not demonstrate your process consistently produces product according to your predetermined specifications.\u003C\u002Fp>\u003Cp>The adequacy of your firm's response cannot be determined at this time. Your response confirms \"The \u003Cstrong>(b)(4)\u003C\u002Fstrong> verified the presence of the system manual but did not mandate verification of operation and maintenance instructions for sub-components like the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This oversight resulted in the absence of specific, detailed \u003Cstrong>(b)(4)\u003C\u002Fstrong> specifications and maintenance procedures for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\" Your firm stated that it has already designed a procedure and setup tool to facilitate \u003Cstrong>(b)(4)\u003C\u002Fstrong> alignment, reassessed PFMEA severity ratings, and evaluated \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment validations to ensure appropriate manuals are included. You plan to update qualification protocols and reports to qualify tool effectiveness, update the alignment procedure, and ensure documentation supports these activities. Your response (Attachment 14) indicates the tool or \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" thickness now specifies the \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cp>Your responses to Observations 1 and 3 include plans to qualify the new \u003Cstrong>(b)(4)\u003C\u002Fstrong> and partially revalidate the process to determine effectiveness of the new \u003Cstrong>(b)(4)\u003C\u002Fstrong> specification. However, the Action Plan for Observation 1 states you plan to \"Update the Qualification protocols\u002Freports to formally qualify the use and effectiveness of the setup tool (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) (Action 1.1) for Puck lines \u003Cstrong>(b)(4)\u003C\u002Fstrong>\" but does not clearly state you intend to validate the process. Partial revalidation described under Observation 3 might be sufficient, but we cannot assess adequacy as it remains in progress without evidence from the revalidation. Please provide updates on revalidation activities as they progress and a summary with supporting documentation upon completion.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For example: Your firm did not adequately identify the actions needed to correct and prevent recurrence of nonconforming product and other quality problems.\u003C\u002Fp>\u003Cp>This cite is related to the quality problem identified in observation 1 where nonfunctioning devices were caused by improper alignment of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> leading to impact to the leads of the connector causing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the PCBA to break. After your firm opened a CAPA on 4\u002F1\u002F2025, it did not identify the actions needed to correct and prevent recurrence of broken components or \u003Cstrong>(b)(4)\u003C\u002Fstrong> connections due to lack of defined specification for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As a result, corrective maintenance requests to adjust the \u003Cstrong>(b)(4)\u003C\u002Fstrong> continued after your corrective actions were initiated.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm’s initial response identified multiple corrective actions including but not limited to the need to strengthen guidance for: a) action plan implementation and verification as well as b) handling changes from approved action plans during implementation and verification. Specifically, your firm identified the need to “clarify the technical analysis”. The technical analysis conducted during the FDA-483 remediation identified that establishing a setpoint for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was critical. The procedural updates are an improvement, but implementation may be subjective for each situation in determining technical analysis (when needed and what is performed) and will have to be reviewed during a subsequent inspection to determine adequacy. Your firm did not include training records, and the status is still in progress. Please provide an update on the verification of effectiveness for this CAPA when it is available later this year.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to ORP EAT 3 Assistant Director Jeff Wooley at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 722180” when replying. If you have any questions about the contents of this letter, please contact: Lauren Priest at Lauren.Priest@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Vincent Madhavan\n\nRecipient Title\n\nGeneral Manager\u002FSr. Director of Quality\n\nFlextronics America LLC\n\n12455 Research Blvd, Bldg. G\n\nAustin, TX 78759\n\nUnited States\n\n(b)(6)@flex.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS 722180\n1\u002F27\u002F2026\nDear Mr. Madhavan,\nDuring an inspection of your firm located in Austin, TX from October 20 through October 30, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm contract manufactures the Freestyle Libre 3 Continuous Glucose Monitor (CGM). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from you dated 11\u002F20\u002F2025 and 12\u002F19\u002F2025 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\nFor example: During puck assembly of the Freestyle Libre 3 sensor, (b)(4) are used load PCBAs onto the (b)(4). These (b)(4) must move the PCBA along all (b)(4) ((b)(4)) to make this transfer. The (b)(4) determines the (b)(4) of the part and therefore has potential affect (in part) on both the (b)(4). Your firm’s employees observed sensor damage after this transfer and provided evidence they often had to make (b)(4) adjustments. Review of the assembly process validation on the (b)(4) lines used in the manufacture of the sensor pucks found no defined setting or acceptable range for the equipment used to (b)(4) set or change the (b)(4).\nAs described, uncontrolled (b)(4) can result in damaged and nonconforming product. Therefore, this parameter must be controlled as part of your process validation. The Installation Qualification Protocol and associated reports for the (b)(4) Puck Assembly machines do not define any specifications or set up activities for the (b)(4) of the (b)(4) puck (b)(4), or related acceptance criteria.\nOver four years of Libre 3 manufacturing, (b)(4) have caused damage or failed to pick up parts, requiring corrective maintenance to adjust (b)(4). FDA investigators observed approximately (b)(4) corrective maintenance activities for puck (b)(4) and (b)(4) since 2021. Records describe parts being damaged or not picked up, with adjustments made without established specifications or controls. For example, REQ-1204527 documents turning \"(b)(4),\" then running cycles until \"(b)(4)\" before resuming manufacturing.\nTherefore, associated process validation for the puck assembly process does not demonstrate your process consistently produces product according to your predetermined specifications.\nThe adequacy of your firm's response cannot be determined at this time. Your response confirms \"The (b)(4) verified the presence of the system manual but did not mandate verification of operation and maintenance instructions for sub-components like the (b)(4). This oversight resulted in the absence of specific, detailed (b)(4) specifications and maintenance procedures for the (b)(4).\" Your firm stated that it has already designed a procedure and setup tool to facilitate (b)(4) alignment, reassessed PFMEA severity ratings, and evaluated (b)(4) equipment validations to ensure appropriate manuals are included. You plan to update qualification protocols and reports to qualify tool effectiveness, update the alignment procedure, and ensure documentation supports these activities. Your response (Attachment 14) indicates the tool or \"(b)(4)\" thickness now specifies the (b)(4) ((b)(4)).\nYour responses to Observations 1 and 3 include plans to qualify the new (b)(4) and partially revalidate the process to determine effectiveness of the new (b)(4) specification. However, the Action Plan for Observation 1 states you plan to \"Update the Qualification protocols\u002Freports to formally qualify the use and effectiveness of the setup tool ((b)(4)) (Action 1.1) for Puck lines (b)(4)\" but does not clearly state you intend to validate the process. Partial revalidation described under Observation 3 might be sufficient, but we cannot assess adequacy as it remains in progress without evidence from the revalidation. Please provide updates on revalidation activities as they progress and a summary with supporting documentation upon completion.\n2. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nFor example: Your firm did not adequately identify the actions needed to correct and prevent recurrence of nonconforming product and other quality problems.\nThis cite is related to the quality problem identified in observation 1 where nonfunctioning devices were caused by improper alignment of the (b)(4) leading to impact to the leads of the connector causing the (b)(4) on the PCBA to break. After your firm opened a CAPA on 4\u002F1\u002F2025, it did not identify the actions needed to correct and prevent recurrence of broken components or (b)(4) connections due to lack of defined specification for the (b)(4). As a result, corrective maintenance requests to adjust the (b)(4) continued after your corrective actions were initiated.\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm’s initial response identified multiple corrective actions including but not limited to the need to strengthen guidance for: a) action plan implementation and verification as well as b) handling changes from approved action plans during implementation and verification. Specifically, your firm identified the need to “clarify the technical analysis”. The technical analysis conducted during the FDA-483 remediation identified that establishing a setpoint for the (b)(4) was critical. The procedural updates are an improvement, but implementation may be subjective for each situation in determining technical analysis (when needed and what is performed) and will have to be reviewed during a subsequent inspection to determine adequacy. Your firm did not include training records, and the status is still in progress. Please provide an update on the verification of effectiveness for this CAPA when it is available later this year.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to ORP EAT 3 Assistant Director Jeff Wooley at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 722180” when replying. If you have any questions about the contents of this letter, please contact: Lauren Priest at Lauren.Priest@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Flextronics America LLC","flextronics-america-llc-722180-01272026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fflextronics-america-llc-722180-01272026","2026-10-26T08:08:42.014361+00:00","2026-02-03","722180","Mr. Vincent Madhavan","2026-08-19T05:07:56.033+00:00","2026-01-27",{"id":145,"raw":146,"subject":151,"body_html":153,"body_text":154,"firm_name":155,"letter_id":156,"created_at":157,"fei_number":19,"letter_url":158,"updated_at":159,"action_type":22,"case_status":160,"posted_date":161,"marcs_cms_no":162,"product_type":163,"closeout_date":164,"issuing_office":150,"recipient_name":165,"body_fetched_at":166,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":167,"medical_device_id":19,"response_letter_date":19},1138,[147,148,149,150,151,13,152,13],"\u003Ctime datetime=\"2024-12-10T14:20:00Z\">12\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-22T05:00:00Z\">11\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmid-america-pet-food-llc-681516-11222024\">Mid America Pet Food LLC\u003C\u002Fa>","Center for Veterinary Medicine","CGMP\u002FFood for Animals\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmid-america-pet-food-llc-681516-08212025\">\u003Ctime datetime=\"2025-08-28T04:00:00Z\">08\u002F28\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeff Caswell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Mid America Pet Food LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2024 N. Frontage Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mount Pleasant\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75455-6474\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS# 681516\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 22, 2024\u003C\u002Fp>\u003Cp>Dear Mr. Caswell:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your pet food manufacturing facility located at 2024 N. Frontage Road, Mount Pleasant, Texas from November 2, 2023, through December 18, 2023. FDA also conducted a subsequent inspection from January 23, 2024, through February 9, 2024, at this facility. We received your responses dated January 10, 2024; March 4, 2024; and July 10, 2024, to the FDA 483 Inspectional Observations. FDA conducted the 2023 inspection in response to your voluntary Class I recalls initiated on September 3, 2023, expanded on October 30, 2023, and further expanded on November 9, 2023, to include all your dog and cat food with best by dates before October 31, because they had the potential to be contaminated with \u003Cem>Salmonella\u003C\u002Fem>. In addition, FDA conducted the 2023 inspection as part of an investigation, along with the Centers for Disease Control (CDC) and state and local partners, into a multi-state foodborne illness outbreak of \u003Cem>Salmonella\u003C\u002Fem> Kiambu implicated in human illnesses through epidemiological traceback.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> A total of seven people from seven states were infected with the outbreak strain from January 14, 2023 to August 19, 2023, and one person was hospitalized. Six of the affected people were children under one year of age. \u003Cem>Salmonella\u003C\u002Fem> can affect animals eating the products, and there is risk to humans from handling contaminated pet products and utensils that came into contact with the affected pet products. Children, the elderly, and individuals with compromised immune systems may be at greater risk for Salmonella infection.\u003C\u002Fp>\u003Cp>These illnesses were linked by whole genome sequencing to dog food manufactured at your facility in 2023 through a sample of Victor Super Premium Dog Food Classic Hi-Pro Plus (lot 1000016385; Best By 4\u002F30\u002F24) collected by the South Carolina Department of Agriculture on August 15, 2023, which you recalled on September 3, 2023. On October 30, 2023, you expanded your initial recall to include Victor Super Premium Dog Food, Select Beef Meal &amp; Brown Rice Formula with best by dates of June 12, 2024 (5 lbs. lot 1000016890; 15 lbs. lot 1000016891; and 40 lbs. lot 1000016892). On November 9, 2023, you expanded your recall to include all products with best by dates before October 31, 2024, because your testing revealed the presence of \u003Cem>Salmonella\u003C\u002Fem> Kiambu in a lot for which you reported receiving a consumer complaint involving human illness. Based on analytical results, FDA considers the Victor Super Premium Dog Food Classic Hi-Pro Plus (lot 1000016385; Best By 4\u002F30\u002F24)lot to be adulterated in that it bears or contains a poisonous or deleterious substance which may render it injurious to health.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA collected environmental samples (i.e., swabs) from surfaces in your manufacturing facility during this inspection and a subsequent inspection, conducted from January 23, 2024, through February 9, 2024, in response to a consumer complaint. Analysis of these samples using whole genome sequencing revealed that three of the Salmonella-positive environmental swabs collected in the post-process area of your facility during the 2024 inspection are closely related to seven Salmonella-positive environmental swabs collected in the pre-process areas of your facility during the 2023 inspection, indicating that your facility may have three resident strains of Salmonella: Salmonella Rissen, Salmonella Minnesota, and Salmonella Mbandaka.\u003C\u002Fp>\u003Cp>During these inspections FDA Investigators found evidence of significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements in Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507), which cause your products to be adulterated in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Additionally, the introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Furthermore, the failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of 21 CFR 507 (located in subparts A, C, D, E, and F of Part 507) is a prohibited act.\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> You may find the FD&amp;C Act and FDA’s regulations through links on the FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of our inspections on December 18, 2023, and February 9, 2024, you were issued two separate Forms FDA 483, Inspectional Observations. We received your written responses to these observations dated January 10, 2024, March 4, 2024, and July 10, 2024, and address your corrective actions below, in relation to each of the noted violations.\u003C\u002Fp>\u003Cp>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls Requirements\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your animal food facility is subject to the hazard analysis and risk-based preventive controls requirements found in 21 CFR Part 507, subparts A, C, D, E, and F. During the inspection of your facility, the FDA Investigators obtained evidence of significant violations of these requirements, which included:\u003C\u002Fp>\u003Cp>1. You did not identify and implement a preventive control to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented, as required by 21 CFR 507.34(a)(1).\u003C\u002Fp>\u003Cp>Specifically, your hazard analysis determined the hazard of Salmonella requires preventive controls and identified sanitation and process controls to control the hazard of Salmonella in your finished pet food.\u003C\u002Fp>\u003Cp>A. Your Food Safety Plan dated January 9, 2024, documents your sanitation control for Salmonella spp. in post-extrusion processing environments by removing residual material on post-extruder surfaces and applying sanitizer in accordance with the sanitizer label. However, you failed to adequately implement your sanitation control.\u003C\u002Fp>\u003Cp>i. You use \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a sanitizer for food-contact equipment and utensils. Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Procedure” (SOP 1500) standard operating procedure (SOP), dated December 5, 2023, documents, “Surfaces must remain thoroughly wetted for \u003Cstrong>(b)(4)\u003C\u002Fstrong> followed by adequate draining and air drying . . . [a]llow the identified surface to air dry before the manufacturing process can resume, or the identified surface is reintroduced for use.” Furthermore, the label for \u003Cstrong>(b)(4)\u003C\u002Fstrong> documents “treated surfaces must remain wet for at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> followed by adequate draining and air drying” for food-processing equipment and food-contact surfaces. On January 30, 2024, FDA Investigators observed an employee designated to the post-extrusion area cleaning food-contact equipment who used \u003Cstrong>(b)(4)\u003C\u002Fstrong> to sanitize the equipment and then immediately dried the surface of the equipment with a paper towel. During this cleaning, the equipment made direct contact with the employee’s clothing which was visibly soiled with apparent dog food.\u003C\u002Fp>\u003Cp>ii. Your “Housekeeping Procedure” (CGMP 2800),” dated February 2, 2022, documents that the sanitation lead employee write their initials on sanitation records to document their inspection and review of sanitation activities on the Master Cleaning Schedule. Your Master Cleaning Schedule, “Housekeeping #5” for December 2023 does not document \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning for the discharge hoppers located in the packaging area for the entire month of December 20\u003Ca>23.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>In addition, there were multiple instances of other equipment and areas where you did not document sanitation activities in accordance with your Master Cleaning Schedule in April 2023, May 2023, June 2023, September 2023, December 2023, and January 2024.\u003C\u002Fp>\u003Cp>iii. On January 26, 2024, FDA Investigators observed visible debris on food-contact surfaces of equipment such as brushes, brooms, and squeegees after cleaning and sanitizing of equipment was performed by your third-party sanitation service. In addition, you could not produce any sanitation records for July and August of 2023 and your records for April 2023 and May 2023 were incomplete. Your lack of complete records in addition to the ineffective cleaning observed by Investigators demonstrates your failure to implement your sanitation preventive control.\u003C\u002Fp>\u003Cp>B. Your Food Safety Plan dated January 9, 2024, documents “CGMP controls” to minimize the hazard of \u003Cem>Salmonella\u003C\u002Fem> spp. in post-extrusion processing environments.\u003C\u002Fp>\u003Cp>i. On January 23, 2024, FDA Investigators observed rainwater entering your facility through the roof while you were manufacturing multiple lots of dog food. FDA Investigators observed standing water and soaked absorbent pads in staging, production, and finished product areas, including in post-process areas such as the dryer room and packaging areas. Your manufacturing facility must be constructed in a manner such does not become a source of potential contamination to your animal food.\u003C\u002Fp>\u003Cp>C. Your Food Safety Plan dated January 9, 2024, documents your process control for \u003Cem>Salmonella\u003C\u002Fem> spp. at the Storage of Liquid Bulk Ingredients step for chicken fat is to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>i. You did not document the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process control applied to your chicken fat prior to January 13, 2024, which demonstrates you did not effectively implement your process control. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Log (SOP-5800F-\u003Cstrong>(b)(4)\u003C\u002Fstrong>), documents that from January 13 through February 4, 2024, you did not routinely \u003Cstrong>(b)(4)\u003C\u002Fstrong> in accordance with the validation study you provided for this process. The target \u003Cstrong>(b)(4)\u003C\u002Fstrong> listed as a parameter in on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Log is \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and your records document that you \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> truckloads of fat received from January 13 through February 4, 2024.\u003C\u002Fp>\u003Cp>ii. You did not document that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process control of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was applied to your chicken fat until January 29, 2024. You produced approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> pounds of Victor Brand Dog Food using this fat from January 13, 2024, to January 28, 2024.\u003C\u002Fp>\u003Cp>\u003Cu>Evaluation of your response:\u003C\u002Fu>\u003Cbr>A. Your response dated January 10, 2024, documents that you updated your Master Sanitation schedule, updated sanitation standard operating procedures, and provided training to your employees. In addition, your response provided a timeline of the steps you took in response to the recalls, which included hiring a consultant and voluntarily closing your facility in November 2023 to perform deep cleaning and implement corrections. However, you did not provide records that document your new sanitation programs are implemented and we were unable to evaluate your corrections. In addition, FDA Investigators observed sanitation deficiencies persisted through the January to February 2024 inspection. Your response dated March 4, 2024, stated, “our programs have been, and are, effective for controlling \u003Cem>Salmonella\u003C\u002Fem> contamination both in finished product, as well as within the facility.” However, sampling conducted by FDA Investigators and by your employees as part of your finished product and environmental testing indicates \u003Cem>Salmonella\u003C\u002Fem> continued to persist in your facility. For example, FDA Investigators found \u003Cem>Salmonella\u003C\u002Fem> in 40 of 100 environmental swabs taken November 2, 2023, of which 17 positive swabs were from the extrusion or post-extrusion areas. In addition, FDA Investigators collected additional environmental swabs from the extrusion and post-extrusion areas on January 25, 2024, three of which were positive for \u003Cem>Salmonella\u003C\u002Fem> and genetically related to seven swabs collected during FDA’s 2023 inspection. Finally, you provided copies of your updated Master Sanitation Schedule, sanitation standard operating procedures, training records, and limited sanitation records (December 22, 2023, and January 4 and 31, 2024) in your response dated March 4, 2024. We are unable to fully evaluate your corrections from these limited records and will verify the status of your corrections during the next inspection. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\u003C\u002Fp>\u003Cp>B. Your response dated July 10, 2024, provided invoices from a roofing company including roof repairs and installing a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We will verify the status of these corrective actions during the next inspection.\u003C\u002Fp>\u003Cp>C. Your response dated March 4, 2024, stated that since January 13, 2024, you have updated your procedure and now \u003Cstrong>(b)(4)\u003C\u002Fstrong> to each new truckload of chicken fat you receive. After \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you stated you \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You stated in your response that you are installing \u003Cstrong>(b)(4)\u003C\u002Fstrong> that will \u003Cstrong>(b)(4)\u003C\u002Fstrong>, have retrained employees, and provided temperature monitoring documents during the FDA inspection. However, you did not demonstrate that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> is appropriately calculated to \u003Cstrong>(b)(4)\u003C\u002Fstrong> required to achieve a \u003Cstrong>(b)(4)\u003C\u002Fstrong> reduction of \u003Cem>Salmonella\u003C\u002Fem> in accordance with the validation study you provided. The target concentration listed as a parameter in on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Log is \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and your records document that you \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> truckloads of chicken fat received from January 13 through February 4, 2024. Therefore, we are unable to fully evaluate your corrections and will verify the status of your corrections during the next inspection. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\u003C\u002Fp>\u003Cp>2. You did not take appropriate corrective action when a preventive control, combination of preventive controls, or the food safety plan as a whole was found to be ineffective, as required by 21 CFR 507.42(b)(1)(ii), in order to identify and correct the problem, reduce the likelihood that the problem will recur, evaluate all affected animal food for safety, and when appropriate, reanalyze the food safety plan as required by 507.42(b)(2).\u003C\u002Fp>\u003Cp>A. Specifically, your Food Safety Plan, dated January 9, 2024, documents your sanitation control for \u003Cem>Salmonella\u003C\u002Fem> spp. in post-extrusion processing environments requires environmental monitoring. Your “Environmental Monitoring Program,” (EMP) (SOP-3525), dated November 22, 2023, documents “[s]ince all finished products are tested using \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling and testing for \u003Cem>Salmonella\u003C\u002Fem>, the EMP will not include Zone \u003Cstrong>(b)(4)\u003C\u002Fstrong> pathogen testing. It is generally accepted that finished product pathogen testing substitute [sic] for Zone \u003Cstrong>(b)(4)\u003C\u002Fstrong> pathogen testing.” Seventeen of the finished product lots you collected between the dates of December 20, 2023, and January 29, 2024, were positive for \u003Cem>Salmonella\u003C\u002Fem>. Ten of these \u003Cem>Salmonella\u003C\u002Fem>-positive samples were collected after you ceased manufacturing to conduct intensive cleaning and sanitation operations from December 23 through 25, 2023. In addition, you collected one additional \u003Cem>Salmonella\u003C\u002Fem>-positive sample on January 29, 2024, after you ceased manufacturing to conduct intensive cleaning and sanitation operations from January 10, 2024, to January 12, 2024.\u003C\u002Fp>\u003Cp>Finished product testing is the only verification procedure of effective implementation for the following of your preventive controls: \u003Cstrong>(b)(4)\u003C\u002Fstrong> process control, zone \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitation control, and extruder \u003Cstrong>(b)(4)\u003C\u002Fstrong> process control. You could not provide Investigators documentation demonstrating you conducted any root cause analyses to determine which of your preventive controls may have failed when samples from your finished product tested positive for \u003Cem>Salmonella\u003C\u002Fem> spp. Furthermore, you did not assess the food safety impact the affected finished product lots may have had on shared equipment prior to distributing subsequent lots made on the shared equipment in interstate commerce.\u003C\u002Fp>\u003Cp>B. Your “Environmental Monitoring Program (EMP)” SOP, (SOP-3525), dated November 22, 2023, documents you will “assess the impact of the [\u003Cem>Salmonella\u003C\u002Fem>] positive on the finished products (for zone \u003Cstrong>(b)(4)\u003C\u002Fstrong> positives only)” and collect a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> “vector swabs” before and after sanitation, \u003Cstrong>(b)(4)\u003C\u002Fstrong> of which will be the original positive site. However, you failed to collect the required minimum \u003Cstrong>(b)(4)\u003C\u002Fstrong> “vector swabs” before and after sanitation (including the original Salmonella positive site), and assess the impact of Salmonella positive environmental positives on the finished product on the following occasions:\u003C\u002Fp>\u003Cp>i. On December 21, 2023, you received \u003Cem>Salmonella\u003C\u002Fem>-positive environmental sampling results for sample “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” from a swab you collected on December 17, 2023, from “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Dryer Zone \u003Cstrong>(b)(4)\u003C\u002Fstrong> South west \u003Cstrong>(b)(4)\u003C\u002Fstrong> door.” Your environmental monitoring program SOP documents that you will collect a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> “vector swabs” before and after sanitation, \u003Cstrong>(b)(4)\u003C\u002Fstrong> of which will be the original positive site. However, you only collected \u003Cstrong>(b)(4)\u003C\u002Fstrong> “vector swabs”, none of which included the original positive site. In addition, you did not assess the food safety impact on any of the finished product lots you manufactured between December 17, 2023, and December 21, 2023, when you conducted cleaning and re-testing of the environment in accordance with your environmental monitoring program SOP. Products manufactured during this time were released to interstate commerce.\u003C\u002Fp>\u003Cp>ii. On December 26, 2023, you received \u003Cem>Salmonella\u003C\u002Fem>-positive environmental sampling results for sample “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” from a swab you collected on December 21, 2023, from the zone \u003Cstrong>(b)(4)\u003C\u002Fstrong> above \u003Cstrong>(b)(4)\u003C\u002Fstrong> leading to \u003Cstrong>(b)(4)\u003C\u002Fstrong> underneath \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment and repair sign on \u003Cstrong>(b)(4)\u003C\u002Fstrong> dryer.” Your environmental monitoring program SOP documents that you will collect a minimum \u003Cstrong>(b)(4)\u003C\u002Fstrong> “vector swabs” before and after sanitation, \u003Cstrong>(b)(4)\u003C\u002Fstrong> of which will be the original positive site. However, you only collected \u003Cstrong>(b)(4)\u003C\u002Fstrong> “vector swabs”, none of which included the original positive site. In addition, you did not assess the food safety impact on any of the finished product lots you manufactured between December 21, 2023, and December 23, 2023, after which you ceased operations through December 26, 2023. Products manufactured during this time were released to interstate commerce.\u003C\u002Fp>\u003Cp>\u003Cu>Evaluation of your response:\u003C\u002Fu>\u003Cbr>Your response dated March 4, 2024, stated that you believe your programs are effective for controlling \u003Cem>Salmonella\u003C\u002Fem> both in the manufacturing environment and in finished product. Additionally, you provided documentation of your sanitation activities for the dates following the Salmonella-positive environmental and product samples and stated that you have updated your procedures to require a root cause analysis for each positive event and would supplement your response with updated root cause analyses with an expected completion in four to eight weeks. Your response dated July 10, 2024, included copies of examples of your facility’s corrective actions when \u003Cem>Salmonella\u003C\u002Fem> is found through your environmental monitoring program. However, your root cause analysis does not consider how you will reduce the likelihood the problem will recur. Additionally, we cannot evaluate your investigation into possibly affected animal food due to illegible documents regarding product testing. Therefore, we are unable to fully evaluate your corrections and will verify the status of your corrections during the next inspection. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\u003C\u002Fp>\u003Cp>\u003Cu>Conclusion\u003C\u002Fu>\u003Cbr>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct the violations cited in this letter. Failure to adequately address this matter may lead to legal action, including, without limitation, seizure, and injunction.\u003C\u002Fp>\u003Cp>For more information about FDA’s current thinking on the requirements of 21 CFR Part 507, see:\u003C\u002Fp>\u003Cul>\u003Cli>Guidance for Industry #235: “Current Good Manufacturing Practice Requirements for Food for Animals”, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\u003C\u002Fa>\u003C\u002Fli>\u003Cli>Guidance for Industry #245: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals”, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\u003C\u002Fa>\u003C\u002Fli>\u003Cli>Draft Guidance for Industry #246: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply Chain Program”, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\u003C\u002Fa>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>In the interest of administrative efficiency, fiscal responsibility, and environmental awareness, the Food &amp; Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance is encouraging electronic submission of correspondence. In support of our efforts, we offer facilities the opportunity to submit all correspondence in electronic format up to 100 megabytes. Files greater than 100 megabytes may be submitted as smaller files in separate emails. There is no need to provide a back-up hard copy of any documentation you submit electronically. If you submit electronic correspondence, please ensure that the facility name, establishment identifier (FEI), and inspection location are included in the correspondence. An electronic acknowledgement will be issued upon receipt of your email. Please direct your electronic correspondence to CVMAnimalFoodCompliance@fda.hhs.gov and copy Compliance Officer Jessica Nanini (jessica.nanini@fda.hhs.gov). Including both email addresses will ensure your correspondence is routed as quickly as possible to the appropriate Agency personnel.\u003C\u002Fp>\u003Cp>If you are unable to submit your correspondence electronically, please direct it to the attention of Compliance Officer Jessica D. Nanini at the following address:\u003C\u002Fp>\u003Cp>United States Food &amp; Drug Administration\u003Cbr>Center for Veterinary Medicine\u003Cbr>Office of Surveillance and Compliance\u003Cbr>MPN 2, Room E436\u003Cbr>12225 Wilkins Avenue\u003Cbr>Rockville, Maryland 20852\u003C\u002Fp>\u003Cp>If you have questions regarding this letter, please contact Compliance Officer Jessica D. Nanini by telephone at (443) 280-1276, or by email at jessica.nanini@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Isaac K. Carney\u003Cbr>Director, Division of Food Compliance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>Cc:\u003Cbr>Mary Sasser, Program Director\u003Cbr>Office of the Texas State Chemist\u003Cbr>445 Agronomy Road\u003Cbr>College Station, Texas 77843\u003C\u002Fp>\u003Cp>Lorey Bell Grady, Feed Safety Program Manager\u003Cbr>South Carolina Department of Agriculture\u003Cbr>123 Ballard Court\u003Cbr>West Columbia, South Carolina 29172\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Centers for Disease Control and Prevention, Investigation Details Salmonella Outbreak Linked to Dry Dog Food, https:\u002F\u002Fwww.cdc.gov\u002Fsalmonella\u002Foutbreaks\u002Fdog-food-10-23\u002Finvestigation.html\u003Cbr>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 342(a)(1)].\u003Cbr>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See section 402(a)(4) of the FD&amp;C Act [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\u003Cbr>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003Cbr>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See section 301(uu) of the FD&amp;C Act [21 U.S.C. § 331(uu)].&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nAnimal & Veterinary\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJeff Caswell\n\nRecipient Title\n\nChief Executive Officer\n\nMid America Pet Food LLC\n\n2024 N. Frontage Road\n\nMount Pleasant, TX 75455-6474\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\nCMS# 681516\nNovember 22, 2024\nDear Mr. Caswell:\nThe U.S. Food and Drug Administration (FDA) inspected your pet food manufacturing facility located at 2024 N. Frontage Road, Mount Pleasant, Texas from November 2, 2023, through December 18, 2023. FDA also conducted a subsequent inspection from January 23, 2024, through February 9, 2024, at this facility. We received your responses dated January 10, 2024; March 4, 2024; and July 10, 2024, to the FDA 483 Inspectional Observations. FDA conducted the 2023 inspection in response to your voluntary Class I recalls initiated on September 3, 2023, expanded on October 30, 2023, and further expanded on November 9, 2023, to include all your dog and cat food with best by dates before October 31, because they had the potential to be contaminated with Salmonella. In addition, FDA conducted the 2023 inspection as part of an investigation, along with the Centers for Disease Control (CDC) and state and local partners, into a multi-state foodborne illness outbreak of Salmonella Kiambu implicated in human illnesses through epidemiological traceback.1 A total of seven people from seven states were infected with the outbreak strain from January 14, 2023 to August 19, 2023, and one person was hospitalized. Six of the affected people were children under one year of age. Salmonella can affect animals eating the products, and there is risk to humans from handling contaminated pet products and utensils that came into contact with the affected pet products. Children, the elderly, and individuals with compromised immune systems may be at greater risk for Salmonella infection.\nThese illnesses were linked by whole genome sequencing to dog food manufactured at your facility in 2023 through a sample of Victor Super Premium Dog Food Classic Hi-Pro Plus (lot 1000016385; Best By 4\u002F30\u002F24) collected by the South Carolina Department of Agriculture on August 15, 2023, which you recalled on September 3, 2023. On October 30, 2023, you expanded your initial recall to include Victor Super Premium Dog Food, Select Beef Meal & Brown Rice Formula with best by dates of June 12, 2024 (5 lbs. lot 1000016890; 15 lbs. lot 1000016891; and 40 lbs. lot 1000016892). On November 9, 2023, you expanded your recall to include all products with best by dates before October 31, 2024, because your testing revealed the presence of Salmonella Kiambu in a lot for which you reported receiving a consumer complaint involving human illness. Based on analytical results, FDA considers the Victor Super Premium Dog Food Classic Hi-Pro Plus (lot 1000016385; Best By 4\u002F30\u002F24)lot to be adulterated in that it bears or contains a poisonous or deleterious substance which may render it injurious to health.2\nFDA collected environmental samples (i.e., swabs) from surfaces in your manufacturing facility during this inspection and a subsequent inspection, conducted from January 23, 2024, through February 9, 2024, in response to a consumer complaint. Analysis of these samples using whole genome sequencing revealed that three of the Salmonella-positive environmental swabs collected in the post-process area of your facility during the 2024 inspection are closely related to seven Salmonella-positive environmental swabs collected in the pre-process areas of your facility during the 2023 inspection, indicating that your facility may have three resident strains of Salmonella: Salmonella Rissen, Salmonella Minnesota, and Salmonella Mbandaka.\nDuring these inspections FDA Investigators found evidence of significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements in Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507), which cause your products to be adulterated in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health.3 Additionally, the introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act.4 Furthermore, the failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of 21 CFR 507 (located in subparts A, C, D, E, and F of Part 507) is a prohibited act.5 You may find the FD&C Act and FDA’s regulations through links on the FDA’s website at www.fda.gov.\nAt the conclusion of our inspections on December 18, 2023, and February 9, 2024, you were issued two separate Forms FDA 483, Inspectional Observations. We received your written responses to these observations dated January 10, 2024, March 4, 2024, and July 10, 2024, and address your corrective actions below, in relation to each of the noted violations.\nHazard Analysis and Risk-Based Preventive Controls Requirements\nYour animal food facility is subject to the hazard analysis and risk-based preventive controls requirements found in 21 CFR Part 507, subparts A, C, D, E, and F. During the inspection of your facility, the FDA Investigators obtained evidence of significant violations of these requirements, which included:\n1. You did not identify and implement a preventive control to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented, as required by 21 CFR 507.34(a)(1).\nSpecifically, your hazard analysis determined the hazard of Salmonella requires preventive controls and identified sanitation and process controls to control the hazard of Salmonella in your finished pet food.\nA. Your Food Safety Plan dated January 9, 2024, documents your sanitation control for Salmonella spp. in post-extrusion processing environments by removing residual material on post-extruder surfaces and applying sanitizer in accordance with the sanitizer label. However, you failed to adequately implement your sanitation control.\ni. You use (b)(4) as a sanitizer for food-contact equipment and utensils. Your “(b)(4) Procedure” (SOP 1500) standard operating procedure (SOP), dated December 5, 2023, documents, “Surfaces must remain thoroughly wetted for (b)(4) followed by adequate draining and air drying . . . [a]llow the identified surface to air dry before the manufacturing process can resume, or the identified surface is reintroduced for use.” Furthermore, the label for (b)(4) documents “treated surfaces must remain wet for at least (b)(4) followed by adequate draining and air drying” for food-processing equipment and food-contact surfaces. On January 30, 2024, FDA Investigators observed an employee designated to the post-extrusion area cleaning food-contact equipment who used (b)(4) to sanitize the equipment and then immediately dried the surface of the equipment with a paper towel. During this cleaning, the equipment made direct contact with the employee’s clothing which was visibly soiled with apparent dog food.\nii. Your “Housekeeping Procedure” (CGMP 2800),” dated February 2, 2022, documents that the sanitation lead employee write their initials on sanitation records to document their inspection and review of sanitation activities on the Master Cleaning Schedule. Your Master Cleaning Schedule, “Housekeeping #5” for December 2023 does not document (b)(4) cleaning for the discharge hoppers located in the packaging area for the entire month of December 2023.\nIn addition, there were multiple instances of other equipment and areas where you did not document sanitation activities in accordance with your Master Cleaning Schedule in April 2023, May 2023, June 2023, September 2023, December 2023, and January 2024.\niii. On January 26, 2024, FDA Investigators observed visible debris on food-contact surfaces of equipment such as brushes, brooms, and squeegees after cleaning and sanitizing of equipment was performed by your third-party sanitation service. In addition, you could not produce any sanitation records for July and August of 2023 and your records for April 2023 and May 2023 were incomplete. Your lack of complete records in addition to the ineffective cleaning observed by Investigators demonstrates your failure to implement your sanitation preventive control.\nB. Your Food Safety Plan dated January 9, 2024, documents “CGMP controls” to minimize the hazard of Salmonella spp. in post-extrusion processing environments.\ni. On January 23, 2024, FDA Investigators observed rainwater entering your facility through the roof while you were manufacturing multiple lots of dog food. FDA Investigators observed standing water and soaked absorbent pads in staging, production, and finished product areas, including in post-process areas such as the dryer room and packaging areas. Your manufacturing facility must be constructed in a manner such does not become a source of potential contamination to your animal food.\nC. Your Food Safety Plan dated January 9, 2024, documents your process control for Salmonella spp. at the Storage of Liquid Bulk Ingredients step for chicken fat is to (b)(4) and (b)(4).\ni. You did not document the (b)(4) process control applied to your chicken fat prior to January 13, 2024, which demonstrates you did not effectively implement your process control. Your (b)(4) Log (SOP-5800F-(b)(4)), documents that from January 13 through February 4, 2024, you did not routinely (b)(4) in accordance with the validation study you provided for this process. The target (b)(4) listed as a parameter in on the (b)(4) Log is (b)(4), and your records document that you (b)(4) to (b)(4) of (b)(4) truckloads of fat received from January 13 through February 4, 2024.\nii. You did not document that the (b)(4) process control of (b)(4) was applied to your chicken fat until January 29, 2024. You produced approximately (b)(4) pounds of Victor Brand Dog Food using this fat from January 13, 2024, to January 28, 2024.\nEvaluation of your response:\nA. Your response dated January 10, 2024, documents that you updated your Master Sanitation schedule, updated sanitation standard operating procedures, and provided training to your employees. In addition, your response provided a timeline of the steps you took in response to the recalls, which included hiring a consultant and voluntarily closing your facility in November 2023 to perform deep cleaning and implement corrections. However, you did not provide records that document your new sanitation programs are implemented and we were unable to evaluate your corrections. In addition, FDA Investigators observed sanitation deficiencies persisted through the January to February 2024 inspection. Your response dated March 4, 2024, stated, “our programs have been, and are, effective for controlling Salmonella contamination both in finished product, as well as within the facility.” However, sampling conducted by FDA Investigators and by your employees as part of your finished product and environmental testing indicates Salmonella continued to persist in your facility. For example, FDA Investigators found Salmonella in 40 of 100 environmental swabs taken November 2, 2023, of which 17 positive swabs were from the extrusion or post-extrusion areas. In addition, FDA Investigators collected additional environmental swabs from the extrusion and post-extrusion areas on January 25, 2024, three of which were positive for Salmonella and genetically related to seven swabs collected during FDA’s 2023 inspection. Finally, you provided copies of your updated Master Sanitation Schedule, sanitation standard operating procedures, training records, and limited sanitation records (December 22, 2023, and January 4 and 31, 2024) in your response dated March 4, 2024. We are unable to fully evaluate your corrections from these limited records and will verify the status of your corrections during the next inspection. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\nB. Your response dated July 10, 2024, provided invoices from a roofing company including roof repairs and installing a (b)(4). We will verify the status of these corrective actions during the next inspection.\nC. Your response dated March 4, 2024, stated that since January 13, 2024, you have updated your procedure and now (b)(4) to each new truckload of chicken fat you receive. After (b)(4), you stated you (b)(4). You stated in your response that you are installing (b)(4) that will (b)(4), have retrained employees, and provided temperature monitoring documents during the FDA inspection. However, you did not demonstrate that your (b)(4) is appropriately calculated to (b)(4) required to achieve a (b)(4) reduction of Salmonella in accordance with the validation study you provided. The target concentration listed as a parameter in on the (b)(4) Log is (b)(4), and your records document that you (b)(4) to (b)(4) of (b)(4) truckloads of chicken fat received from January 13 through February 4, 2024. Therefore, we are unable to fully evaluate your corrections and will verify the status of your corrections during the next inspection. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\n2. You did not take appropriate corrective action when a preventive control, combination of preventive controls, or the food safety plan as a whole was found to be ineffective, as required by 21 CFR 507.42(b)(1)(ii), in order to identify and correct the problem, reduce the likelihood that the problem will recur, evaluate all affected animal food for safety, and when appropriate, reanalyze the food safety plan as required by 507.42(b)(2).\nA. Specifically, your Food Safety Plan, dated January 9, 2024, documents your sanitation control for Salmonella spp. in post-extrusion processing environments requires environmental monitoring. Your “Environmental Monitoring Program,” (EMP) (SOP-3525), dated November 22, 2023, documents “[s]ince all finished products are tested using (b)(4) sampling and testing for Salmonella, the EMP will not include Zone (b)(4) pathogen testing. It is generally accepted that finished product pathogen testing substitute [sic] for Zone (b)(4) pathogen testing.” Seventeen of the finished product lots you collected between the dates of December 20, 2023, and January 29, 2024, were positive for Salmonella. Ten of these Salmonella-positive samples were collected after you ceased manufacturing to conduct intensive cleaning and sanitation operations from December 23 through 25, 2023. In addition, you collected one additional Salmonella-positive sample on January 29, 2024, after you ceased manufacturing to conduct intensive cleaning and sanitation operations from January 10, 2024, to January 12, 2024.\nFinished product testing is the only verification procedure of effective implementation for the following of your preventive controls: (b)(4) process control, zone (b)(4) sanitation control, and extruder (b)(4) process control. You could not provide Investigators documentation demonstrating you conducted any root cause analyses to determine which of your preventive controls may have failed when samples from your finished product tested positive for Salmonella spp. Furthermore, you did not assess the food safety impact the affected finished product lots may have had on shared equipment prior to distributing subsequent lots made on the shared equipment in interstate commerce.\nB. Your “Environmental Monitoring Program (EMP)” SOP, (SOP-3525), dated November 22, 2023, documents you will “assess the impact of the [Salmonella] positive on the finished products (for zone (b)(4) positives only)” and collect a minimum of (b)(4) “vector swabs” before and after sanitation, (b)(4) of which will be the original positive site. However, you failed to collect the required minimum (b)(4) “vector swabs” before and after sanitation (including the original Salmonella positive site), and assess the impact of Salmonella positive environmental positives on the finished product on the following occasions:\ni. On December 21, 2023, you received Salmonella-positive environmental sampling results for sample “(b)(4)” from a swab you collected on December 17, 2023, from “(b)(4) Dryer Zone (b)(4) South west (b)(4) door.” Your environmental monitoring program SOP documents that you will collect a minimum of (b)(4) “vector swabs” before and after sanitation, (b)(4) of which will be the original positive site. However, you only collected (b)(4) “vector swabs”, none of which included the original positive site. In addition, you did not assess the food safety impact on any of the finished product lots you manufactured between December 17, 2023, and December 21, 2023, when you conducted cleaning and re-testing of the environment in accordance with your environmental monitoring program SOP. Products manufactured during this time were released to interstate commerce.\nii. On December 26, 2023, you received Salmonella-positive environmental sampling results for sample “(b)(4)” from a swab you collected on December 21, 2023, from the zone (b)(4) above (b)(4) leading to (b)(4) underneath (b)(4) equipment and repair sign on (b)(4) dryer.” Your environmental monitoring program SOP documents that you will collect a minimum (b)(4) “vector swabs” before and after sanitation, (b)(4) of which will be the original positive site. However, you only collected (b)(4) “vector swabs”, none of which included the original positive site. In addition, you did not assess the food safety impact on any of the finished product lots you manufactured between December 21, 2023, and December 23, 2023, after which you ceased operations through December 26, 2023. Products manufactured during this time were released to interstate commerce.\nEvaluation of your response:\nYour response dated March 4, 2024, stated that you believe your programs are effective for controlling Salmonella both in the manufacturing environment and in finished product. Additionally, you provided documentation of your sanitation activities for the dates following the Salmonella-positive environmental and product samples and stated that you have updated your procedures to require a root cause analysis for each positive event and would supplement your response with updated root cause analyses with an expected completion in four to eight weeks. Your response dated July 10, 2024, included copies of examples of your facility’s corrective actions when Salmonella is found through your environmental monitoring program. However, your root cause analysis does not consider how you will reduce the likelihood the problem will recur. Additionally, we cannot evaluate your investigation into possibly affected animal food due to illegible documents regarding product testing. Therefore, we are unable to fully evaluate your corrections and will verify the status of your corrections during the next inspection. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct the violations cited in this letter. Failure to adequately address this matter may lead to legal action, including, without limitation, seizure, and injunction.\nFor more information about FDA’s current thinking on the requirements of 21 CFR Part 507, see:\nGuidance for Industry #235: “Current Good Manufacturing Practice Requirements for Food for Animals”, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\nGuidance for Industry #245: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals”, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\nDraft Guidance for Industry #246: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply Chain Program”, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\nIn the interest of administrative efficiency, fiscal responsibility, and environmental awareness, the Food & Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance is encouraging electronic submission of correspondence. In support of our efforts, we offer facilities the opportunity to submit all correspondence in electronic format up to 100 megabytes. Files greater than 100 megabytes may be submitted as smaller files in separate emails. There is no need to provide a back-up hard copy of any documentation you submit electronically. If you submit electronic correspondence, please ensure that the facility name, establishment identifier (FEI), and inspection location are included in the correspondence. An electronic acknowledgement will be issued upon receipt of your email. Please direct your electronic correspondence to CVMAnimalFoodCompliance@fda.hhs.gov and copy Compliance Officer Jessica Nanini (jessica.nanini@fda.hhs.gov). Including both email addresses will ensure your correspondence is routed as quickly as possible to the appropriate Agency personnel.\nIf you are unable to submit your correspondence electronically, please direct it to the attention of Compliance Officer Jessica D. Nanini at the following address:\nUnited States Food & Drug Administration\nCenter for Veterinary Medicine\nOffice of Surveillance and Compliance\nMPN 2, Room E436\n12225 Wilkins Avenue\nRockville, Maryland 20852\nIf you have questions regarding this letter, please contact Compliance Officer Jessica D. Nanini by telephone at (443) 280-1276, or by email at jessica.nanini@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nIsaac K. Carney\nDirector, Division of Food Compliance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\nCc:\nMary Sasser, Program Director\nOffice of the Texas State Chemist\n445 Agronomy Road\nCollege Station, Texas 77843\nLorey Bell Grady, Feed Safety Program Manager\nSouth Carolina Department of Agriculture\n123 Ballard Court\nWest Columbia, South Carolina 29172\n____________________\n1 Centers for Disease Control and Prevention, Investigation Details Salmonella Outbreak Linked to Dry Dog Food, https:\u002F\u002Fwww.cdc.gov\u002Fsalmonella\u002Foutbreaks\u002Fdog-food-10-23\u002Finvestigation.html\n2 See section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 342(a)(1)].\n3 See section 402(a)(4) of the FD&C Act [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\n4 See section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n5 See section 301(uu) of the FD&C Act [21 U.S.C. § 331(uu)].","Mid America Pet Food LLC","mid-america-pet-food-llc-681516-11222024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmid-america-pet-food-llc-681516-11222024","2026-10-26T08:09:24.969178+00:00","Closed Out","2024-12-10","681516","Animal & VeterinaryFood & Beverages","2025-08-28","Jeff Caswell","2026-08-19T17:39:53.894+00:00","2024-11-22",{"id":169,"raw":170,"subject":176,"body_html":177,"body_text":178,"firm_name":179,"letter_id":180,"created_at":18,"fei_number":19,"letter_url":181,"updated_at":182,"action_type":22,"case_status":23,"posted_date":183,"marcs_cms_no":184,"product_type":185,"closeout_date":19,"issuing_office":174,"recipient_name":186,"body_fetched_at":187,"delivery_method":188,"recipient_title":19,"reference_number":19,"action_taken_date":189,"medical_device_id":19,"response_letter_date":19},2337,[171,172,173,174,175,13,13,13],"\u003Ctime datetime=\"2022-11-17T13:30:00Z\">11\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-14T05:00:00Z\">11\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbergamet-north-america-llc-636315-11142022\">BergaMet North America LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","New Drug\u002FMisbranded\u003Cbr \u002F>\r\n","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jay Decker\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>BergaMet North America LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6445 S. Tenaya Way Suite B110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89113-1989\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:orders@bergametna.com\"> orders@bergametna.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 14, 2022\u003C\u002Fp>\n\n\u003Cp>RE: 636315\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jay Decker:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fbergametna.com in October 2022 and has determined that you take orders there for your Cholesterol Command product. We also reviewed your social media website,\u003Cbr>\nwww.facebook.com\u002FBergametNorthAmerica.com which directs consumers to your website, https:\u002F\u002Fbergametna.com to purchase your product. Additionally, we reviewed the product listing on www.walmart.com, where your product is available for purchase. The claims on your websites establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>On your Cholesterol Command product page at https:\u002F\u002Fbergametna.com\u002Fproducts\u002Fcholesterol-command:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“BergaMet Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Anti-inflammatory”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Magnesium [an ingredient in Cholesterol Command] . . . Deficiency is related to . . . T2D [type 2 diabetes], chronic inflammation, heart disease and high blood pressure.”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Zinc [an ingredient in Cholesterol Command] . . . This key mineral has specific properties that may address inflammatory or immune system conditions.”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“WHEN YOU ORDER BERGAMET . . . Take our supplements with confidence knowing that if they do not improve your LDL levels. You get 100% of your money back down to the penny.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your “What is Bergamot” page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Flearn-about-bergamot:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Reduces cholesterol”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Anti-Inflammatory Citrus Bergamot [an ingredient in your Cholesterol Command product] has been clinically shown to reduce inflammation.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Walmart product page at https:\u002F\u002Fwww.walmart.com\u002Fip\u002FCitrus-Bergamot-Cholesterol-Command-80-Polyphenol-Formula-Supplement-Cholesterol-Heart-Health-Blood-Glucose-Levels-Highest-Strength\u002F543149759:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“BergaMet products follow the correct dosage and extract concentrations used and recommended in recent clinical studies as a bergamot supplement for high cholesterol . . . and help improve blood vessel function”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your websites also contain evidence of intended use in the form of personal testimonials recommending or describing the use of Cholesterol Command for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\u003Cbr>\n\u003Cbr>\nOn your testimonial page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Ftestimonials:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Love Cholesterol Command! My ldl is down 28 points, my doctor was extremely surprised because I am allergic to statins so working on my cholesterol levels has been difficult until I found out about BergaMet ... haven’t seen my cholesterol this low in 15 years”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Facebook page at www.facebook.com\u002FBergametNorthAmerica.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;On a graphic titled “CAN CITRUS BERGAMOT [an ingredient in your Cholesterol Command product] IMPROVE YOUR CHOLESTEROL?” posted on March 14, 2022, you endorsed the following customer replies:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o “Yes, it really works! my bad cholesterol drooped by 60 pts . . .” You endorsed this testimonial by responding, “That is amazing Jon! Thank you for sharing.”\u003Cbr>\n&nbsp; o “I have had amazing results with this supplement it brought down all my levels out of the red and into a very healthy range … this is the answer not a statin!” You endorsed this testimonial by responding, “that is AMAZING Lori! Thank you for sharing and congrats!”\u003Cbr>\n&nbsp; o “That’s what I use I stopped taking my prescription and my lab test number are great.” You endorsed this testimonial by responding, “That is great to hear Emmanuel! Thank you for sharing”\u003Cbr>\n&nbsp; o You also endorsed the following responses to your post by liking them:\u003Cbr>\n&nbsp; &nbsp; 􀂃 “I just got my blood test back my total cholesterol went down 56 points and my bad cholesterol went down 82 points.”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Yes!! Mine went down 38 points.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Cholesterol Command product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Cholesterol Command is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Cholesterol Command fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003Cbr>\n\u003Cbr>\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jay Decker\n\nBergaMet North America LLC\n\n6445 S. Tenaya Way Suite B110\n\nLas Vegas, NV 89113-1989\n\nUnited States\n\norders@bergametna.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nNovember 14, 2022\n\nRE: 636315\n\nDear Mr. Jay Decker:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fbergametna.com in October 2022 and has determined that you take orders there for your Cholesterol Command product. We also reviewed your social media website,\n\nwww.facebook.com\u002FBergametNorthAmerica.com which directs consumers to your website, https:\u002F\u002Fbergametna.com to purchase your product. Additionally, we reviewed the product listing on www.walmart.com, where your product is available for purchase. The claims on your websites establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\n\nOn your Cholesterol Command product page at https:\u002F\u002Fbergametna.com\u002Fproducts\u002Fcholesterol-command:\n\n“BergaMet Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL”\n\n“Anti-inflammatory”\n\n“Magnesium [an ingredient in Cholesterol Command] . . . Deficiency is related to . . . T2D [type 2 diabetes], chronic inflammation, heart disease and high blood pressure.”\n\n“Zinc [an ingredient in Cholesterol Command] . . . This key mineral has specific properties that may address inflammatory or immune system conditions.”\n\n“WHEN YOU ORDER BERGAMET . . . Take our supplements with confidence knowing that if they do not improve your LDL levels. You get 100% of your money back down to the penny.”\n\nOn your “What is Bergamot” page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Flearn-about-bergamot:\n\n“Reduces cholesterol”\n\n“Anti-Inflammatory Citrus Bergamot [an ingredient in your Cholesterol Command product] has been clinically shown to reduce inflammation.”\n\nOn your Walmart product page at https:\u002F\u002Fwww.walmart.com\u002Fip\u002FCitrus-Bergamot-Cholesterol-Command-80-Polyphenol-Formula-Supplement-Cholesterol-Heart-Health-Blood-Glucose-Levels-Highest-Strength\u002F543149759:\n\n“BergaMet products follow the correct dosage and extract concentrations used and recommended in recent clinical studies as a bergamot supplement for high cholesterol . . . and help improve blood vessel function”\n\nYour websites also contain evidence of intended use in the form of personal testimonials recommending or describing the use of Cholesterol Command for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\nOn your testimonial page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Ftestimonials:\n\n“Love Cholesterol Command! My ldl is down 28 points, my doctor was extremely surprised because I am allergic to statins so working on my cholesterol levels has been difficult until I found out about BergaMet ... haven’t seen my cholesterol this low in 15 years”\n\nOn your Facebook page at www.facebook.com\u002FBergametNorthAmerica.com:\n\nOn a graphic titled “CAN CITRUS BERGAMOT [an ingredient in your Cholesterol Command product] IMPROVE YOUR CHOLESTEROL?” posted on March 14, 2022, you endorsed the following customer replies:\n\no “Yes, it really works! my bad cholesterol drooped by 60 pts . . .” You endorsed this testimonial by responding, “That is amazing Jon! Thank you for sharing.”\n\no “I have had amazing results with this supplement it brought down all my levels out of the red and into a very healthy range … this is the answer not a statin!” You endorsed this testimonial by responding, “that is AMAZING Lori! Thank you for sharing and congrats!”\n\no “That’s what I use I stopped taking my prescription and my lab test number are great.” You endorsed this testimonial by responding, “That is great to hear Emmanuel! Thank you for sharing”\n\no You also endorsed the following responses to your post by liking them:\n\n􀂃 “I just got my blood test back my total cholesterol went down 56 points and my bad cholesterol went down 82 points.”\n\n“Yes!! Mine went down 38 points.”\n\nYour Cholesterol Command product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Cholesterol Command is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Cholesterol Command fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition\n\nFood and Drug Administration","BergaMet North America LLC","bergamet-north-america-llc-636315-11142022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbergamet-north-america-llc-636315-11142022","2026-10-26T08:08:03.414177+00:00","2022-11-17","636315","Dietary SupplementsDrugs","Mr. Jay Decker","2026-08-20T01:25:33.357+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2022-11-14",{"id":191,"raw":192,"subject":196,"body_html":198,"body_text":199,"firm_name":200,"letter_id":201,"created_at":202,"fei_number":19,"letter_url":203,"updated_at":204,"action_type":22,"case_status":160,"posted_date":205,"marcs_cms_no":206,"product_type":26,"closeout_date":207,"issuing_office":11,"recipient_name":208,"body_fetched_at":209,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":210,"medical_device_id":19,"response_letter_date":19},3279,[193,194,195,11,196,13,197,13],"\u003Ctime datetime=\"2021-07-06T13:20:00Z\">07\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-07T04:00:00Z\">05\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnikkiso-medical-america-inc-613109-05072021\">Nikkiso Medical America, Inc\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnikkiso-co-ltd-613109-07232025\">\u003Ctime datetime=\"2025-07-29T04:00:00Z\">07\u002F29\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Toshihiko Kai \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Nikkiso Medical America, Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>20-3, Ebisu 4-Chome, Shibuya-ku\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tokyo\u003C\u002Fspan>,\u003Cbr>\n\u003Cspan>150-6022\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:T.Kai@nikkiso.co.jp\"> T.Kai@nikkiso.co.jp\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 7, 2021\u003Cbr>\n\u003Cbr>\nRefer to CPT1900751; CMS #613109\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Toshihiko Kai:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is marketing the Nikkiso DBB-06 (DBB-06) in the United States without the necessary marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\u003C\u002Fp>\n\n\u003Cp>Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>FDA reviewed on February 5, 2021 Nikkiso’s marketing materials for DBB-06. This review revealed that DBB-06 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the device as described and marketed. The DBB-06 is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with a significant change or modification, specifically the introduction of a physiological closed loop controller (PCLC) system (also referred to as PCLC function or functionality in this letter) which is a change or modification in the device that could significantly affect the safety or effectiveness of the device, without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm’s marketing materials for DBB-06 provide evidence that the device is intended for dialysis with a PCLC system, which would constitute a significant change or modification to the device, for which your firm lacks clearance or approval. Examples include:\u003Cbr>\n\u003Cbr>\n• In the online version of your firm’s product brochure found at http:\u002F\u002Fnikkisoamerica.com\u002Fwp-content\u002Fuploads\u002F2011\u002F08\u002FNIKKISO-DBB06-RV09262016-V3.pdf, your firmclaims that the DBB-06 Haemo-Master Blood Volume Monitor (BVM) uses “adaptive feedback” to regulate the “blood volume trend.”\u003C\u002Fp>\n\n\u003Cp>• The website also includes the following statement: “The unique adaptive feedback feature of the BVM allows for automatic changes of fluid removal to achieve desired outcomes.”\u003C\u002Fp>\n\n\u003Cp>Although the DBB-06 device was cleared via the 510(k) pathway under K091978 and K152938, neither K091978 nor K152938 adequately described the PCLC function. For example, there is no mention of PCLC functionality in the 510(k) summary or in the Indications for Use statement for either 510(k). Notably, on page 6 of the 510(k) summary for K091978, the Blood Volume Monitor’s intended use is described as follows: “The healthcare provider may increase or decrease the rate at which fluid is removed from the blood based on the data that blood volume monitor provides.” This description contrasts with your firm’s current marketing materials, which describe PCLC functionality, i.e., the use of “adaptive feedback” to change dialysis therapy parameters (e.g., ultrafiltration rate) automatically with no clinician involvement. As discussed above, the introduction of a PCLC system is considered a change or modification in the device that could significantly affect the safety or effectiveness of the device, and therefore, requires clearance or approval. For example, the introduction of a PCLC system creates new risks, including reduced monitoring and adjustment of dialysis therapy by the clinician due to increased reliance on automation technology to monitor and adjust dialysis therapy.\u003C\u002Fp>\n\n\u003Cp>This is not the first time that FDA has communicated with your firm that the PCLC function was not cleared under either K091978 or K152938 for the device. \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Please provide a justification for inclusion of this feature with supportive performance data for its safe and effective use. If your intent is to reference the DBB-06 device (K091978 and K152938), we do not believe this function was cleared.” On August 16, 2019, FDA issued your firm an “It has come to our attention” letter advising your firm that FDA believed the “Haemo-Master Blood Volume Monitor as an adaptive feedback controller of the ultrafiltration rate for a patient” was not cleared under the 510(k) pathway. In additional correspondence in 2019, Nikkiso continued to take the position that the PCLC function had been addressed by validation testing included in an Appendix to K091978 and that the PCLC function had been cleared. Nonetheless, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Regardless of whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, along with all the previous communication, illustrates that the firm understands FDA’s position on the regulatory status of the DBB-06 device with the PCLC function.\u003Cbr>\n\u003Cbr>\nBased on the information reviewed by FDA, Nikkiso’s marketing of the DBB-06 device with the PCLC function, which has not been cleared or approved, has resulted, as noted above, in the misbranding and adulteration of the device.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Our office requests that Nikkiso America, Inc. immediately cease activities that result in the misbranding or adulteration of the Nikkiso DBB-06, such as the commercial distribution of the device with the PCLC function as discussed above.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the identification number CPT1900751 and CMS# 613109 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact Carolyn Y. Neuland, Ph.D. at 301-796-6523.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nActing Office Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC: US Agent:\u003Cbr>\nDeno Zachary\u003Cbr>\nMIC International\u003Cbr>\n206 East 75th Street, Suite 4\u003Cbr>\nNew York , NY US 10021\u003Cbr>\nPhone: 917 3315789 Ext\u003Cbr>\nEmail: Dzachary@Micinternational.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Toshihiko Kai\n\nRecipient Title\n\nPresident & Chief Executive Officer\n\nNikkiso Medical America, Inc\n\n20-3, Ebisu 4-Chome, Shibuya-ku\n\nTokyo,\n\n150-6022\n\nJapan\n\nT.Kai@nikkiso.co.jp\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nMay 7, 2021\n\nRefer to CPT1900751; CMS #613109\n\nDear Mr. Toshihiko Kai:\n\nThe United States Food and Drug Administration (FDA) has learned that your firm is marketing the Nikkiso DBB-06 (DBB-06) in the United States without the necessary marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\n\nUnder section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nFDA reviewed on February 5, 2021 Nikkiso’s marketing materials for DBB-06. This review revealed that DBB-06 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the device as described and marketed. The DBB-06 is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with a significant change or modification, specifically the introduction of a physiological closed loop controller (PCLC) system (also referred to as PCLC function or functionality in this letter) which is a change or modification in the device that could significantly affect the safety or effectiveness of the device, without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3).\n\nSpecifically, your firm’s marketing materials for DBB-06 provide evidence that the device is intended for dialysis with a PCLC system, which would constitute a significant change or modification to the device, for which your firm lacks clearance or approval. Examples include:\n\n• In the online version of your firm’s product brochure found at http:\u002F\u002Fnikkisoamerica.com\u002Fwp-content\u002Fuploads\u002F2011\u002F08\u002FNIKKISO-DBB06-RV09262016-V3.pdf, your firmclaims that the DBB-06 Haemo-Master Blood Volume Monitor (BVM) uses “adaptive feedback” to regulate the “blood volume trend.”\n\n• The website also includes the following statement: “The unique adaptive feedback feature of the BVM allows for automatic changes of fluid removal to achieve desired outcomes.”\n\nAlthough the DBB-06 device was cleared via the 510(k) pathway under K091978 and K152938, neither K091978 nor K152938 adequately described the PCLC function. For example, there is no mention of PCLC functionality in the 510(k) summary or in the Indications for Use statement for either 510(k). Notably, on page 6 of the 510(k) summary for K091978, the Blood Volume Monitor’s intended use is described as follows: “The healthcare provider may increase or decrease the rate at which fluid is removed from the blood based on the data that blood volume monitor provides.” This description contrasts with your firm’s current marketing materials, which describe PCLC functionality, i.e., the use of “adaptive feedback” to change dialysis therapy parameters (e.g., ultrafiltration rate) automatically with no clinician involvement. As discussed above, the introduction of a PCLC system is considered a change or modification in the device that could significantly affect the safety or effectiveness of the device, and therefore, requires clearance or approval. For example, the introduction of a PCLC system creates new risks, including reduced monitoring and adjustment of dialysis therapy by the clinician due to increased reliance on automation technology to monitor and adjust dialysis therapy.\n\nThis is not the first time that FDA has communicated with your firm that the PCLC function was not cleared under either K091978 or K152938 for the device. (b)(4). Please provide a justification for inclusion of this feature with supportive performance data for its safe and effective use. If your intent is to reference the DBB-06 device (K091978 and K152938), we do not believe this function was cleared.” On August 16, 2019, FDA issued your firm an “It has come to our attention” letter advising your firm that FDA believed the “Haemo-Master Blood Volume Monitor as an adaptive feedback controller of the ultrafiltration rate for a patient” was not cleared under the 510(k) pathway. In additional correspondence in 2019, Nikkiso continued to take the position that the PCLC function had been addressed by validation testing included in an Appendix to K091978 and that the PCLC function had been cleared. Nonetheless, (b)(4).\n\nRegardless of whether the (b)(4), along with all the previous communication, illustrates that the firm understands FDA’s position on the regulatory status of the DBB-06 device with the PCLC function.\n\nBased on the information reviewed by FDA, Nikkiso’s marketing of the DBB-06 device with the PCLC function, which has not been cleared or approved, has resulted, as noted above, in the misbranding and adulteration of the device.\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOur office requests that Nikkiso America, Inc. immediately cease activities that result in the misbranding or adulteration of the Nikkiso DBB-06, such as the commercial distribution of the device with the PCLC function as discussed above.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nYour firm’s response should be sent to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the identification number CPT1900751 and CMS# 613109 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact Carolyn Y. Neuland, Ph.D. at 301-796-6523.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nActing Office Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC: US Agent:\n\nDeno Zachary\n\nMIC International\n\n206 East 75th Street, Suite 4\n\nNew York , NY US 10021\n\nPhone: 917 3315789 Ext\n\nEmail: Dzachary@Micinternational.com","Nikkiso Medical America, Inc","nikkiso-medical-america-inc-613109-05072021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnikkiso-medical-america-inc-613109-05072021","2026-10-26T08:09:33.866363+00:00","2021-07-06","613109","2025-07-29","Mr. Toshihiko Kai","2026-08-20T03:00:01.467+00:00","2021-05-07",{"id":212,"raw":213,"subject":218,"body_html":220,"body_text":221,"firm_name":222,"letter_id":223,"created_at":224,"fei_number":19,"letter_url":225,"updated_at":226,"action_type":22,"case_status":160,"posted_date":227,"marcs_cms_no":228,"product_type":229,"closeout_date":230,"issuing_office":217,"recipient_name":231,"body_fetched_at":232,"delivery_method":233,"recipient_title":19,"reference_number":19,"action_taken_date":234,"medical_device_id":19,"response_letter_date":19},3547,[214,215,216,217,218,13,219,13],"\u003Ctime datetime=\"2021-02-09T14:20:00Z\">02\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-29T05:00:00Z\">01\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fucc-ueshima-coffee-company-america-inc-612006-01292021\">UCC Ueshima Coffee Company America Inc. \u003C\u002Fa>","Division of West Coast Imports","Foreign Supplier Verification Program (FSVP)","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fucc-ueshima-coffee-company-inc-612006-america\">\u003Ctime datetime=\"2022-04-01T04:00:00Z\">04\u002F01\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jay S. Egami\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>UCC Ueshima Coffee Company America Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>723 A Liggett Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Francisco\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94129-1480\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nJanuary 29, 2021\u003C\u002Fp>\n\n\u003Cp>Re: CMS #612006\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jay S. Egami:\u003C\u002Fp>\n\n\u003Cp>On August 27-28, September 1-3, 8-9 and 11, 2020, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of FSVP records that you submitted to FDA electronically. We also conducted an inspection on May 23, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation under 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for your UCC black coffee (ready-to-drink) and UCC green tea (ready-to-drink), imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and UCC Hawaii Kona coffee (ready-to-drink) imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You did not have FSVPs for these products. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the FSVP inspection, our investigator provided you with Form FDA 483a, FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your three responses to the Form FDA 483a, including your stated intent to work with a consultant to address our concerns, a presentation by the consultant that describes an FSVP “compliance procedure” ranging from responding to the Form FDA 483a to “FSVP document preparation,” a list of milestones extending to February 2021 for completing tasks related to FSVP compliance, and general commitments to complete SOPs to implement various FSVP requirements. We are unable to fully evaluate your responses because you did not provide any written procedures or documentation of your FSVP activities to show that you have made corrections or developed FSVPs for the foods you import from your foreign suppliers. You also have not provided progress reports to FDA on the schedule indicated in your list of milestones.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, your firm did not develop FSVPs for each of the following foods:\u003Cbr>\n&nbsp; a. UCC black coffee (ready-to-drink) imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>;\u003Cbr>\n&nbsp; b. UCC green tea (ready-to-drink) imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and\u003Cbr>\n&nbsp; c. UCC Hawaii Kona coffee (ready-to-drink) imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>During our inspection you provided an audit certificate for your supplier&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, you did not provide a record of your review of this document or explain how it would apply to your FSVP program. You also provided two other documents, an audit certificate and supplier questionnaire, but it was not clear that they were for one of the identified suppliers.\u003C\u002Fp>\n\n\u003Cp>2. For thermally processed low-acid foods packaged in hermetically sealed containers (low-acid canned foods), with respect to those microbiological hazards that are controlled by following 21 CFR part 113, you must verify and document that the food was produced in\u003Cbr>\naccordance with 21 CFR part 113, as required by 21 CFR 1.502(b)(1). You did not verify and document that your products – UCC black coffee (ready-to-drink), UCC green tea (ready-to-drink), and UCC Hawaii Kona coffee (ready-to-drink) – low-acid canned foods, were produced in accordance with 21 CFR part 113, as required by 21 CFR 1.502(b)(1).\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address the above violations. If you do not promptly address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of UCC black coffee (ready-to-drink) and UCC green tea (ready-to-drink), both imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and UCC Hawaii Kona coffee (ready-to-drink) imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>We may place products that appear to be adulterated or misbranded from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Debbie Giang, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Debbie Giang via phone at \u003Cspan>(562) 256-9235\u003Ca>\u003C\u002Fa>\u003C\u002Fspan> or via email at debbie.giang@fda.hhs.gov. Please reference CMS # 612006 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Gordon Chu\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJay S. Egami\n\nRecipient Title\n\nPresident\n\nUCC Ueshima Coffee Company America Inc.\n\n723 A Liggett Ave\n\nSan Francisco, CA 94129-1480\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nWARNING LETTER\n\nJanuary 29, 2021\n\nRe: CMS #612006\n\nDear Mr. Jay S. Egami:\n\nOn August 27-28, September 1-3, 8-9 and 11, 2020, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of FSVP records that you submitted to FDA electronically. We also conducted an inspection on May 23, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation under 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for your UCC black coffee (ready-to-drink) and UCC green tea (ready-to-drink), imported from (b)(4); and UCC Hawaii Kona coffee (ready-to-drink) imported from (b)(4). You did not have FSVPs for these products. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the FSVP inspection, our investigator provided you with Form FDA 483a, FSVP Observations.\n\nWe acknowledge receipt of your three responses to the Form FDA 483a, including your stated intent to work with a consultant to address our concerns, a presentation by the consultant that describes an FSVP “compliance procedure” ranging from responding to the Form FDA 483a to “FSVP document preparation,” a list of milestones extending to February 2021 for completing tasks related to FSVP compliance, and general commitments to complete SOPs to implement various FSVP requirements. We are unable to fully evaluate your responses because you did not provide any written procedures or documentation of your FSVP activities to show that you have made corrections or developed FSVPs for the foods you import from your foreign suppliers. You also have not provided progress reports to FDA on the schedule indicated in your list of milestones.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, your firm did not develop FSVPs for each of the following foods:\n\na. UCC black coffee (ready-to-drink) imported from (b)(4);\n\nb. UCC green tea (ready-to-drink) imported from (b)(4); and\n\nc. UCC Hawaii Kona coffee (ready-to-drink) imported from (b)(4).\n\nDuring our inspection you provided an audit certificate for your supplier (b)(4); however, you did not provide a record of your review of this document or explain how it would apply to your FSVP program. You also provided two other documents, an audit certificate and supplier questionnaire, but it was not clear that they were for one of the identified suppliers.\n\n2. For thermally processed low-acid foods packaged in hermetically sealed containers (low-acid canned foods), with respect to those microbiological hazards that are controlled by following 21 CFR part 113, you must verify and document that the food was produced in\n\naccordance with 21 CFR part 113, as required by 21 CFR 1.502(b)(1). You did not verify and document that your products – UCC black coffee (ready-to-drink), UCC green tea (ready-to-drink), and UCC Hawaii Kona coffee (ready-to-drink) – low-acid canned foods, were produced in accordance with 21 CFR part 113, as required by 21 CFR 1.502(b)(1).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nYou should take prompt action to address the above violations. If you do not promptly address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of UCC black coffee (ready-to-drink) and UCC green tea (ready-to-drink), both imported from (b)(4); and UCC Hawaii Kona coffee (ready-to-drink) imported from (b)(4).\n\nWe may place products that appear to be adulterated or misbranded from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert (b)(4). In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Debbie Giang, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Debbie Giang via phone at (562) 256-9235 or via email at debbie.giang@fda.hhs.gov. Please reference CMS # 612006 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nGordon Chu\n\nActing Program Division Director\n\nDivision of West Coast Imports","UCC Ueshima Coffee Company America Inc.","ucc-ueshima-coffee-company-america-inc-612006-01292021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fucc-ueshima-coffee-company-america-inc-612006-01292021","2026-10-26T08:10:16.679615+00:00","2021-02-09","612006","Food & Beverages","2022-04-01","Jay S. Egami","2026-08-20T03:24:47.328+00:00","United Parcel Service","2021-01-29",{"id":236,"raw":237,"subject":241,"body_html":242,"body_text":243,"firm_name":244,"letter_id":245,"created_at":43,"fei_number":19,"letter_url":246,"updated_at":247,"action_type":22,"case_status":23,"posted_date":248,"marcs_cms_no":249,"product_type":70,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":250,"delivery_method":251,"recipient_title":19,"reference_number":19,"action_taken_date":252,"medical_device_id":19,"response_letter_date":19},391,[238,239,240,37,241,13,13,13],"\u003Ctime datetime=\"2025-12-23T05:00:00Z\">12\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-12T05:00:00Z\">12\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdynamic-health-group-dba-sarms-america-719257-12122025\">Dynamic Health Group dba SARMS AMERICA\u003C\u002Fa>","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Dynamic Health Group dba SARMS AMERICA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2232 Dell Range Blvd, Suite 245\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cheyenne\u003C\u002Fspan>, \u003Cspan>WY\u003C\u002Fspan> \u003Cspan>82009\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@sarmsamerica.co\"> support@sarmsamerica.co\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dynamicgrouphealth@gmail.com\"> dynamicgrouphealth@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dynamichealthgroupp@gmail.com\"> dynamichealthgroupp@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 12, 2025\u003C\u002Fp>\u003Cp>RE: 719257\u003C\u002Fp>\u003Cp>Dynamic Health Group dba SARMS AMERICA:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fsarmsamerica.co\u002F in November 2025. The FDA has observed that you offer products marketed on your firm’s website as selective androgen receptor modulators (SARMs) including, but not limited to, “Ostarine MK-2866,” “MK-677 Ibutamoren,” “Cardarine GW501516,” and “LGD-4033 Ligandrol” (hereinafter products marketed as SARMs) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>FDA has safety concerns about products that contain SARMs. Life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs. SARMs also have the potential to increase the risk of heart attack and stroke.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Despite statements on your product labeling marketing your products, “[F]or research use only,” and “[F]or research purposes only,” evidence obtained from your product labeling, including your website establishes that your products are intended to be drugs for human use. Based on a review of your website, your products marketed as SARMs are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Ostarine MK-2866\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fsarmsamerica.co\u002Fproducts\u002Fostarine-mk-2866\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“MK-2866 has demonstrated a variety of potential benefits in research\u003C\u002Fli>\u003C\u002Ful>\u003Cp>1. Increased strength\u003Cbr>2. Enhanced protein synthesis\u003Cbr>3. Accelerated muscle growth\u003Cbr>4. Boosted energy levels\u003Cbr>5. Improved bone health\u003Cbr>6. Better heart health\u003Cbr>7. Weight loss and reduction in body fat\u003Cbr>8. Enhanced recovery of connective tissue.”\u003C\u002Fp>\u003Cul>\u003Cli>“Studies involving Ostarine\u003Cbr>1. A 2011 study showed that MK2866 significantly boosted lean body mass, muscle mass, and overall physical functionality in elderly males and postmenopausal females.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>MK-677 Ibutamoren\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fsarmsamerica.co\u002Fproducts\u002Fibutamoren-mk-677\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“MK677, also recognized as Ibutamoren, Oratrope, or Nutrobal . . . functions as a ghrelin agonist. It acts on the pituitary gland to stimulate the secretion of human growth hormone, making it a human growth hormone secretagogue.”\u003C\u002Fli>\u003Cli>“Administered orally, MK677 Ibutamoren mimics the action of the hunger hormone ghrelin, thereby increasing growth hormone (GH) levels in the body. It is notably effective in elevating insulin-like growth factor 1 (IGF-1) levels.”\u003C\u002Fli>\u003Cli>“MK 677 Benefits in Clinical Research\u003Cbr>1. MK-677 has demonstrated various effects in vivo, including:\u003Cbr> Increased GH levels\u003Cbr> Enhanced muscle mass and lean body mass\u003Cbr> Reduction in body fat\u003Cbr> Increased bone density\u003Cbr> Accelerated muscle growth\u003Cbr> Improved immune function\u003Cbr> Enhanced REM sleep\u003Cbr> Increased appetite\u003Cbr> Reversal of growth hormone deficiency\u003Cbr> Alleviation of pathology associated with beta-amyloid”\u003C\u002Fli>\u003Cli>“MK 677 and Body Composition\u003Cbr>1. Research has shown that MK677 increases bone turnover, bone mineral density, muscle mass, and osteoblast activity in older adults, thereby improving overall body composition.\u003Cbr>2. A randomized controlled trial conducted with health older adults revealed that daily administration of 25 mg of MK-677 improved body composition, bone mineral density, and cholesterol levels over several months, concurrently enhancing appetite.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Cardarine GW501516\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fsarmsamerica.co\u002Fproducts\u002Fcardarine-gw501516\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Also known as Cardarine GW 501516 or Endurobol, this compound is a PPARδ receptor agonist. These receptors regulate various biological processes within the body. Research indicates that GW-501516 binds to these receptors, activating AMP-activated protein kinase (AMPK). According to studies, AMPK plays a crucial role in energy regulation and helps the body survive metabolic stress. By activating AMPK, GW-501516 can significantly boost fat loss and increase overall energy output.”\u003C\u002Fli>\u003Cli>“About Cardarine SARM . . .\u003Cbr>It has shown potential in aiding fat burning and possibly preventing obesity in users.\u003Cbr>o Increases fatty acid oxidation and promotes fat loss\u003Cbr>o Lower LDL cholesterol (“bad cholesterol”)\u003Cbr>o Higher HDL cholesterol (“good cholesterol”)\u003Cbr>o Increases endurance\u003Cbr>o Reduces inflammation\u003Cbr>o Decreases insulin resistance and improves glucose tolerance”\u003C\u002Fli>\u003Cli>“Maintaining Heart Health with Cardarine\u003Cbr>o In a twelve-week study, participants were administered varying dosages of GW-501516 (Cardarine), including 2.5mg, 5.0mg, and 10mg. . . . Fasting insulin, glucose, lipids, and free fatty acid levels were of the levels taken for said baseline. By the end of this twelve-week study, those involved had experienced a significant change in both cholesterol levels, meaning HDL and LDL. It was therefore concluded that GW 501516 has potential as a cardiovascular protection compound.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>LGD-4033 Ligandrol\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fsarmsamerica.co\u002Fproducts\u002Flgd4033-ligandrol\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“The popular SARM, LGD-4033, is known by various names in the scientific community, including Ligandrol, VK5211, and Anabolicum. Researchers have found that Ligandrol is effective in creating lean muscle mass and treating bone conditions such as osteoporosis.”\u003C\u002Fli>\u003Cli>“LGD 4033, also known as Ligandrol, is a selective androgen receptor modulator (SARM) that can provide the benefits of anabolic steroids without the associated negative side effects. It promotes an increase in lean muscle mass, enhances libido, and improves stamina. . . . Taken orally, this tissue-selective SARM can positively impact muscle weakness caused by osteoporosis, cancer, and aging.”\u003C\u002Fli>\u003Cli>“Potential Research Findings\u003Cbr>1. Lean Muscle Development:\u003Cbr> LGD-4033 has been studied for its ability to promote increases in lean muscle mass by activating androgen receptors in skeletal muscle.\u003Cbr>2. Strength Enhancement:\u003Cbr> Research suggests LGD-4033 may improve strength and power, supporting muscle performance under experimental conditions.\u003Cbr>3. Endurance Support:\u003Cbr> Some studies indicate its potential to enhance stamina and physical endurance, aiding in prolonged physical activity during research trials.\u003Cbr>4. Fat Mass Reduction:\u003Cbr> Findings suggest LGD-4033 may assist in reducing fat mass while preserving lean tissue, making it a focus of studies related to metabolic health.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products marketed as SARMs are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “719257” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002Ffda-warns-use-selective-androgen-receptor-modulators-sarms-among-teens-young-adults.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nDynamic Health Group dba SARMS AMERICA\n\n2232 Dell Range Blvd, Suite 245\n\nCheyenne, WY 82009\n\nUnited States\n\nsupport@sarmsamerica.co\n\ndynamicgrouphealth@gmail.com\n\ndynamichealthgroupp@gmail.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nDecember 12, 2025\nRE: 719257\nDynamic Health Group dba SARMS AMERICA:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fsarmsamerica.co\u002F in November 2025. The FDA has observed that you offer products marketed on your firm’s website as selective androgen receptor modulators (SARMs) including, but not limited to, “Ostarine MK-2866,” “MK-677 Ibutamoren,” “Cardarine GW501516,” and “LGD-4033 Ligandrol” (hereinafter products marketed as SARMs) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nFDA has safety concerns about products that contain SARMs. Life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs. SARMs also have the potential to increase the risk of heart attack and stroke.1\nDespite statements on your product labeling marketing your products, “[F]or research use only,” and “[F]or research purposes only,” evidence obtained from your product labeling, including your website establishes that your products are intended to be drugs for human use. Based on a review of your website, your products marketed as SARMs are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nOstarine MK-2866\nOn the webpage https:\u002F\u002Fsarmsamerica.co\u002Fproducts\u002Fostarine-mk-2866\u002F:\n“MK-2866 has demonstrated a variety of potential benefits in research\n1. Increased strength\n2. Enhanced protein synthesis\n3. Accelerated muscle growth\n4. Boosted energy levels\n5. Improved bone health\n6. Better heart health\n7. Weight loss and reduction in body fat\n8. Enhanced recovery of connective tissue.”\n“Studies involving Ostarine\n1. A 2011 study showed that MK2866 significantly boosted lean body mass, muscle mass, and overall physical functionality in elderly males and postmenopausal females.”\nMK-677 Ibutamoren\nOn the webpage https:\u002F\u002Fsarmsamerica.co\u002Fproducts\u002Fibutamoren-mk-677\u002F:\n“MK677, also recognized as Ibutamoren, Oratrope, or Nutrobal . . . functions as a ghrelin agonist. It acts on the pituitary gland to stimulate the secretion of human growth hormone, making it a human growth hormone secretagogue.”\n“Administered orally, MK677 Ibutamoren mimics the action of the hunger hormone ghrelin, thereby increasing growth hormone (GH) levels in the body. It is notably effective in elevating insulin-like growth factor 1 (IGF-1) levels.”\n“MK 677 Benefits in Clinical Research\n1. MK-677 has demonstrated various effects in vivo, including:\n Increased GH levels\n Enhanced muscle mass and lean body mass\n Reduction in body fat\n Increased bone density\n Accelerated muscle growth\n Improved immune function\n Enhanced REM sleep\n Increased appetite\n Reversal of growth hormone deficiency\n Alleviation of pathology associated with beta-amyloid”\n“MK 677 and Body Composition\n1. Research has shown that MK677 increases bone turnover, bone mineral density, muscle mass, and osteoblast activity in older adults, thereby improving overall body composition.\n2. A randomized controlled trial conducted with health older adults revealed that daily administration of 25 mg of MK-677 improved body composition, bone mineral density, and cholesterol levels over several months, concurrently enhancing appetite.”\nCardarine GW501516\nOn the webpage https:\u002F\u002Fsarmsamerica.co\u002Fproducts\u002Fcardarine-gw501516\u002F:\n“Also known as Cardarine GW 501516 or Endurobol, this compound is a PPARδ receptor agonist. These receptors regulate various biological processes within the body. Research indicates that GW-501516 binds to these receptors, activating AMP-activated protein kinase (AMPK). According to studies, AMPK plays a crucial role in energy regulation and helps the body survive metabolic stress. By activating AMPK, GW-501516 can significantly boost fat loss and increase overall energy output.”\n“About Cardarine SARM . . .\nIt has shown potential in aiding fat burning and possibly preventing obesity in users.\no Increases fatty acid oxidation and promotes fat loss\no Lower LDL cholesterol (“bad cholesterol”)\no Higher HDL cholesterol (“good cholesterol”)\no Increases endurance\no Reduces inflammation\no Decreases insulin resistance and improves glucose tolerance”\n“Maintaining Heart Health with Cardarine\no In a twelve-week study, participants were administered varying dosages of GW-501516 (Cardarine), including 2.5mg, 5.0mg, and 10mg. . . . Fasting insulin, glucose, lipids, and free fatty acid levels were of the levels taken for said baseline. By the end of this twelve-week study, those involved had experienced a significant change in both cholesterol levels, meaning HDL and LDL. It was therefore concluded that GW 501516 has potential as a cardiovascular protection compound.”\nLGD-4033 Ligandrol\nOn the webpage https:\u002F\u002Fsarmsamerica.co\u002Fproducts\u002Flgd4033-ligandrol\u002F:\n“The popular SARM, LGD-4033, is known by various names in the scientific community, including Ligandrol, VK5211, and Anabolicum. Researchers have found that Ligandrol is effective in creating lean muscle mass and treating bone conditions such as osteoporosis.”\n“LGD 4033, also known as Ligandrol, is a selective androgen receptor modulator (SARM) that can provide the benefits of anabolic steroids without the associated negative side effects. It promotes an increase in lean muscle mass, enhances libido, and improves stamina. . . . Taken orally, this tissue-selective SARM can positively impact muscle weakness caused by osteoporosis, cancer, and aging.”\n“Potential Research Findings\n1. Lean Muscle Development:\n LGD-4033 has been studied for its ability to promote increases in lean muscle mass by activating androgen receptors in skeletal muscle.\n2. Strength Enhancement:\n Research suggests LGD-4033 may improve strength and power, supporting muscle performance under experimental conditions.\n3. Endurance Support:\n Some studies indicate its potential to enhance stamina and physical endurance, aiding in prolonged physical activity during research trials.\n4. Fat Mass Reduction:\n Findings suggest LGD-4033 may assist in reducing fat mass while preserving lean tissue, making it a focus of studies related to metabolic health.”\nYour products marketed as SARMs are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “719257” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\n_____________________\n1 See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002Ffda-warns-use-selective-androgen-receptor-modulators-sarms-among-teens-young-adults.","Dynamic Health Group dba SARMS AMERICA","dynamic-health-group-dba-sarms-america-719257-12122025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdynamic-health-group-dba-sarms-america-719257-12122025","2026-10-26T08:08:28.851438+00:00","2025-12-23","719257","2026-08-19T07:19:41.555+00:00","Via Email","2025-12-12",{"id":254,"raw":255,"subject":262,"body_html":263,"body_text":264,"firm_name":265,"letter_id":266,"created_at":224,"fei_number":19,"letter_url":267,"updated_at":268,"action_type":22,"case_status":160,"posted_date":269,"marcs_cms_no":270,"product_type":70,"closeout_date":271,"issuing_office":259,"recipient_name":272,"body_fetched_at":273,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":269,"medical_device_id":19,"response_letter_date":19},3572,[256,257,258,259,260,13,261,13],"\u003Ctime datetime=\"2021-01-27T20:45:00Z\">01\u002F27\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-27T05:00:00Z\">01\u002F27\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprofessional-compounding-centers-america-dba-pcca-597638-01272021\">Professional Compounding Centers of America dba PCCA\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprofessional-compounding-centers-america-dba-pcca-597638-11212023-0\">\u003Ctime datetime=\"2023-12-01T05:00:00Z\">12\u002F01\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Fabian V. Zaccardo\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Operating Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Professional Compounding Centers of America dba PCCA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9901 South Wilcrest Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Houston\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77099-5132\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-15\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nJanuary 27, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AMENDED\u003C\u002Fstrong>\u003Cbr>\n(This letter replaces Warning Letter No. 320-21-15 dated January 7, 2021)\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Zaccardo:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Professional Compounding Centers of America, Inc. (PCCA), FEI 1629694, at 9901 South Wilcrest Drive, Houston, Texas from October 22 to 29, 2019.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations, including deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API). CGMP violations identified at your suppliers caused drugs manufactured by these firms to be adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). Your receipt in interstate commerce of adulterated drugs and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&amp;C Act, 21 U.S.C. 331(c).\u003C\u002Fp>\n\n\u003Cp>Additionally, your glycerin United States Pharmacopeia (USP) product is adulterated under section 501(b) of the FD&amp;C Act, 21 U.S.C. 351(b), for failure to conform to compendial standards for identity, strength, quality, or purity. Your glycerin USP product is also misbranded under section 502(e)(3)(B) and (g) of the FD&amp;C Act because it fails to meet the applicable USP standard of identity. Furthermore, because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your glycerin API is adulterated within the meaning of section 501(a)(2)(B) of FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Finally, your drug products tramadol HCl, fentanyl citrate, buprenorphine HCl and morphine sulfate are misbranded under section 502(a) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>We reviewed your November 19, 2019, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations and deviations including, but not limited to, the following.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Receipt of Adulterated Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your receipt in interstate commerce of adulterated drugs (i.e., those listed on an import alert) and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&amp;C Act, 21 U.S.C. 331(c).\u003C\u002Fp>\n\n\u003Cp>Our inspection and review of import data revealed your firm received \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, on July 30, 2018. An inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;in \u003Cstrong>(b)(4)\u003C\u002Fstrong> revealed significant CGMP deviations including sourcing drugs from a firm that refused an FDA inspection, destruction of batch records in a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on product contact surfaces. As a result of these and other deviations, all drugs manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on Import Alert 66-40 (IA 66-40) on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the firm was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. remain listed on IA 66-40 at this time.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Other Drug Suppliers in Your Supply Chain with a History of Non-Compliance\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We note that an inspection of records at your facility and a review of FDA import data demonstrated that FDA has, in the past, taken regulatory action against at least 23 of your other API suppliers for the manufacture of adulterated drugs under section 501 of the FD&amp;C Act by either listing their drugs on import alert and\u002For issuing them warning letters. Drugs from multiple API suppliers used by PCCA were listed on an import alert, including IA 66-40 for the supplier’s failure to conform to CGMP within the meaning of section 501(a)(2)(B) and Import Alert 99-32 (IA 99-32) for the supplier’s conduct in delaying, denying, or limiting FDA inspections of foreign facilities or providing reasonable access to FDA's inspectional personnel. To understand whether PCCA has received or introduced additional adulterated drugs in interstate commerce, we are therefore requesting information regarding timing of receipt and distribution of drugs from the 23 facilities listed below.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>PCCA suppliers with drugs listed on Import Alert 66-40 for suppliers’ failure to comply with CGMP\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>1. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and all drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, the firm’s failure to have procedures for change control, out-of-specification investigations, process deviation investigations, laboratory incidents and failure to validate the manufacturing process. FDA determined that this facility had adequately addressed the deviations and after \u003Cstrong>(b)(4)\u003C\u002Fstrong> the firm’s drugs were removed from IA 66-40. A Warning Letter Close Out (WLCO) letter was issued on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>2. Drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>,\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and the firm was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA determined the firm had adequately addressed the deviations on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The firm’s drug products were removed from IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and a WLCO letter was issued on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>3. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the firm was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, manipulating analytical data, including deleting chromatograms and retesting samples into compliance. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;remain listed on IA 66-40 at this time.\u003C\u002Fp>\n\n\u003Cp>4. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the firm was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, inadequate impurity testing, and lack of audit trails to support CGMP activities. FDA determined that the firm had adequately addressed the deviations on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A WLCO letter was issued on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the firm’s drug products were removed from IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>5. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the firm was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. All drugs from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;remain listed on IA 66-40 at this time.\u003C\u002Fp>\n\n\u003Cp>6. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the firm was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;remain listed on IA 66-40 at this time.\u003C\u002Fp>\n\n\u003Cp>7. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the firm was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, a failure to ensure that quality-related complaints are investigated and resolved. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 66-40 at this time.\u003C\u002Fp>\n\n\u003Cp>8. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 66-40 at this time.\u003C\u002Fp>\n\n\u003Cp>For manufacturers whose drugs are listed on IA 66-40 for failure to conform to CGMP within the meaning of section 501(a)(2)(B), FDA has evidence that the drugs listed in the import alert appear to be adulterated. You are responsible for ensuring that the drugs you distribute are manufactured in compliance with all relevant CGMP requirements for drugs. Up to date information regarding import alerts can be found at the following FDA website: \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>PCCA suppliers with drugs listed on Import Alert 99-32 for Delaying, Denying, Limiting, or Refusing an FDA Drug Inspection\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>9. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>10. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>11. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>12. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s delaying and ultimately denying an inspection. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>13. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI: \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s refusing to accept proposed inspection dates. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>14. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>15. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>16. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong> remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>17. All drugs from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were listed on IA 99-32 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to the firm’s delaying and ultimately denying an inspection. All drugs from \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>remain listed on IA 99-32 at this time.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>PCCA suppliers that received warning letters not otherwise listed above\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>18. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>19. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Furthermore, buildings used in the production of API were observed to contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> material on the floors. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA determined that the firm had adequately addressed the deviations contained in that warning letter, and a WLCO letter was issued.\u003C\u002Fp>\n\n\u003Cp>20. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, failure to ensure cleaning practices were adequate to prevent contamination on shared equipment used for API manufacture.\u003C\u002Fp>\n\n\u003Cp>21. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, inadequate investigation of failing test results, and failure to maintain complete data for API tested and distributed to the United States. This warning letter also noted that similar CGMP deficiencies were cited in earlier inspections of the firm, and that the recurring deviations demonstrate that the facility’s oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>22. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>23. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was issued a warning letter on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for among other things, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the lot numbers and dates of distribution for all drugs received from each facility listed above. Include the identity of PCCA’s customers who received drugs from the facilities listed above, and whether you distributed the drugs from a listed facility during the time period after the aforementioned warning letters and\u002For import alerts were issued and before a close-out letter was issued and\u002For the firm’s drugs were removed from the import alert. For lots of drug product API received and distributed by PCCA during the relevant time frame, include whether you have notified your customers that they received adulterated drugs from PCCA. If you have not notified any customer who received adulterated drug API from PCCA, notify them, and provide a copy of that notification in your response.\u003C\u002Fp>\n\n\u003Cp>Considering that FDA has found a pattern of drug manufacturers with serious CGMP or other adulteration violations in your supply chain, in response to this letter, also provide a detailed plan to ensure you do not receive or deliver adulterated drugs in interstate commerce, in violation of section 301(c) of the FD&amp;C Act, 21 U.S.C. 331(c). Items in your plan should include a full evaluation of your supplier program, including a plan to audit your suppliers. Furthermore, you should also include a full reconciliation of any drugs from the manufacturers listed above, as well as for all firms or drugs currently on FDA import alerts, to determine if you have any remaining drugs in your possession. Up to date information regarding import alerts can be found at the following FDA website: \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration and Misbranding of Glycerin API\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You repackage glycerin USP and distribute this drug to your customers which include pharmacy compounders. Repackaged glycerin intended as an excipient or other component of a drug product is a drug as defined by section 201(g)(1) the FD&amp;C Act, 21 U.S.C. 321(g)(1). Glycerin is also a drug the name of which is recognized in an official compendium (the USP).\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> A drug with a name recognized in USP–NF must comply with compendial identity standards or be deemed adulterated, misbranded, or both. Sections 501(b) and 502(e)(3)(B) and (g) of the FD&amp;C Act, 21 U.S.C. 351(b), 352(e)(3)(B); see also 21 CFR 299.5(a) and (b). In such cases, the identity is determined by the official tests, procedures and acceptance criteria in the applicable USP-NF monograph. USP-NF General Notices 2.30. Furthermore, in accordance with section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B), a drug is adulterated “if the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice to assure that such drug meets the requirements of this chapter as to safety and has the identity and strength, and meets the quality and purity characteristics, which it purports or is represented to possess.”\u003C\u002Fp>\n\n\u003Cp>FDA compared the testing required in the identification section of the USP monograph for glycerin with PCCA analytical test results, which reference the USP method, and determined the testing for identity of glycerin conducted by PCCA was incomplete and therefore was not adequate to assure that your glycerin conformed to the compendial standards of identity. \u003Cstrong>(b)(4)\u003C\u002Fstrong>. While your \u003Cstrong>(b)(4)\u003C\u002Fstrong> test using \u003Cstrong>(b)(4)\u003C\u002Fstrong> can identify glycerin, it is not an adequate test for detecting DEG and EG in glycerin at USP specified limits. Therefore, you failed to conduct adequate identity testing for glycerin USP and your glycerin drug product is adulterated and misbranded within the meaning of sections 501(b), 501(a)(2)(B), and 502(e)(3)(b) and (g) of the FD&amp;C Act, 21 U.S.C. 351(b), 351(a)(2)(B), and 352(e)(3)(B) and (g), in that you do not have test data to demonstrate its identity meets the standards set forth in an official compendium (the USP) recognized in the FD&amp;C Act. See also 21 CFR 299.5(a) and (b).\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Your response stated that your firm has complied with the regulatory requirement because your firm performed identity testing on each lot prior to release. You further stated that each lot had been previously tested by the manufacturer prior to receipt by your firm. You note that during the initial supplier qualification, you tested the purchased glycerin using a third-party laboratory. You also stated in your response that with your efforts to “know (its) supply chain for glycerin, PCCA is confident that its supply of glycerin is free from DEG contamination.” Moving forward, you committed to requalify your supplier on an \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis. You further stated that you believe that you do not need to test your incoming glycerin for the presence of DEG and EG impurities as it is “superfluous, and simply not required.”\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because the test you perform for identity on the bulk glycerin that you repackage cannot determine if a batch of glycerin is adulterated with DEG and EG contaminants and does not conform to the identification section of the applicable USP monograph. You cannot ensure the quality and security of the supply chain with regard to DEG and EG adulteration given your current practice because you do not independently verify that the API manufacturer’s reports are reliable through adequate identity testing consistent with the applicable USP monograph upon receipt. Reliability of a supplier is generally established by the receiving entity’s own testing which, when compared to the supplier’s data, shows agreement within the specified limits over a period of time. Periodic monitoring is also generally necessary in order to assure the continued reliability of a supplier’s test results. Relying solely on the manufacturer’s COA is not adequate to comply with applicable requirements as described above. Although, in your response to FDA’s 483, PCCA does commit to re-qualifying its supplier of glycerin on an \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis, it is unclear whether PCCA will verify the API supplier’s COA as part of that \u003Cstrong>(b)(4)\u003C\u002Fstrong> qualification process using an adequate identity test that meets applicable standards.\u003C\u002Fp>\n\n\u003Cp>FDA has received reports about fatal DEG poisoning of consumers who ingested medicinal syrups, such as cough syrup or acetaminophen syrup, that were manufactured with DEG-contaminated glycerin. Historical DEG-related poisonings and fatalities stemmed from multiple violative practices in the glycerin supply chain, including manufacturers not conducting full and adequate identity testing; manufacturers relying on COAs; and COAs, such as those you provide with your glycerin and other drugs, not providing the name of the true manufacturer and thus masking the chain of custody of an adulterated product.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• An update regarding implementation of DEG and EG testing for all lots of glycerin.\u003C\u002Fp>\n\n\u003Cp>• A detailed risk assessment for drug products distributed by your firm that contain glycerin and are within expiry in the U.S. market.\u003C\u002Fp>\n\n\u003Cp>• Test reserve samples of all lots of glycerin for DEG and EG with the test method and provide test results.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding Due to False or Misleading Labeling of Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 502(a) of the FD&amp;C Act, a drug is misbranded if its label is “false or misleading in any particular.” Further, 21 CFR 201.1(h)(2) specifies that “The appearance on a drug product label of a person's name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the [FD&amp;C] act, if the person is not the manufacturer of the product in accordance with this section.”\u003C\u002Fp>\n\n\u003Cp>The labels your firm affixed to the following repackaged\u002Frelabeled API identify PCCA, but do not designate your firm’s role:\u003C\u002Fp>\n\n\u003Cp>• tramadol HCl (lot # C191954);\u003Cbr>\n• fentanyl citrate (lot # C189348);\u003Cbr>\n• buprenorphine HCl (lot # C191213); and,\u003Cbr>\n• morphine sulfate (lot # C192769).\u003C\u002Fp>\n\n\u003Cp>Evidence collected during the inspection of your facility establishes that other firms were involved in the manufacturing of these API. Because these API labels bear only the PCCA name without further qualifications, the labels falsely represent that PCCA is the sole drug manufacturer. Therefore, these repackaged\u002Frelabeled API are misbranded under section 502(a) of the FD&amp;C Act because the labels are false and misleading.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Regulatory Meeting\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Upon submission of your response to this letter, email CDR John W. Diehl, Director, Compliance Branch, FDA\u002FORA\u002FOPQO Division II, at John.Diehl@fda.hhs.gov to schedule a meeting to discuss the adequacy of the corrective actions you proposed to prevent the continued introduction of adulterated and misbranded goods into interstate commerce. Topics of the regulatory meeting will also include supply chain controls and compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The deviations and violations cited in this letter are not intended to be an all-inclusive list of deviations and violations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and violations and for preventing their recurrence or the occurrence of other violations and deviations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003Cbr>\nProfessional Compounding Centers of America, Inc., Houston FEI: 1629694 Page 9\u003C\u002Fp>\n\n\u003Cp>Failure to promptly address these deviations and violations may result in legal action without further notice including, without limitation, seizure and injunction. Other Federal agencies may take your compliance history into account when awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations of FD&amp;C Act sections may be cause for FDA to withhold issuance of Export Certificates and may be cause for FDA to withhold approval of new applications or supplements listing your firm as a drug manufacturer. We may re-inspect to verify that you have completed your corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to address any deviations and violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address deviations and violations within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with FEI 1629694 and Case # 597638. Send your electronic reply to Monica R. Maxwell, Program Division Director, FDA\u002FORA\u002FOPQO Division II at ORAPharm2_Responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have any questions concerning the letter, please direct those to CDR Diehl at \u003Cspan>(214) 253-5288\u003Ca>\u003C\u002Fa>\u003C\u002Fspan> or john.diehl@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Alonza Cruse\u003Cbr>\nDirector\u003Cbr>\nOffice of Pharmaceutical Quality Operations\u003Cbr>\nOffice of Medical Products and Tobacco Operations&nbsp;\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Products from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>, have also been placed on IA 66-40 because that facility ships products manufactured at FEI \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Certain drugs were carved out due to shortage concerns.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Throughout this letter, where applicable, we have provided the date of the memorandum documenting FDA’s internal determination that a firm’s deviations were adequately addressed prior to the final removal of the firm’s products from import alert.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> USP Glycerin monograph, Document ID: GUID-6A5A5AD2-0762-4830-8E99-D593E5400FF0_4_en-US\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See the identity test for glycerin included in the USP Monograph for glycerin, supra note 1\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Fabian V. Zaccardo\n\nRecipient Title\n\nChief Operating Officer\n\nProfessional Compounding Centers of America dba PCCA\n\n9901 South Wilcrest Drive\n\nHouston, TX 77099-5132\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-15\n\nJanuary 27, 2021\n\nAMENDED\n\n(This letter replaces Warning Letter No. 320-21-15 dated January 7, 2021)\n\nDear Mr. Zaccardo:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Professional Compounding Centers of America, Inc. (PCCA), FEI 1629694, at 9901 South Wilcrest Drive, Houston, Texas from October 22 to 29, 2019.\n\nThis warning letter summarizes significant violations, including deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API). CGMP violations identified at your suppliers caused drugs manufactured by these firms to be adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Your receipt in interstate commerce of adulterated drugs and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&C Act, 21 U.S.C. 331(c).\n\nAdditionally, your glycerin United States Pharmacopeia (USP) product is adulterated under section 501(b) of the FD&C Act, 21 U.S.C. 351(b), for failure to conform to compendial standards for identity, strength, quality, or purity. Your glycerin USP product is also misbranded under section 502(e)(3)(B) and (g) of the FD&C Act because it fails to meet the applicable USP standard of identity. Furthermore, because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your glycerin API is adulterated within the meaning of section 501(a)(2)(B) of FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nFinally, your drug products tramadol HCl, fentanyl citrate, buprenorphine HCl and morphine sulfate are misbranded under section 502(a) of the FD&C Act.\n\nWe reviewed your November 19, 2019, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigator observed specific violations and deviations including, but not limited to, the following.\n\nReceipt of Adulterated Drugs\n\nYour receipt in interstate commerce of adulterated drugs (i.e., those listed on an import alert) and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&C Act, 21 U.S.C. 331(c).\n\nOur inspection and review of import data revealed your firm received (b)(4) from (b)(4), FEI (b)(4), on July 30, 2018. An inspection of (b)(4) in (b)(4) revealed significant CGMP deviations including sourcing drugs from a firm that refused an FDA inspection, destruction of batch records in a (b)(4), and (b)(4) on product contact surfaces. As a result of these and other deviations, all drugs manufactured by (b)(4), were listed on Import Alert 66-40 (IA 66-40) on (b)(4), and the firm was issued a warning letter on (b)(4).1 All drugs from (b)(4). remain listed on IA 66-40 at this time.\n\nOther Drug Suppliers in Your Supply Chain with a History of Non-Compliance\n\nWe note that an inspection of records at your facility and a review of FDA import data demonstrated that FDA has, in the past, taken regulatory action against at least 23 of your other API suppliers for the manufacture of adulterated drugs under section 501 of the FD&C Act by either listing their drugs on import alert and\u002For issuing them warning letters. Drugs from multiple API suppliers used by PCCA were listed on an import alert, including IA 66-40 for the supplier’s failure to conform to CGMP within the meaning of section 501(a)(2)(B) and Import Alert 99-32 (IA 99-32) for the supplier’s conduct in delaying, denying, or limiting FDA inspections of foreign facilities or providing reasonable access to FDA's inspectional personnel. To understand whether PCCA has received or introduced additional adulterated drugs in interstate commerce, we are therefore requesting information regarding timing of receipt and distribution of drugs from the 23 facilities listed below.\n\nPCCA suppliers with drugs listed on Import Alert 66-40 for suppliers’ failure to comply with CGMP\n\n1. (b)(4), FEI (b)(4), was issued a warning letter on (b)(4), and all drugs from (b)(4) were listed on IA 66-40 on (b)(4), for among other things, the firm’s failure to have procedures for change control, out-of-specification investigations, process deviation investigations, laboratory incidents and failure to validate the manufacturing process. FDA determined that this facility had adequately addressed the deviations and after (b)(4) the firm’s drugs were removed from IA 66-40. A Warning Letter Close Out (WLCO) letter was issued on (b)(4).\n\n2. Drugs from (b)(4), FEI (b)(4), were listed on IA 66-40 on (b)(4),2 and the firm was issued a warning letter on (b)(4), for among other things, (b)(4). FDA determined the firm had adequately addressed the deviations on (b)(4).3 The firm’s drug products were removed from IA 66-40 on (b)(4) and a WLCO letter was issued on (b)(4).\n\n3. All drugs from (b)(4), FEI (b)(4), were listed on IA 66-40 on (b)(4), and the firm was issued a warning letter on (b)(4), for among other things, manipulating analytical data, including deleting chromatograms and retesting samples into compliance. All drugs from (b)(4) remain listed on IA 66-40 at this time.\n\n4. All drugs from (b)(4), FEI (b)(4), were listed on IA 66-40 on (b)(4), and the firm was issued a warning letter on (b)(4), for among other things, inadequate impurity testing, and lack of audit trails to support CGMP activities. FDA determined that the firm had adequately addressed the deviations on (b)(4). A WLCO letter was issued on (b)(4) and the firm’s drug products were removed from IA 66-40 on (b)(4).\n\n5. All drugs from (b)(4), FEI (b)(4), were listed on IA 66-40 on (b)(4), and the firm was issued a warning letter on (b)(4), for among other things, (b)(4). All drugs from (b)(4) remain listed on IA 66-40 at this time.\n\n6. All drugs from (b)(4), FEI (b)(4), were listed on IA 66-40 on (b)(4), and the firm was issued a warning letter on (b)(4), for among other things, (b)(4). All drugs from (b)(4) remain listed on IA 66-40 at this time.\n\n7. All drugs from (b)(4), FEI (b)(4), were listed on IA 66-40 on (b)(4), and the firm was issued a warning letter on (b)(4), for among other things, a failure to ensure that quality-related complaints are investigated and resolved. All drugs from (b)(4) remain listed on IA 66-40 at this time.\n\n8. All drugs from (b)(4), FEI (b)(4), were listed on IA 66-40 on (b)(4). All drugs from (b)(4) remain listed on IA 66-40 at this time.\n\nFor manufacturers whose drugs are listed on IA 66-40 for failure to conform to CGMP within the meaning of section 501(a)(2)(B), FDA has evidence that the drugs listed in the import alert appear to be adulterated. You are responsible for ensuring that the drugs you distribute are manufactured in compliance with all relevant CGMP requirements for drugs. Up to date information regarding import alerts can be found at the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\n\nPCCA suppliers with drugs listed on Import Alert 99-32 for Delaying, Denying, Limiting, or Refusing an FDA Drug Inspection\n\n9. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n10. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n11. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n12. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s delaying and ultimately denying an inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n13. All drugs from (b)(4), FEI: (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s refusing to accept proposed inspection dates. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n14. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n15. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n16. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s denying FDA’s attempt to schedule a pre-announced inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\n17. All drugs from (b)(4), FEI (b)(4), were listed on IA 99-32 on (b)(4), due to the firm’s delaying and ultimately denying an inspection. All drugs from (b)(4) remain listed on IA 99-32 at this time.\n\nPCCA suppliers that received warning letters not otherwise listed above\n\n18. (b)(4), FEI (b)(4), was issued a warning letter on (b)(4), for among other things, (b)(4).\n\n19. (b)(4), FEI (b)(4), was issued a warning letter on (b)(4), for among other things, (b)(4). Furthermore, buildings used in the production of API were observed to contain (b)(4), and (b)(4) material on the floors. On (b)(4), FDA determined that the firm had adequately addressed the deviations contained in that warning letter, and a WLCO letter was issued.\n\n20. (b)(4), FEI (b)(4), was issued a warning letter on (b)(4), for among other things, failure to ensure cleaning practices were adequate to prevent contamination on shared equipment used for API manufacture.\n\n21. (b)(4), FEI (b)(4), was issued a warning letter on (b)(4), for among other things, inadequate investigation of failing test results, and failure to maintain complete data for API tested and distributed to the United States. This warning letter also noted that similar CGMP deficiencies were cited in earlier inspections of the firm, and that the recurring deviations demonstrate that the facility’s oversight and control over the manufacture of drugs is inadequate.\n\n22. (b)(4), FEI (b)(4), was issued a warning letter on (b)(4), for among other things, (b)(4).\n\n23. (b)(4), FEI (b)(4), was issued a warning letter on (b)(4), for among other things, (b)(4).\n\nIn response to this letter, provide the lot numbers and dates of distribution for all drugs received from each facility listed above. Include the identity of PCCA’s customers who received drugs from the facilities listed above, and whether you distributed the drugs from a listed facility during the time period after the aforementioned warning letters and\u002For import alerts were issued and before a close-out letter was issued and\u002For the firm’s drugs were removed from the import alert. For lots of drug product API received and distributed by PCCA during the relevant time frame, include whether you have notified your customers that they received adulterated drugs from PCCA. If you have not notified any customer who received adulterated drug API from PCCA, notify them, and provide a copy of that notification in your response.\n\nConsidering that FDA has found a pattern of drug manufacturers with serious CGMP or other adulteration violations in your supply chain, in response to this letter, also provide a detailed plan to ensure you do not receive or deliver adulterated drugs in interstate commerce, in violation of section 301(c) of the FD&C Act, 21 U.S.C. 331(c). Items in your plan should include a full evaluation of your supplier program, including a plan to audit your suppliers. Furthermore, you should also include a full reconciliation of any drugs from the manufacturers listed above, as well as for all firms or drugs currently on FDA import alerts, to determine if you have any remaining drugs in your possession. Up to date information regarding import alerts can be found at the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\n\nAdulteration and Misbranding of Glycerin API\n\nYou repackage glycerin USP and distribute this drug to your customers which include pharmacy compounders. Repackaged glycerin intended as an excipient or other component of a drug product is a drug as defined by section 201(g)(1) the FD&C Act, 21 U.S.C. 321(g)(1). Glycerin is also a drug the name of which is recognized in an official compendium (the USP).4 A drug with a name recognized in USP–NF must comply with compendial identity standards or be deemed adulterated, misbranded, or both. Sections 501(b) and 502(e)(3)(B) and (g) of the FD&C Act, 21 U.S.C. 351(b), 352(e)(3)(B); see also 21 CFR 299.5(a) and (b). In such cases, the identity is determined by the official tests, procedures and acceptance criteria in the applicable USP-NF monograph. USP-NF General Notices 2.30. Furthermore, in accordance with section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B), a drug is adulterated “if the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice to assure that such drug meets the requirements of this chapter as to safety and has the identity and strength, and meets the quality and purity characteristics, which it purports or is represented to possess.”\n\nFDA compared the testing required in the identification section of the USP monograph for glycerin with PCCA analytical test results, which reference the USP method, and determined the testing for identity of glycerin conducted by PCCA was incomplete and therefore was not adequate to assure that your glycerin conformed to the compendial standards of identity. (b)(4). While your (b)(4) test using (b)(4) can identify glycerin, it is not an adequate test for detecting DEG and EG in glycerin at USP specified limits. Therefore, you failed to conduct adequate identity testing for glycerin USP and your glycerin drug product is adulterated and misbranded within the meaning of sections 501(b), 501(a)(2)(B), and 502(e)(3)(b) and (g) of the FD&C Act, 21 U.S.C. 351(b), 351(a)(2)(B), and 352(e)(3)(B) and (g), in that you do not have test data to demonstrate its identity meets the standards set forth in an official compendium (the USP) recognized in the FD&C Act. See also 21 CFR 299.5(a) and (b).5\n\nYour response stated that your firm has complied with the regulatory requirement because your firm performed identity testing on each lot prior to release. You further stated that each lot had been previously tested by the manufacturer prior to receipt by your firm. You note that during the initial supplier qualification, you tested the purchased glycerin using a third-party laboratory. You also stated in your response that with your efforts to “know (its) supply chain for glycerin, PCCA is confident that its supply of glycerin is free from DEG contamination.” Moving forward, you committed to requalify your supplier on an (b)(4) basis. You further stated that you believe that you do not need to test your incoming glycerin for the presence of DEG and EG impurities as it is “superfluous, and simply not required.”\n\nYour response is inadequate because the test you perform for identity on the bulk glycerin that you repackage cannot determine if a batch of glycerin is adulterated with DEG and EG contaminants and does not conform to the identification section of the applicable USP monograph. You cannot ensure the quality and security of the supply chain with regard to DEG and EG adulteration given your current practice because you do not independently verify that the API manufacturer’s reports are reliable through adequate identity testing consistent with the applicable USP monograph upon receipt. Reliability of a supplier is generally established by the receiving entity’s own testing which, when compared to the supplier’s data, shows agreement within the specified limits over a period of time. Periodic monitoring is also generally necessary in order to assure the continued reliability of a supplier’s test results. Relying solely on the manufacturer’s COA is not adequate to comply with applicable requirements as described above. Although, in your response to FDA’s 483, PCCA does commit to re-qualifying its supplier of glycerin on an (b)(4) basis, it is unclear whether PCCA will verify the API supplier’s COA as part of that (b)(4) qualification process using an adequate identity test that meets applicable standards.\n\nFDA has received reports about fatal DEG poisoning of consumers who ingested medicinal syrups, such as cough syrup or acetaminophen syrup, that were manufactured with DEG-contaminated glycerin. Historical DEG-related poisonings and fatalities stemmed from multiple violative practices in the glycerin supply chain, including manufacturers not conducting full and adequate identity testing; manufacturers relying on COAs; and COAs, such as those you provide with your glycerin and other drugs, not providing the name of the true manufacturer and thus masking the chain of custody of an adulterated product.\n\nIn response to this letter, provide the following:\n\n• An update regarding implementation of DEG and EG testing for all lots of glycerin.\n\n• A detailed risk assessment for drug products distributed by your firm that contain glycerin and are within expiry in the U.S. market.\n\n• Test reserve samples of all lots of glycerin for DEG and EG with the test method and provide test results.\n\nMisbranding Due to False or Misleading Labeling of Drug Products\n\nUnder section 502(a) of the FD&C Act, a drug is misbranded if its label is “false or misleading in any particular.” Further, 21 CFR 201.1(h)(2) specifies that “The appearance on a drug product label of a person's name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the [FD&C] act, if the person is not the manufacturer of the product in accordance with this section.”\n\nThe labels your firm affixed to the following repackaged\u002Frelabeled API identify PCCA, but do not designate your firm’s role:\n\n• tramadol HCl (lot # C191954);\n\n• fentanyl citrate (lot # C189348);\n\n• buprenorphine HCl (lot # C191213); and,\n\n• morphine sulfate (lot # C192769).\n\nEvidence collected during the inspection of your facility establishes that other firms were involved in the manufacturing of these API. Because these API labels bear only the PCCA name without further qualifications, the labels falsely represent that PCCA is the sole drug manufacturer. Therefore, these repackaged\u002Frelabeled API are misbranded under section 502(a) of the FD&C Act because the labels are false and misleading.\n\nRegulatory Meeting\n\nUpon submission of your response to this letter, email CDR John W. Diehl, Director, Compliance Branch, FDA\u002FORA\u002FOPQO Division II, at John.Diehl@fda.hhs.gov to schedule a meeting to discuss the adequacy of the corrective actions you proposed to prevent the continued introduction of adulterated and misbranded goods into interstate commerce. Topics of the regulatory meeting will also include supply chain controls and compliance with CGMP.\n\nConclusion\n\nThe deviations and violations cited in this letter are not intended to be an all-inclusive list of deviations and violations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and violations and for preventing their recurrence or the occurrence of other violations and deviations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nProfessional Compounding Centers of America, Inc., Houston FEI: 1629694 Page 9\n\nFailure to promptly address these deviations and violations may result in legal action without further notice including, without limitation, seizure and injunction. Other Federal agencies may take your compliance history into account when awarding contracts.\n\nFailure to address violations of FD&C Act sections may be cause for FDA to withhold issuance of Export Certificates and may be cause for FDA to withhold approval of new applications or supplements listing your firm as a drug manufacturer. We may re-inspect to verify that you have completed your corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to address any deviations and violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address deviations and violations within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease identify your response with FEI 1629694 and Case # 597638. Send your electronic reply to Monica R. Maxwell, Program Division Director, FDA\u002FORA\u002FOPQO Division II at ORAPharm2_Responses@fda.hhs.gov.\n\nIf you have any questions concerning the letter, please direct those to CDR Diehl at (214) 253-5288 or john.diehl@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAlonza Cruse\n\nDirector\n\nOffice of Pharmaceutical Quality Operations\n\nOffice of Medical Products and Tobacco Operations\n\nOffice of Regulatory Affairs\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n___________________________\n\n1 Products from (b)(4), FEI (b)(4), have also been placed on IA 66-40 because that facility ships products manufactured at FEI (b)(4).\n\n2 Certain drugs were carved out due to shortage concerns.\n\n3 Throughout this letter, where applicable, we have provided the date of the memorandum documenting FDA’s internal determination that a firm’s deviations were adequately addressed prior to the final removal of the firm’s products from import alert.\n\n4 USP Glycerin monograph, Document ID: GUID-6A5A5AD2-0762-4830-8E99-D593E5400FF0_4_en-US\n\n5 See the identity test for glycerin included in the USP Monograph for glycerin, supra note 1","Professional Compounding Centers of America dba PCCA","professional-compounding-centers-america-dba-pcca-597638-01272021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprofessional-compounding-centers-america-dba-pcca-597638-01272021","2026-10-26T08:09:44.708578+00:00","2021-01-27","597638","2023-12-01","Mr. Fabian V. Zaccardo","2026-08-20T03:26:25.345+00:00",{"id":275,"raw":276,"subject":282,"body_html":283,"body_text":284,"firm_name":285,"letter_id":286,"created_at":65,"fei_number":19,"letter_url":287,"updated_at":288,"action_type":22,"case_status":23,"posted_date":289,"marcs_cms_no":290,"product_type":291,"closeout_date":19,"issuing_office":280,"recipient_name":292,"body_fetched_at":293,"delivery_method":294,"recipient_title":19,"reference_number":19,"action_taken_date":289,"medical_device_id":19,"response_letter_date":19},2973,[277,278,279,280,281,13,13,13],"\u003Ctime datetime=\"2021-12-15T20:00:00Z\">12\u002F15\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-15T05:00:00Z\">12\u002F15\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkuegel-enterprise-llc-dba-americas-choice-e-cigarettes-619866-12152021\">Kuegel Enterprise LLC d\u002Fb\u002Fa America&#039;s Choice E-Cigarettes\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded ","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Verena Kuegel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Kuegel Enterprise LLC d\u002Fb\u002Fa America's Choice E-Cigarettes\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2475 Village Drive, Suite 102\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kingsland\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>31548\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ovkuegel@gmail.com\"> ovkuegel@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Kuegel:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Kuegel Enterprise LLC d\u002Fb\u002Fa America’s Choice E-Cigarettes manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e- cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at&nbsp;https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under&nbsp;section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States America’s Choice Mint Chill 4mg 60ml e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 40 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other- deemed-products-market.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products&nbsp;offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or ref used admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100291, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center f or Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002Fs\u002F\u003Cbr>\nAnn Simoneau, J.D. Director\u003Cbr>\nOffice of Compliance and Enforcement Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nVerena Kuegel\n\nRecipient Title\n\nOwner\n\nKuegel Enterprise LLC d\u002Fb\u002Fa America's Choice E-Cigarettes\n\n2475 Village Drive, Suite 102\n\nKingsland, GA 31548\n\nUnited States\n\novkuegel@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Ms. Kuegel:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Kuegel Enterprise LLC d\u002Fb\u002Fa America’s Choice E-Cigarettes manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e- cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States America’s Choice Mint Chill 4mg 60ml e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 40 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other- deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or ref used admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100291, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center f or Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002Fs\u002F\n\nAnn Simoneau, J.D. Director\n\nOffice of Compliance and Enforcement Center for Tobacco Products","Kuegel Enterprise LLC d\u002Fb\u002Fa America's Choice E-Cigarettes","kuegel-enterprise-llc-dba-americas-choice-e-cigarettes-619866-12152021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkuegel-enterprise-llc-dba-americas-choice-e-cigarettes-619866-12152021","2026-10-26T08:09:10.597518+00:00","2021-12-15","619866","Tobacco","Verena Kuegel","2026-08-20T02:20:22.302+00:00","VIA UPS and Electronic Mail",{"id":296,"raw":297,"subject":301,"body_html":302,"body_text":303,"firm_name":304,"letter_id":305,"created_at":306,"fei_number":19,"letter_url":307,"updated_at":308,"action_type":22,"case_status":23,"posted_date":309,"marcs_cms_no":310,"product_type":311,"closeout_date":19,"issuing_office":37,"recipient_name":312,"body_fetched_at":313,"delivery_method":251,"recipient_title":19,"reference_number":314,"action_taken_date":315,"medical_device_id":19,"response_letter_date":19},686,[298,299,300,37,301,13,13,13],"\u003Ctime datetime=\"2025-09-02T04:00:00Z\">09\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-20T04:00:00Z\">08\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchromatography-institute-america-dba-compounders-international-analytical-laboratory-708944-08202025\">Chromatography Institute of America dba Compounder’s International Analytical Laboratory \u003C\u002Fa>","CGMP\u002FFinished Pharmaceutical\u002FAPI\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-101\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ronald E. Sutton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Chromatography Institute of America dba Compounder’s International Analytical Laboratory \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4760 Castleton Way, Suite A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Castle Rock\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80109\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rsutton@compounderslab.com\"> rsutton@compounderslab.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-101\u003C\u002Fp>\u003Cp>August 20, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Sutton:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your contract testing laboratory, Chromatography Institute of America dba Compounder’s International Analytical Laboratory, FEI 3012069146, at 4760 Castleton Way, Suite A, Castle Rock, Colorado, from February 24 to March 5, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) requirements for finished pharmaceuticals and significant deviations from CGMP for active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drugs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your March 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations and deviations including but not limited to the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Lack of adequate laboratory control mechanisms\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm conducts chemical and microbiological testing of APIs, drug products compounded by outsourcing facilities registered under section 503B of the FD&amp;C Act, and finished drug products for human and animal use. Records and information collected during the inspection demonstrate that you use the same methods and procedures whether you are testing APIs, drug products compounded by outsourcing facilities registered under section 503B of the FD&amp;C Act, or finished drug products for human and animal use.\u003C\u002Fp>\u003Cp>You lacked adequate controls to ensure the reliability of your microbiological testing results. For example, you documented sterility failures for several samples prepared in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> media lot, but you were unable to show that you performed growth promotion testing on this lot before use. In your investigations into these sterility failures, you noted “false positives” with this lot, but you did not include appropriate negative controls corresponding to this lot in your tests and lacked sufficient evidence to support your “false positives” statement. Moreover, after obtaining a failing sterility test result, you repeated the test on a fraction of the original sample amount, which is not in accordance with USP &lt;71&gt; and is an unacceptable practice.\u003C\u002Fp>\u003Cp>In your response, you state that you rely on your manufacturer’s certificates of analysis to establish media suitability. You indicate that you perform growth promotion testing \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that moving forward, you commit to performing growth promotion testing on \u003Cstrong>(b)(4)\u003C\u002Fstrong> media lot. Additionally, you assert that you will revise your procedures to note that you will perform retesting of a failed sample, provided that sufficient sample quantity remains after initial testing. You also assert that you follow all aspects of USP &lt;71&gt; “as best as is possible.”\u003C\u002Fp>\u003Cp>Your response is inadequate because you did not include a comparability analysis of your sterility test method and USP &lt;71&gt; method, to show that your method is equivalent despite the deviations from USP &lt;71&gt; requirements, such as growth promotion testing, negative controls, and sterility retest sample amounts. You also did not include any documentary evidence to support your assertions about random testing and updated procedures.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to evaluate and remediate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan for your sterility testing procedure to ensure that it satisfies all requirements specified in USP &lt;71&gt;. Include:\u003Cbr>o Instructions for how you determine which of your method kits (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) purchased from third-party suppliers are suitable for sterility testing of your laboratory samples.\u003Cbr>o A requirement that each media lot used in the preparation of sterility samples on a given day will include an appropriate negative control.\u003Cbr>o Requirements for appropriate sample amounts needed for a sterility retest.\u003C\u002Fli>\u003Cli>A remediation plan for qualification of your suppliers of growth media. Include a commitment to perform growth promotion testing on all incoming media lots used for microbial and sterility testing, to verify their suitability for use.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Lack of adequate investigations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your investigations into multiple failed sterility test results were inadequate. In 2024, you had nine drug product sterility test failures, for which your investigation concluded that the probable root cause was “technician error – environmental contamination.” However, your root cause was not supported by the environmental monitoring data on the dates when the failing sterility samples were prepared. You did not recover any microorganisms on settle plates from your ISO 7 sterility suite, on ISO 5 “compounding aseptic isolators” where your sterility samples are prepared, or on contact plates used for monitoring of personnel who prepared the sterility samples. You subsequently performed a new analysis on the drug product samples, and you recorded the passing results.\u003C\u002Fp>\u003Cp>In your response, you indicate that you initiated corrective and preventive actions (CAPA), which included the retraining of technicians and their dismissal upon repeated infractions, review of your sterility procedures and cleaning agents, and the frequency of cleaning the sterility suite.\u003C\u002Fp>\u003Cp>Your response is inadequate. You initially identified the potential root cause “technician error – environmental contamination” in 2024, and you continued to note this root cause in several subsequent sterility out-of-specification (OOS) investigations, without identifying and implementing the appropriate CAPA from these investigations to prevent similar future errors.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products for the last three years from the initial date of inspection, and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and the evidence relating to the invalidated OOS result conclusively or inconclusively demonstrate causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide the rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but should not be limited to addressing the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequate scoping of each investigation and its CAPA\u003Cbr>o Revised OOS investigation procedures with these and other remediations\u003C\u002Fli>\u003Cli>A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include but should not be limited to significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure that all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Lack of adequate Quality Unit oversight\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your Quality Unit (QU) failed to exercise adequate oversight over your contract testing operations. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of restricted access and appropriate controls on computerized systems to prevent any potential alteration or deletion of laboratory data.\u003C\u002Fli>\u003Cli>Implementation of an effective document control system for issuance, tracking, and reconciliation of CGMP documents used for laboratory testing and analysis.\u003C\u002Fli>\u003Cli>Review and approval of an uncontrolled document, “Sample Prep Tips and Tricks,” used by laboratory staff for preparation of analytical samples.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response you state that moving forward, you will create individual logins on your computers, and you are looking into installing technology with audit trail capability. Further, you state that you will create templates for your forms and bind them into a book. You also commit to placing the unapproved sample preparation document, “Sample Prep Tips and Tricks,” into your controlled document system.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not include a comprehensive assessment into the vulnerabilities in your computerized systems that may have affected data integrity, nor do you explain how binding the templates into a book will remedy the deficiencies in your documentation control practices. Your response does not indicate whether your sample preparation protocols have been validated, to ensure that sample preparation is consistent and suitable for analysis. Finally, your response lacks details on how your QU will oversee CAPA implementation and evaluate their effectiveness.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure that your QU is given the authority and resources to function effectively. The assessment should also include but should not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations, to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU makes a decision concerning its disposition.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities and provides appropriate remediations for each of your laboratory and manufacturing computer systems. This should include but should not be limited to:\u003Cbr>Compounder’s International Analytical Laboratory, Castle Rock 3012069146 page 5\u003Cbr>o A list of all hardware that includes all equipment, both stand-alone and network, in your laboratory.\u003Cbr>o A list of all software configurations (both equipment software and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and versions, details concerning all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, with their organizational affiliation and title. Also describe how you will ensure that staff are not given administrative rights or other permissions that may compromise data retention or reliability.\u003Cbr>o System security provisions, including but not limited to whether unique usernames\u002Fpasswords are always used and their confidentiality is safeguarded.\u003Cbr>o Detailed procedures for robust use and review of audit trail data, and the current status of audit trail implementation for each of your systems.\u003Cbr>o Technological improvements to increase the integration of data generated through electronic systems from stand-alone equipment (for example, balances, pH meters, water-content testing equipment) into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> network.\u003Cbr>o A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, and to ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\u003C\u002Fli>\u003Cli>A comprehensive evaluation of your document “Sample Prep Tips and Tricks” and how it is used to determine the preparation method for analytical samples. Describe how you verify the suitability of the sample preparation method, and if you document the method in a sample preparation protocol that is reviewed and approved by the QU.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. In addition to the lack of effective management oversight of your laboratory operations, we found that your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>See FDA’s guidance for industry \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help in implementing an adequate Quality Unit (QU) in your laboratory operations to meet the requirements of CGMP.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responsibilities of a Contract Testing Lab\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients. It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any OOS results or significant problems encountered during the testing of these drugs.\u003C\u002Fp>\u003Cp>We also have concerns about the validity and integrity of the data you provided to outsourcing facilities registered under section 503B of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Testing Ceased\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the FDA inspection, you communicated your intention to shut down your contract testing laboratory and to cease operations. However, several statements made in your responses to the FDA Form 483 observations conflict with this declaration.\u003C\u002Fp>\u003Cp>In response to this letter, clarify the current operational status of your contract testing laboratory. If you plan to sell your laboratory, provide the name and address of the acquiring party.\u003C\u002Fp>\u003Cp>If you plan to resume contract laboratory testing operations regulated under the FD&amp;C Act, notify this office before resuming your drug testing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure that your firm can comply with ongoing CGMP. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>Note that remediating these CGMP violations will be necessary if Compounder’s International Analytical Laboratory, a successor, or an acquirer resumes drug testing operations at this site.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>If your firm intends to resume testing drugs for the U.S. market, you should engage a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations and deviations cited in this letter are not intended to be an all-inclusive list of violations and deviations that exist at your facility. You are responsible for investigating and determining the causes of any violations and deviations and for preventing their recurrence or the occurrence of other violations and deviations.\u003C\u002Fp>\u003Cp>Correct any violations and deviations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations and deviations may also prevent other federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations and deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations and deviations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration while we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012069146 and address it “ATTN: Christopher Keating.”\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Johnetta Walters, Ph.D.\u003Cbr>Acting Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>Cc:&nbsp;\u003C\u002Fp>\u003Cp>Nancy G. Sutton\u003Cbr>Vice President &amp; Owner\u003Cbr>Email: nsutton@compounderslab.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-101\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Ronald E. Sutton\n\nRecipient Title\n\nPresident & Owner\n\nChromatography Institute of America dba Compounder’s International Analytical Laboratory\n\n4760 Castleton Way, Suite A\n\nCastle Rock, CO 80109\n\nUnited States\n\nrsutton@compounderslab.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWarning Letter 320-25-101\nAugust 20, 2025\nDear Mr. Sutton:\nThe United States Food and Drug Administration (FDA) inspected your contract testing laboratory, Chromatography Institute of America dba Compounder’s International Analytical Laboratory, FEI 3012069146, at 4760 Castleton Way, Suite A, Castle Rock, Colorado, from February 24 to March 5, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) requirements for finished pharmaceuticals and significant deviations from CGMP for active pharmaceutical ingredients (APIs).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drugs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your March 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations and deviations including but not limited to the following:\n1. Lack of adequate laboratory control mechanisms\nYour firm conducts chemical and microbiological testing of APIs, drug products compounded by outsourcing facilities registered under section 503B of the FD&C Act, and finished drug products for human and animal use. Records and information collected during the inspection demonstrate that you use the same methods and procedures whether you are testing APIs, drug products compounded by outsourcing facilities registered under section 503B of the FD&C Act, or finished drug products for human and animal use.\nYou lacked adequate controls to ensure the reliability of your microbiological testing results. For example, you documented sterility failures for several samples prepared in a (b)(4) media lot, but you were unable to show that you performed growth promotion testing on this lot before use. In your investigations into these sterility failures, you noted “false positives” with this lot, but you did not include appropriate negative controls corresponding to this lot in your tests and lacked sufficient evidence to support your “false positives” statement. Moreover, after obtaining a failing sterility test result, you repeated the test on a fraction of the original sample amount, which is not in accordance with USP \u003C71> and is an unacceptable practice.\nIn your response, you state that you rely on your manufacturer’s certificates of analysis to establish media suitability. You indicate that you perform growth promotion testing (b)(4) and that moving forward, you commit to performing growth promotion testing on (b)(4) media lot. Additionally, you assert that you will revise your procedures to note that you will perform retesting of a failed sample, provided that sufficient sample quantity remains after initial testing. You also assert that you follow all aspects of USP \u003C71> “as best as is possible.”\nYour response is inadequate because you did not include a comparability analysis of your sterility test method and USP \u003C71> method, to show that your method is equivalent despite the deviations from USP \u003C71> requirements, such as growth promotion testing, negative controls, and sterility retest sample amounts. You also did not include any documentary evidence to support your assertions about random testing and updated procedures.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to evaluate and remediate the effectiveness of your laboratory system.\nA comprehensive assessment and remediation plan for your sterility testing procedure to ensure that it satisfies all requirements specified in USP \u003C71>. Include:\no Instructions for how you determine which of your method kits ((b)(4)) purchased from third-party suppliers are suitable for sterility testing of your laboratory samples.\no A requirement that each media lot used in the preparation of sterility samples on a given day will include an appropriate negative control.\no Requirements for appropriate sample amounts needed for a sterility retest.\nA remediation plan for qualification of your suppliers of growth media. Include a commitment to perform growth promotion testing on all incoming media lots used for microbial and sterility testing, to verify their suitability for use.\n2. Lack of adequate investigations\nYour investigations into multiple failed sterility test results were inadequate. In 2024, you had nine drug product sterility test failures, for which your investigation concluded that the probable root cause was “technician error – environmental contamination.” However, your root cause was not supported by the environmental monitoring data on the dates when the failing sterility samples were prepared. You did not recover any microorganisms on settle plates from your ISO 7 sterility suite, on ISO 5 “compounding aseptic isolators” where your sterility samples are prepared, or on contact plates used for monitoring of personnel who prepared the sterility samples. You subsequently performed a new analysis on the drug product samples, and you recorded the passing results.\nIn your response, you indicate that you initiated corrective and preventive actions (CAPA), which included the retraining of technicians and their dismissal upon repeated infractions, review of your sterility procedures and cleaning agents, and the frequency of cleaning the sterility suite.\nYour response is inadequate. You initially identified the potential root cause “technician error – environmental contamination” in 2024, and you continued to note this root cause in several subsequent sterility out-of-specification (OOS) investigations, without identifying and implementing the appropriate CAPA from these investigations to prevent similar future errors.\nIn response to this letter, provide:\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products for the last three years from the initial date of inspection, and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and the evidence relating to the invalidated OOS result conclusively or inconclusively demonstrate causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide the rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but should not be limited to addressing the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequate scoping of each investigation and its CAPA\no Revised OOS investigation procedures with these and other remediations\nA comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include but should not be limited to significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure that all phases of investigations are appropriately conducted.\n3. Lack of adequate Quality Unit oversight\nYour Quality Unit (QU) failed to exercise adequate oversight over your contract testing operations. For example, your QU failed to ensure:\nEstablishment of restricted access and appropriate controls on computerized systems to prevent any potential alteration or deletion of laboratory data.\nImplementation of an effective document control system for issuance, tracking, and reconciliation of CGMP documents used for laboratory testing and analysis.\nReview and approval of an uncontrolled document, “Sample Prep Tips and Tricks,” used by laboratory staff for preparation of analytical samples.\nIn your response you state that moving forward, you will create individual logins on your computers, and you are looking into installing technology with audit trail capability. Further, you state that you will create templates for your forms and bind them into a book. You also commit to placing the unapproved sample preparation document, “Sample Prep Tips and Tricks,” into your controlled document system.\nYour response is inadequate because it does not include a comprehensive assessment into the vulnerabilities in your computerized systems that may have affected data integrity, nor do you explain how binding the templates into a book will remedy the deficiencies in your documentation control practices. Your response does not indicate whether your sample preparation protocols have been validated, to ensure that sample preparation is consistent and suitable for analysis. Finally, your response lacks details on how your QU will oversee CAPA implementation and evaluate their effectiveness.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure that your QU is given the authority and resources to function effectively. The assessment should also include but should not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations, to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU makes a decision concerning its disposition.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities and provides appropriate remediations for each of your laboratory and manufacturing computer systems. This should include but should not be limited to:\nCompounder’s International Analytical Laboratory, Castle Rock 3012069146 page 5\no A list of all hardware that includes all equipment, both stand-alone and network, in your laboratory.\no A list of all software configurations (both equipment software and (b)(4)) and versions, details concerning all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, with their organizational affiliation and title. Also describe how you will ensure that staff are not given administrative rights or other permissions that may compromise data retention or reliability.\no System security provisions, including but not limited to whether unique usernames\u002Fpasswords are always used and their confidentiality is safeguarded.\no Detailed procedures for robust use and review of audit trail data, and the current status of audit trail implementation for each of your systems.\no Technological improvements to increase the integration of data generated through electronic systems from stand-alone equipment (for example, balances, pH meters, water-content testing equipment) into the (b)(4) network.\no A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, and to ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\nA comprehensive evaluation of your document “Sample Prep Tips and Tricks” and how it is used to determine the preparation method for analytical samples. Describe how you verify the suitability of the sample preparation method, and if you document the method in a sample preparation protocol that is reviewed and approved by the QU.\nIneffective Quality System\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. In addition to the lack of effective management oversight of your laboratory operations, we found that your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nSee FDA’s guidance for industry Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help in implementing an adequate Quality Unit (QU) in your laboratory operations to meet the requirements of CGMP.\nResponsibilities of a Contract Testing Lab\nFDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients. It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any OOS results or significant problems encountered during the testing of these drugs.\nWe also have concerns about the validity and integrity of the data you provided to outsourcing facilities registered under section 503B of the FD&C Act.\nDrug Testing Ceased\nDuring the FDA inspection, you communicated your intention to shut down your contract testing laboratory and to cease operations. However, several statements made in your responses to the FDA Form 483 observations conflict with this declaration.\nIn response to this letter, clarify the current operational status of your contract testing laboratory. If you plan to sell your laboratory, provide the name and address of the acquiring party.\nIf you plan to resume contract laboratory testing operations regulated under the FD&C Act, notify this office before resuming your drug testing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure that your firm can comply with ongoing CGMP. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nNote that remediating these CGMP violations will be necessary if Compounder’s International Analytical Laboratory, a successor, or an acquirer resumes drug testing operations at this site.\nCGMP Consultant Recommended\nIf your firm intends to resume testing drugs for the U.S. market, you should engage a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP.\nConclusion\nThe violations and deviations cited in this letter are not intended to be an all-inclusive list of violations and deviations that exist at your facility. You are responsible for investigating and determining the causes of any violations and deviations and for preventing their recurrence or the occurrence of other violations and deviations.\nCorrect any violations and deviations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations and deviations may also prevent other federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations and deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations and deviations.\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration while we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012069146 and address it “ATTN: Christopher Keating.”\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nJohnetta Walters, Ph.D.\nActing Director\nDivision of Drug Compliance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\nCc:\nNancy G. Sutton\nVice President & Owner\nEmail: nsutton@compounderslab.com","Chromatography Institute of America dba Compounder’s International Analytical Laboratory","chromatography-institute-america-dba-compounders-international-analytical-laboratory-708944-08202025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchromatography-institute-america-dba-compounders-international-analytical-laboratory-708944-08202025","2026-10-26T08:08:15.132992+00:00","2025-09-02","708944","Animal & VeterinaryDrugs","Mr. Ronald E. Sutton","2026-08-19T16:26:38.524+00:00","320-25-101","2025-08-20",{"id":317,"raw":318,"subject":323,"body_html":324,"body_text":325,"firm_name":326,"letter_id":327,"created_at":328,"fei_number":19,"letter_url":329,"updated_at":330,"action_type":22,"case_status":23,"posted_date":331,"marcs_cms_no":19,"product_type":70,"closeout_date":19,"issuing_office":332,"recipient_name":333,"body_fetched_at":334,"delivery_method":335,"recipient_title":19,"reference_number":19,"action_taken_date":336,"medical_device_id":19,"response_letter_date":19},1837,[319,320,321,322,323,13,13,13],"\u003Ctime datetime=\"2023-09-19T13:20:00Z\">09\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-01T04:00:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmoorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national\">Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations East VI","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Maria S. LeMay-Bey, Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Isaiah Orton-Bey, Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>16136 W. 7 Mile Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Detroit\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48235\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Moorherbs13@gmail.com\"> Moorherbs13@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS Case #655674\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 1, 2023\u003Cbr>\n\u003Cbr>\nDear Isaiah Orton-Bey and Maria LeMay-Bey:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) has conducted an inspection of your manufacturing facility at 16136 W. 7 Mile Road, Livonia, MI 48235-2903 from February 13, 2023 to March 16, 2023. Additionally, FDA reviewed your website at https:\u002F\u002Fmoorherbs.com in May 2023. The inspection and our review of your website revealed serious violations of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) and FDA regulations. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We received your response to the FDA 483 on April 3, 2023. We address your response below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs and Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA reviewed your website, https:\u002F\u002Fmoorherbs.com, in May 2023 and has determined that you take orders there for the products “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Appendix Support,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Cardiovascular System,” “Headache &amp; Pain Relief,” “Healthy Mommy Healthy Baby,” “Quit Smoking,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThyroidism” (also referred to as “HypoThyroid Support”), “Mucus Release,” “Parasite Cleanse,” “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Un-Vax,” “Venereal Defense,” “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”), and “Lungs &amp; Respiratory.” The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>\u003Cbr>\nOn the “Full Body Antibiotic” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Full Body Antibiotic” or “AntiBiotic, Full Body”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ AntiBiotic Formulae targets it all! Use it to help heal respiratory and sinus infections, bronchitis, pneumonia, strep throat, colds, flues [sic], colic, seizures, cough, diabetes, urinary problems, menstrual problems, fever, liver problems, constipation, vaginal discharge, smallpox, enlarged spleen, swelling, asthma, eye cataracts, depression, digestion problems, stomach ulcers, heart trouble, infections, migraine, stroke, pain, . . . as well as urinary tract, kidney, and bladder infections.”\u003Cbr>\n• “Also beneficial for women with yeast infections, trichonomosas, bacterial vaginosis, and chlamydia.”\u003Cbr>\n• “It can be helpful for people with chronic fatigue, HIV, cancer, herpes, and other chronic conditions related with depressed immunity.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Anti-Viral”\u003C\u002Fu>\u003Cbr>\nOn the “Anti-Viral” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Anti-Viral”\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Anti-Viral Formulae is a potent and effective herbal anti-viral conducive for countering all viral conditions.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Appendix Support”\u003C\u002Fu>\u003Cbr>\nOn the “Appendix Support” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs High Science Appendix Support herbal blend is formulated to address the issues that lead to appendicitis: Constipation, Inflammation, and Infection.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Blood Pressure” (also referred to as “Blood Pressure Normalizer”)\u003C\u002Fu>\u003Cbr>\nOn the “Blood Pressure” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Blood Pressure Normalizer”\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Blood Pressure Normalizor [sic] is supported by an Indian medicinal herb belonging to Caesalpiniaceae family of plants.…What makes these seeds really popular, is their ability to lower blood pressure. Acting as a hypotensive agent, this humble seed works wonders for those looking to control their BP naturally.”\u003Cbr>\n• “It is a strong anti bacterial agent...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Brain Tune-Up”\u003C\u002Fu>\u003Cbr>\nOn the “Brain Tune-Up” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “The 2 main ingredients in this blend are Gotu Kola and Ginko Biloba[.] Gotu Kola Leaf… is anti-inflammatory, antiviral, antibacterial, . . . and antifungal. In human studies, gotu kola . . . reduced symptoms of anxiety and depression. It has been used to treat brain-related disorders including mental fatigue, anxiety, depression, memory loss, and insomnia.”\u003Cbr>\n• “Protects the brain from damage”\u003Cbr>\n• “Alleviates stress, anxiety, and depression”\u003Cbr>\n• “Improves memory and mood in Alzheimer’s patients”\u003Cbr>\n• “Ginko Biloba has been repeatedly evaluated for its ability to reduce anxiety, stress and other symptoms associated with Alzheimer’s disease …”\u003Cbr>\n• “Can Help Fight Inflammation.”\u003Cbr>\n• “Reduces Symptoms of Psychiatric Disorders and Dementia.”\u003Cbr>\n• “Can Reduce Anxiety.”\u003Cbr>\n• “Can Treat Depression.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Cardiovascular System”\u003C\u002Fu>\u003Cbr>\nOn the “Cardiovascular System” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “This ‘High Science’ Formula is designed to rebuild a degenerative heart...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Headache &amp; Pain Relief”\u003C\u002Fu>\u003Cbr>\nOn the “Headache &amp; Pain Relief” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Headache &amp; Pain Relief”\u003Cbr>\n• “Our Headache and Pain formula is a natural anodyne concoction that contains plants naturally rich in salicin that naturally breaks down into salicylic acid in the body that is anti-inflammatory in nature and thus effective where there is pain, which is a sensor that something is wrong on a deeper level.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Healthy Mommy Healthy Baby”\u003C\u002Fu>\u003Cbr>\nOn the “Healthy Mommy Healthy Baby” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Note: This blend is also helpful for the following conditions: anemia, low blood, arthritis, asthma, hay fever, sinusitis, gout, emphysema, bronchitis, sinus relief, allergies, high blood pressure, nosebleeds, hemorrhaging, miscarriage (vitamin K), hardened arteries, tooth decay, peptic ulcers, duodenum ulcers, infections, drug and chemical toxins, skin problems, edema, water retention, bowels, gas pains...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Quit Smoking”\u003C\u002Fu>\u003Cbr>\nOn the “Quit Smoking” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Quit Smoking”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Quit Smoking Formulae is a herbal compound of Nature’s best herbs that have been utilized traditionally to help purify the bloodstream of pollutants and toxins, cleanse the liver…and develop a distaste of insidious addictive man- chemicals.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“HyperThyroidism” (also referred to as “HyperThyroid Support”)\u003C\u002Fu>\u003Cbr>\nOn the “HyperThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “HyperThyroidism” or “HyperThyroid Support”\u003Cbr>\n• “For an overactive Thyroid”\u003Cbr>\n• “Moor Herbs High Science HyperThyroidism Relief Formulae is designed for an over-active thyroid gland. Effective for calming down an overactive thyroid and reducing symptoms of hyperthyroidism such as agitation, restlessness, sweating and insomnia.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“HypoThyroidism” (also referred to as “HypoThyroid Support”)\u003C\u002Fu>\u003Cbr>\nOn the “HypoThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “HypoThyroidism” or “HypoThyroid Support”\u003Cbr>\n• “For an underactive Thyroid”\u003Cbr>\n• “Moor Herbs High Science Thyroid Support Formula consists of Nature’s plants high in organic iodine and which perform a myriad of beneficial functions for the thyroid gland including…normalizing the function of metabolism. An impaired thyroid gland can lead to a host of negative health problems so good thyroid health is imperative for overall good health.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Mucus Release”\u003C\u002Fu>\u003Cbr>\nOn the “Mucus Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Mucus Release is a powerful ‘High Science’ formula that consists of effective expectorant herbs that help dissolve hardened, stubborn mucus and phlegm that obstruct the mucous membranes and lead to pathology throughout the body…Mucus Release is great for all mucus conditions!”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Parasite Cleanse”\u003C\u002Fu>\u003Cbr>\nOn the “Parasite Cleanse” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Parasite Cleanse”\u003Cbr>\n• “Parasite Cleanse ‘High Science’ Formula contain[s] some of Nature’s best anthelmintic herbs that have been traditionally used for centuries by various cultures to remove parasites and worms from the tissues of the body. These creepy critters most certainly rob the body of nutrients and impair critical functions of the organs, glands, and systems of the body.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“ResErection Extra Strength w\u002F Yohimbe Bark”\u003C\u002Fu>\u003Cbr>\nOn the “ResErection Extra Strength w\u002F Yohimbe Bark” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Resurrection formulae, is a 100% all-natural herbal-based formula for men experiencing difficulty with attaining and maintaining an erection (penile erectile dysfunction) with the root cause being poor circulation due to poor diet (and lifestyle) – a diet too high in animal protein (meat, flesh, cadavaer, carion, etc.) and animal fat which clogs the veins and arteries and thus impairing circulation which is vital for a healthy, solid, firm, and stiff erection.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Tumor Release” (also referred to as “Tumor &amp; Cyst Support”)\u003C\u002Fu>\u003Cbr>\nOn the “Tumor Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Tumor Release” or “Tumor &amp; Cyst Support”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Tumor Release Formulae is a safe, sane and effective plant-based anti-neoplastic formulae that is helpful in natural, noninvasive, benign and malignant tumor dissolution.”\u003Cbr>\n• “The formula is useful for all tumor and cyst formations in the body, including uterine and ovarian cysts\u002Ftumors. Good for both internal and external tumors.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Un-Vax”\u003C\u002Fu>\u003Cbr>\nOn the “Un-Vax” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Herbal UN-VAX Formulae is an unique formula designed to remove heavy metal toxins from the body. It is an ideal Formulae to combat mercury (ethyl and methyl) toxicity and aluminum toxicity, both of which are known to cause a plethora of adverse health conditions, especially in children.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Venereal Defense”\u003C\u002Fu>\u003Cbr>\nOn the “Venereal Defense” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Venereal Defense”\u003Cbr>\n• “Our Moor Herbs High Science Venereal Defense Formulae helps foment natural healing of adverse conditions that are passed on from one person to another through intimate contact.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”)\u003C\u002Fu>\u003Cbr>\nOn the “Womb Care Cramp Relief &amp; Fibroid Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Womb Care Cramp Relief &amp; Fibroid Release” or “Womb Care: Fibroid and Tumor Release”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Fibroid\u002FTumor Release Formulae is an all-natural herbal formulation consisting of Nature’s herbs that have an affinity for the female uterus, e.g. Chaste berry and Dong Quai and that are also anti-neoplastic (anti-tumor growth and formation) in nature, e.g. Burdock and Comfrey, thus combating tumorous growth on the uterus, e.g. fibroid tumors or uterine fibroids, facilitating dissolution via the vaginal canal and other eliminative channels.”\u003Cbr>\n• “Fibroids\u002FTumor Release, is a product that can be used in an overall regimen to help females naturally dissolve tumors of the reproductive system and is a great post Womb Cleanse formulae to consume daily.”\u003Cbr>\n• “Recommended for: Uterine fibroids or fibroid tumors, cervical tumors, uterine cysts.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Lungs &amp; Respiratory”\u003C\u002Fu>\u003Cbr>\nOn the “Lungs &amp; Respiratory” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003C\u002Fp>\n\n\u003Cp>• “This High Science Formula is a highly effective anti-tussive and expectorant science formulae.”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act [21 U.S.C. 321(p)].\u003C\u002Fp>\n\n\u003Cp>With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&amp;C Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The dietary supplements manufactured at your facility are adulterated under section 402(g)(1) of the FD&amp;C Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet the Current Good Manufacturing Practice (CGMP) regulation for dietary supplements (21 CFR Part 111). During the inspection of your facility, FDA investigators observed the following significant violations of the CGMP regulation for dietary supplements:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish the specifications required under 21 CFR 111.70. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. You failed to establish the following required component specifications under 21 CFR 111.70(b) for each component that you use in the manufacture of a dietary supplement: (1) identity specifications, as required by 21 CFR 111.70(b)(1); and (2) component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically, when our investigators requested such component specifications for the Coltsfoot, Wild Cherry Bark, and Boneset Herb ingredients used in the manufacturing of your “Lungs &amp; Respiratory” finished dietary supplement product, you were unable to provide such component specifications. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing component specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>b. You failed to establish specifications for dietary supplement labels (labeling specifications), as required by 21 CFR 111.70(d). Specifically, you were unable to provide labeling specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you are in the process of establishing written labeling specifications. We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>c. You failed to establish specifications for each dietary supplement that you manufacture for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you were unable to provide finished product specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing product specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>We note that once you have established these specifications, you must determine whether the specifications that you establish under 21 CFR 111.70 are met, as required by 21 CFR 111.73 and 21 CFR 111.75(c). Specifically, once you have established component specifications and before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must also confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). Further, you must verify that your finished batch of the dietary supplement meets product specifications for the identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.75(c).\u003C\u002Fp>\n\n\u003Cp>You must also make and keep records, including records for the specifications you establish, in accordance with 21 CFR 111.95.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103, and make and keep records of such procedures, as required by 21 CFR 111.140(b)(1). Specifically, you told our investigators that you have no written procedures for quality control operations and that you do not have a quality control program in place.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of implementing quality control operations to ensure the quality of dietary supplements” and “are also in the process of establishing written procedures and training quality control personnel to ensure all is produced safely, accurately, and according to the standards we have, and are putting, in place.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>3. You did not prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Upon request, you could not provide written MMRs for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products to our investigators. You stated that you did not have these records, and none were provided.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of establishing Master Manufacturing Records for each dietary supplement and size.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>4. Your batch production record did not include complete information relating to the production and control of each batch, as required under 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, batch production records for “Anti-Viral” manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”) manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and “Lungs &amp; Respiratory” manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, were collected and reviewed. These records do not include complete information required to be in batch production records. The required information that your records are missing includes, but is not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• The identity of equipment and processing lines used in producing the batch [21 CFR 111.260(b)];\u003Cbr>\n• The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained [21 CFR 111.260(c)]; The unique identifier that you assigned to each component, packaging, and label used [21 CFR 111.260(d)];\u003Cbr>\n• A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing [21 CFR 111.260(f)];\u003Cbr>\n• The actual results obtained during any monitoring operation [21 CFR 111.260(g)];\u003Cbr>\n• The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\u003Cbr>\n• Documentation at the time of performance of the manufacture of the batch, including [21 CFR 111.260(j)]:\u003Cbr>\no The date on which each step of the MMR was performed [21 CFR 111.260(j)(1)]; and\u003Cbr>\no The initials of the persons performing each step [21 CFR 111.260(j)(2)], including:\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for weighing or measuring each component used in the batch;\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for verifying the weight or measure of each component used in the batch;\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for adding the component to the batch; and\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for verifying the addition of components to the batch;\u003Cbr>\n• Documentation at the time of performance of packaging and labeling operations [21 CFR 111.260(k)], including:\u003Cbr>\n&nbsp; &nbsp; o The unique identifier that you assigned to packaging and labels used, the quantity of the packaging and labels used, and, when label reconciliation is required, reconciliation of any discrepancies between issuance and use of labels [21 CFR 111.260(k)(1)];\u003Cbr>\n&nbsp; &nbsp; o An actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the MMR [21 CFR 111.260(k)(2)]; and\u003Cbr>\n&nbsp; &nbsp; o The results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results [21 CFR 111.260(k)(3)];\u003Cbr>\n• Documentation at the time of performance that quality control personnel [21 CFR 111.260(l):\u003Cbr>\n&nbsp; &nbsp; o Reviewed the batch production record [21 CFR 111.260(l)(1), including:\u003Cbr>\n Review of any monitoring operation required under subpart E of 21 CFR part 111 [21 CFR 111.260(l)(i)]; and\u003Cbr>\n Review of the results of any tests and examinations, including tests and examinations conducted on components, in-process materials, finished batches of dietary supplements, and packaged and labeled dietary supplements [21 CFR 111.260(l)(ii)];\u003Cbr>\n&nbsp; &nbsp; o Approved or rejected any reprocessing or repackaging [21 CFR 111.260(l)(2)]; and\u003Cbr>\n&nbsp; &nbsp; o Approved and released, or rejected, the batch for distribution, including any reprocessed batch [21 CFR 111.260(l)(3)]; and\u003Cbr>\n&nbsp; &nbsp; o Approved and released, or rejected, the packaged and labeled dietary supplement, including any repackaged or relabeled dietary supplement [21 CFR 111.260(l)(4)].\u003Cbr>\n• Documentation at the time of performance of any required material review and disposition decision [21 CFR 111.260(m)];\u003Cbr>\n• Documentation at the time of performance of any reprocessing [21 CFR 111.260(n)].\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are still in the process of establishing and implementing the systems (as discussed throughout this document and the investigators observations) that will allow us to produce complete batch records.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>5. You failed to establish and follow written procedures for the requirements to review and investigate a product complaint, as required under 21 CFR 111.553. Specifically, our investigators requested your written procedures to review and investigate a product complaint. You stated that you did not have this procedure, and you did not provide it.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state, “We’ve been operating since March of 2015 and have never received a complaint. However, we are in the process of establishing written procedures for reviewing and investigating product\u002Fcustomer complaints.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>6. You failed to establish and follow written procedures for when a returned dietary supplement is received, as required under 21 CFR 111.503. Specifically, our investigators requested your written procedures for when a returned dietary supplement is received. You stated that you did not have these written procedures, and none were provided.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for when a returned dietary supplement is received.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>7. You failed to establish and follow written procedures for holding and distributing operations, as required by 21 CFR 111.453. Specifically, during the inspection, you said you had not established written procedures for holding and distributing operations.\u003C\u002Fp>\n\n\u003Cp>Once have you established written procedures for your holding and distributing operations, you must make and keep records of such written procedures, as required by 21 CFR 111.475(b)(1).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for holding and distributing operations.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>8. You did not maintain and clean equipment, utensils, and contact surfaces used to manufacture, package, label, or hold components or dietary supplements, as required under 21 CFR 111.27(d). P\u003C\u002Fp>\n\n\u003Cp>Specifically, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, during the manufacturing of your “Lungs &amp; Respiratory” finished dietary supplement product, your multi-functional grinder was observed with a light green and brown residue inside the bowl and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> plastic capsule filling equipment was observed with a light brown powder and brown staining. Furthermore, the method you used for cleaning and sanitizing your utensils and equipment does not align with, and directly contradicts, the manufacturer’s written instructions on the cleaning and sanitizing products. Additionally, you do not have any written procedures for cleaning or sanitizing your utensils and equipment, as required under 21 CFR 111.25(c).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “have since corrected the way we wash and sanitize our utensils and equipment, according to the instructions indicated on the cleaning agents we use, combined with regulations outlined under Michigan Food Law.” These corrections will be evaluated during the next FDA inspection of your firm. You also stated in your response that you “are in the process of establishing written procedures for cleaning and sanitizing utensils and equipment.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”),, “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded dietary supplements under Section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements as required by 21 CFR 101 as follows:\u003C\u002Fp>\n\n\u003Cp>1. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the labels is are incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Your Lungs and Respiratory, Full Body Antibiotic, Antiviral, Blood Pressure Normalizer, Headache &amp; Pain Relief, and Bright Eyes product labels’ serving sizes is declared as “3 Capsules or 3 Scoops” and are not specific to each product.\u003C\u002Fp>\n\n\u003Cp>2. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of sections 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling of the products does not comply with 21 CFR 101.36. Specifically,\u003Cbr>\n• The title “Supplement Facts” is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(e)(1).\u003Cbr>\n• The dietary ingredients are not indented under the title “Proprietary Herbal Blend”, in accordance with 21 CFR 101.36(c)(2).\u003Cbr>\n• The quantitative amount by weight per serving of proprietary blend does not use metric measures in appropriate units (i.e., 1000 units must be declared in the next higher set of units, e.g., 10000 mg must be expressed as 10 g), in accordance with 21 CFR 101.36(b)(3)(ii)(A).\u003C\u002Fp>\n\n\u003Cp>3. Your Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>,, “Headache &amp; Pain Relief,\" and “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) products are misbranded within the meaning of section 403(s)(2)(C) of the Act [U.S.C. § 343(s)(2)(C)] in that the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1) and 101.36(d)(1). If the whole or entire part is used, this must be declared.\u003C\u002Fp>\n\n\u003Cp>4. Your “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) and “Headache &amp; Pain Relief” products are misbranded within the meaning of section 403(i)(2) of the Act in that the labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4(h). For example:\u003Cbr>\n• The Blood Pressure Normalizer product label lists “manjishtha”, but this is not the standardized common name of the dietary ingredient. The label must list the standardized common name (SCN) given in the reference Herbs of Commerce, “Indian madder”. The Ayurvedic name for Indian madder (manjishtha) may follow the SCN in parentheses.\u003Cbr>\n• The SCN for the term “Chaksu” must be declared; in the absence of a SCN, the Latin binomial name must be declared.\u003Cbr>\n• The Headache &amp; Pain Relief product declares “dashmoola”. The dietary ingredient(s) that make up the “dashmoola” must be declared by the SCN; in the absence of a SCN, the Latin binomial name for the dietary ingredient must be declared.\u003C\u002Fp>\n\n\u003Cp>5. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(i)(2) [21 U.S.C. § 343(i)(2)] of the Act because the labels fail to declare all ingredients, as required by 21 CFR 101.4. Specifically, the products fail to declare the ingredients of the capsule material.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>We offer the following additional comments:\u003C\u002Fp>\n\n\u003Cp>1. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” product labels do not bear a symbol next to the structure\u002Ffunction claim linking the claim to the disclaimer. Furthermore, the disclaimer fails to be enclosed in a box, in accordance with 21 CFR 101.93(d).\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the U.S. Food and Drug Administration; Attn: Katie Cutajar, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov, or at 300 River Place Suite 5900, Detroit, MI 48207. If you have questions regarding this letter, please contact CO Cutajar at (313) 680-6962 or via email at Kathryn.Cutajar@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>William R. Weissinger, MS\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nEast Division 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMaria S. LeMay-Bey, Owner\n\nRecipient Title\n\nIsaiah Orton-Bey, Owner\n\nMoorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\n\n16136 W. 7 Mile Road\n\nDetroit, MI 48235\n\nUnited States\n\nMoorherbs13@gmail.com\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East VI\n\nUnited States\n\nWARNING LETTER\n\nCMS Case #655674\n\nAugust 1, 2023\n\nDear Isaiah Orton-Bey and Maria LeMay-Bey:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) has conducted an inspection of your manufacturing facility at 16136 W. 7 Mile Road, Livonia, MI 48235-2903 from February 13, 2023 to March 16, 2023. Additionally, FDA reviewed your website at https:\u002F\u002Fmoorherbs.com in May 2023. The inspection and our review of your website revealed serious violations of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) and FDA regulations. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nAt the close of the inspection, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We received your response to the FDA 483 on April 3, 2023. We address your response below.\n\nUnapproved New Drugs and Misbranded Drugs\n\nFDA reviewed your website, https:\u002F\u002Fmoorherbs.com, in May 2023 and has determined that you take orders there for the products “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Appendix Support,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Cardiovascular System,” “Headache & Pain Relief,” “Healthy Mommy Healthy Baby,” “Quit Smoking,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThyroidism” (also referred to as “HypoThyroid Support”), “Mucus Release,” “Parasite Cleanse,” “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Un-Vax,” “Venereal Defense,” “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”), and “Lungs & Respiratory.” The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the FD&C Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\n“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\n\nOn the “Full Body Antibiotic” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Full Body Antibiotic” or “AntiBiotic, Full Body”\n\n• “Our Moor Herbs ‘High Science’ AntiBiotic Formulae targets it all! Use it to help heal respiratory and sinus infections, bronchitis, pneumonia, strep throat, colds, flues [sic], colic, seizures, cough, diabetes, urinary problems, menstrual problems, fever, liver problems, constipation, vaginal discharge, smallpox, enlarged spleen, swelling, asthma, eye cataracts, depression, digestion problems, stomach ulcers, heart trouble, infections, migraine, stroke, pain, . . . as well as urinary tract, kidney, and bladder infections.”\n\n• “Also beneficial for women with yeast infections, trichonomosas, bacterial vaginosis, and chlamydia.”\n\n• “It can be helpful for people with chronic fatigue, HIV, cancer, herpes, and other chronic conditions related with depressed immunity.”\n\n“Anti-Viral”\n\nOn the “Anti-Viral” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Anti-Viral”\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Anti-Viral Formulae is a potent and effective herbal anti-viral conducive for countering all viral conditions.”\n\n“Appendix Support”\n\nOn the “Appendix Support” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs High Science Appendix Support herbal blend is formulated to address the issues that lead to appendicitis: Constipation, Inflammation, and Infection.”\n\n“Blood Pressure” (also referred to as “Blood Pressure Normalizer”)\n\nOn the “Blood Pressure” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Blood Pressure Normalizer”\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Blood Pressure Normalizor [sic] is supported by an Indian medicinal herb belonging to Caesalpiniaceae family of plants.…What makes these seeds really popular, is their ability to lower blood pressure. Acting as a hypotensive agent, this humble seed works wonders for those looking to control their BP naturally.”\n\n• “It is a strong anti bacterial agent...”\n\n“Brain Tune-Up”\n\nOn the “Brain Tune-Up” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “The 2 main ingredients in this blend are Gotu Kola and Ginko Biloba[.] Gotu Kola Leaf… is anti-inflammatory, antiviral, antibacterial, . . . and antifungal. In human studies, gotu kola . . . reduced symptoms of anxiety and depression. It has been used to treat brain-related disorders including mental fatigue, anxiety, depression, memory loss, and insomnia.”\n\n• “Protects the brain from damage”\n\n• “Alleviates stress, anxiety, and depression”\n\n• “Improves memory and mood in Alzheimer’s patients”\n\n• “Ginko Biloba has been repeatedly evaluated for its ability to reduce anxiety, stress and other symptoms associated with Alzheimer’s disease …”\n\n• “Can Help Fight Inflammation.”\n\n• “Reduces Symptoms of Psychiatric Disorders and Dementia.”\n\n• “Can Reduce Anxiety.”\n\n• “Can Treat Depression.”\n\n“Cardiovascular System”\n\nOn the “Cardiovascular System” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “This ‘High Science’ Formula is designed to rebuild a degenerative heart...”\n\n“Headache & Pain Relief”\n\nOn the “Headache & Pain Relief” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Headache & Pain Relief”\n\n• “Our Headache and Pain formula is a natural anodyne concoction that contains plants naturally rich in salicin that naturally breaks down into salicylic acid in the body that is anti-inflammatory in nature and thus effective where there is pain, which is a sensor that something is wrong on a deeper level.”\n\n“Healthy Mommy Healthy Baby”\n\nOn the “Healthy Mommy Healthy Baby” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Note: This blend is also helpful for the following conditions: anemia, low blood, arthritis, asthma, hay fever, sinusitis, gout, emphysema, bronchitis, sinus relief, allergies, high blood pressure, nosebleeds, hemorrhaging, miscarriage (vitamin K), hardened arteries, tooth decay, peptic ulcers, duodenum ulcers, infections, drug and chemical toxins, skin problems, edema, water retention, bowels, gas pains...”\n\n“Quit Smoking”\n\nOn the “Quit Smoking” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Quit Smoking”\n\n• “Our Moor Herbs ‘High Science’ Quit Smoking Formulae is a herbal compound of Nature’s best herbs that have been utilized traditionally to help purify the bloodstream of pollutants and toxins, cleanse the liver…and develop a distaste of insidious addictive man- chemicals.”\n\n“HyperThyroidism” (also referred to as “HyperThyroid Support”)\n\nOn the “HyperThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “HyperThyroidism” or “HyperThyroid Support”\n\n• “For an overactive Thyroid”\n\n• “Moor Herbs High Science HyperThyroidism Relief Formulae is designed for an over-active thyroid gland. Effective for calming down an overactive thyroid and reducing symptoms of hyperthyroidism such as agitation, restlessness, sweating and insomnia.”\n\n“HypoThyroidism” (also referred to as “HypoThyroid Support”)\n\nOn the “HypoThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “HypoThyroidism” or “HypoThyroid Support”\n\n• “For an underactive Thyroid”\n\n• “Moor Herbs High Science Thyroid Support Formula consists of Nature’s plants high in organic iodine and which perform a myriad of beneficial functions for the thyroid gland including…normalizing the function of metabolism. An impaired thyroid gland can lead to a host of negative health problems so good thyroid health is imperative for overall good health.”\n\n“Mucus Release”\n\nOn the “Mucus Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Mucus Release is a powerful ‘High Science’ formula that consists of effective expectorant herbs that help dissolve hardened, stubborn mucus and phlegm that obstruct the mucous membranes and lead to pathology throughout the body…Mucus Release is great for all mucus conditions!”\n\n“Parasite Cleanse”\n\nOn the “Parasite Cleanse” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Parasite Cleanse”\n\n• “Parasite Cleanse ‘High Science’ Formula contain[s] some of Nature’s best anthelmintic herbs that have been traditionally used for centuries by various cultures to remove parasites and worms from the tissues of the body. These creepy critters most certainly rob the body of nutrients and impair critical functions of the organs, glands, and systems of the body.”\n\n“ResErection Extra Strength w\u002F Yohimbe Bark”\n\nOn the “ResErection Extra Strength w\u002F Yohimbe Bark” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs ‘High Science’ Resurrection formulae, is a 100% all-natural herbal-based formula for men experiencing difficulty with attaining and maintaining an erection (penile erectile dysfunction) with the root cause being poor circulation due to poor diet (and lifestyle) – a diet too high in animal protein (meat, flesh, cadavaer, carion, etc.) and animal fat which clogs the veins and arteries and thus impairing circulation which is vital for a healthy, solid, firm, and stiff erection.”\n\n“Tumor Release” (also referred to as “Tumor & Cyst Support”)\n\nOn the “Tumor Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Tumor Release” or “Tumor & Cyst Support”\n\n• “Our Moor Herbs ‘High Science’ Tumor Release Formulae is a safe, sane and effective plant-based anti-neoplastic formulae that is helpful in natural, noninvasive, benign and malignant tumor dissolution.”\n\n• “The formula is useful for all tumor and cyst formations in the body, including uterine and ovarian cysts\u002Ftumors. Good for both internal and external tumors.”\n\n“Un-Vax”\n\nOn the “Un-Vax” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Herbal UN-VAX Formulae is an unique formula designed to remove heavy metal toxins from the body. It is an ideal Formulae to combat mercury (ethyl and methyl) toxicity and aluminum toxicity, both of which are known to cause a plethora of adverse health conditions, especially in children.”\n\n“Venereal Defense”\n\nOn the “Venereal Defense” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Venereal Defense”\n\n• “Our Moor Herbs High Science Venereal Defense Formulae helps foment natural healing of adverse conditions that are passed on from one person to another through intimate contact.”\n\n“Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”)\n\nOn the “Womb Care Cramp Relief & Fibroid Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Womb Care Cramp Relief & Fibroid Release” or “Womb Care: Fibroid and Tumor Release”\n\n• “Our Moor Herbs ‘High Science’ Fibroid\u002FTumor Release Formulae is an all-natural herbal formulation consisting of Nature’s herbs that have an affinity for the female uterus, e.g. Chaste berry and Dong Quai and that are also anti-neoplastic (anti-tumor growth and formation) in nature, e.g. Burdock and Comfrey, thus combating tumorous growth on the uterus, e.g. fibroid tumors or uterine fibroids, facilitating dissolution via the vaginal canal and other eliminative channels.”\n\n• “Fibroids\u002FTumor Release, is a product that can be used in an overall regimen to help females naturally dissolve tumors of the reproductive system and is a great post Womb Cleanse formulae to consume daily.”\n\n• “Recommended for: Uterine fibroids or fibroid tumors, cervical tumors, uterine cysts.”\n\n“Lungs & Respiratory”\n\nOn the “Lungs & Respiratory” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “This High Science Formula is a highly effective anti-tussive and expectorant science formulae.”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act [21 U.S.C. 321(p)].\n\nWith certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\n\nAdulterated Dietary Supplements\n\nThe dietary supplements manufactured at your facility are adulterated under section 402(g)(1) of the FD&C Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet the Current Good Manufacturing Practice (CGMP) regulation for dietary supplements (21 CFR Part 111). During the inspection of your facility, FDA investigators observed the following significant violations of the CGMP regulation for dietary supplements:\n\n1. You failed to establish the specifications required under 21 CFR 111.70. Specifically:\n\na. You failed to establish the following required component specifications under 21 CFR 111.70(b) for each component that you use in the manufacture of a dietary supplement: (1) identity specifications, as required by 21 CFR 111.70(b)(1); and (2) component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically, when our investigators requested such component specifications for the Coltsfoot, Wild Cherry Bark, and Boneset Herb ingredients used in the manufacturing of your “Lungs & Respiratory” finished dietary supplement product, you were unable to provide such component specifications. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing component specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nb. You failed to establish specifications for dietary supplement labels (labeling specifications), as required by 21 CFR 111.70(d). Specifically, you were unable to provide labeling specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you are in the process of establishing written labeling specifications. We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nc. You failed to establish specifications for each dietary supplement that you manufacture for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you were unable to provide finished product specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing product specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nWe note that once you have established these specifications, you must determine whether the specifications that you establish under 21 CFR 111.70 are met, as required by 21 CFR 111.73 and 21 CFR 111.75(c). Specifically, once you have established component specifications and before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must also confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). Further, you must verify that your finished batch of the dietary supplement meets product specifications for the identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.75(c).\n\nYou must also make and keep records, including records for the specifications you establish, in accordance with 21 CFR 111.95.\n\n2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103, and make and keep records of such procedures, as required by 21 CFR 111.140(b)(1). Specifically, you told our investigators that you have no written procedures for quality control operations and that you do not have a quality control program in place.\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of implementing quality control operations to ensure the quality of dietary supplements” and “are also in the process of establishing written procedures and training quality control personnel to ensure all is produced safely, accurately, and according to the standards we have, and are putting, in place.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n3. You did not prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Upon request, you could not provide written MMRs for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products to our investigators. You stated that you did not have these records, and none were provided.\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of establishing Master Manufacturing Records for each dietary supplement and size.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n4. Your batch production record did not include complete information relating to the production and control of each batch, as required under 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, batch production records for “Anti-Viral” manufactured on (b)(4) with lot #(b)(4), “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”) manufactured on (b)(4) with lot #(b)(4), and “Lungs & Respiratory” manufactured on (b)(4) with lot #(b)(4), were collected and reviewed. These records do not include complete information required to be in batch production records. The required information that your records are missing includes, but is not limited to, the following:\n\n• The identity of equipment and processing lines used in producing the batch [21 CFR 111.260(b)];\n\n• The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained [21 CFR 111.260(c)]; The unique identifier that you assigned to each component, packaging, and label used [21 CFR 111.260(d)];\n\n• A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing [21 CFR 111.260(f)];\n\n• The actual results obtained during any monitoring operation [21 CFR 111.260(g)];\n\n• The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\n\n• Documentation at the time of performance of the manufacture of the batch, including [21 CFR 111.260(j)]:\n\no The date on which each step of the MMR was performed [21 CFR 111.260(j)(1)]; and\n\no The initials of the persons performing each step [21 CFR 111.260(j)(2)], including:\n\n The initials of the person responsible for weighing or measuring each component used in the batch;\n\n The initials of the person responsible for verifying the weight or measure of each component used in the batch;\n\n The initials of the person responsible for adding the component to the batch; and\n\n The initials of the person responsible for verifying the addition of components to the batch;\n\n• Documentation at the time of performance of packaging and labeling operations [21 CFR 111.260(k)], including:\n\no The unique identifier that you assigned to packaging and labels used, the quantity of the packaging and labels used, and, when label reconciliation is required, reconciliation of any discrepancies between issuance and use of labels [21 CFR 111.260(k)(1)];\n\no An actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the MMR [21 CFR 111.260(k)(2)]; and\n\no The results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results [21 CFR 111.260(k)(3)];\n\n• Documentation at the time of performance that quality control personnel [21 CFR 111.260(l):\n\no Reviewed the batch production record [21 CFR 111.260(l)(1), including:\n\n Review of any monitoring operation required under subpart E of 21 CFR part 111 [21 CFR 111.260(l)(i)]; and\n\n Review of the results of any tests and examinations, including tests and examinations conducted on components, in-process materials, finished batches of dietary supplements, and packaged and labeled dietary supplements [21 CFR 111.260(l)(ii)];\n\no Approved or rejected any reprocessing or repackaging [21 CFR 111.260(l)(2)]; and\n\no Approved and released, or rejected, the batch for distribution, including any reprocessed batch [21 CFR 111.260(l)(3)]; and\n\no Approved and released, or rejected, the packaged and labeled dietary supplement, including any repackaged or relabeled dietary supplement [21 CFR 111.260(l)(4)].\n\n• Documentation at the time of performance of any required material review and disposition decision [21 CFR 111.260(m)];\n\n• Documentation at the time of performance of any reprocessing [21 CFR 111.260(n)].\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are still in the process of establishing and implementing the systems (as discussed throughout this document and the investigators observations) that will allow us to produce complete batch records.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n5. You failed to establish and follow written procedures for the requirements to review and investigate a product complaint, as required under 21 CFR 111.553. Specifically, our investigators requested your written procedures to review and investigate a product complaint. You stated that you did not have this procedure, and you did not provide it.\n\nWe have reviewed your April 3, 2023, written response, in which you state, “We’ve been operating since March of 2015 and have never received a complaint. However, we are in the process of establishing written procedures for reviewing and investigating product\u002Fcustomer complaints.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n6. You failed to establish and follow written procedures for when a returned dietary supplement is received, as required under 21 CFR 111.503. Specifically, our investigators requested your written procedures for when a returned dietary supplement is received. You stated that you did not have these written procedures, and none were provided.\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for when a returned dietary supplement is received.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n7. You failed to establish and follow written procedures for holding and distributing operations, as required by 21 CFR 111.453. Specifically, during the inspection, you said you had not established written procedures for holding and distributing operations.\n\nOnce have you established written procedures for your holding and distributing operations, you must make and keep records of such written procedures, as required by 21 CFR 111.475(b)(1).\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for holding and distributing operations.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n8. You did not maintain and clean equipment, utensils, and contact surfaces used to manufacture, package, label, or hold components or dietary supplements, as required under 21 CFR 111.27(d). P\n\nSpecifically, on (b)(4), during the manufacturing of your “Lungs & Respiratory” finished dietary supplement product, your multi-functional grinder was observed with a light green and brown residue inside the bowl and the (b)(4) plastic capsule filling equipment was observed with a light brown powder and brown staining. Furthermore, the method you used for cleaning and sanitizing your utensils and equipment does not align with, and directly contradicts, the manufacturer’s written instructions on the cleaning and sanitizing products. Additionally, you do not have any written procedures for cleaning or sanitizing your utensils and equipment, as required under 21 CFR 111.25(c).\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “have since corrected the way we wash and sanitize our utensils and equipment, according to the instructions indicated on the cleaning agents we use, combined with regulations outlined under Michigan Food Law.” These corrections will be evaluated during the next FDA inspection of your firm. You also stated in your response that you “are in the process of establishing written procedures for cleaning and sanitizing utensils and equipment.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nMisbranded Dietary Supplements\n\nIn addition, your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”),, “Headache & Pain Relief,” and “Bright Eyes” products are misbranded dietary supplements under Section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements as required by 21 CFR 101 as follows:\n\n1. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the labels is are incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Your Lungs and Respiratory, Full Body Antibiotic, Antiviral, Blood Pressure Normalizer, Headache & Pain Relief, and Bright Eyes product labels’ serving sizes is declared as “3 Capsules or 3 Scoops” and are not specific to each product.\n\n2. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of sections 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling of the products does not comply with 21 CFR 101.36. Specifically,\n\n• The title “Supplement Facts” is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(e)(1).\n\n• The dietary ingredients are not indented under the title “Proprietary Herbal Blend”, in accordance with 21 CFR 101.36(c)(2).\n\n• The quantitative amount by weight per serving of proprietary blend does not use metric measures in appropriate units (i.e., 1000 units must be declared in the next higher set of units, e.g., 10000 mg must be expressed as 10 g), in accordance with 21 CFR 101.36(b)(3)(ii)(A).\n\n3. Your Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”),, “Headache & Pain Relief,\" and “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) products are misbranded within the meaning of section 403(s)(2)(C) of the Act [U.S.C. § 343(s)(2)(C)] in that the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1) and 101.36(d)(1). If the whole or entire part is used, this must be declared.\n\n4. Your “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) and “Headache & Pain Relief” products are misbranded within the meaning of section 403(i)(2) of the Act in that the labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4(h). For example:\n\n• The Blood Pressure Normalizer product label lists “manjishtha”, but this is not the standardized common name of the dietary ingredient. The label must list the standardized common name (SCN) given in the reference Herbs of Commerce, “Indian madder”. The Ayurvedic name for Indian madder (manjishtha) may follow the SCN in parentheses.\n\n• The SCN for the term “Chaksu” must be declared; in the absence of a SCN, the Latin binomial name must be declared.\n\n• The Headache & Pain Relief product declares “dashmoola”. The dietary ingredient(s) that make up the “dashmoola” must be declared by the SCN; in the absence of a SCN, the Latin binomial name for the dietary ingredient must be declared.\n\n5. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(i)(2) [21 U.S.C. § 343(i)(2)] of the Act because the labels fail to declare all ingredients, as required by 21 CFR 101.4. Specifically, the products fail to declare the ingredients of the capsule material.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nWe offer the following additional comments:\n\n1. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” product labels do not bear a symbol next to the structure\u002Ffunction claim linking the claim to the disclaimer. Furthermore, the disclaimer fails to be enclosed in a box, in accordance with 21 CFR 101.93(d).\n\nYour response should be sent to the U.S. Food and Drug Administration; Attn: Katie Cutajar, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov, or at 300 River Place Suite 5900, Detroit, MI 48207. If you have questions regarding this letter, please contact CO Cutajar at (313) 680-6962 or via email at Kathryn.Cutajar@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam R. Weissinger, MS\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nEast Division 6","Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.","moorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmoorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national","2026-10-26T08:09:27.900006+00:00","2023-09-19","Division of Human and Animal Food Operations East VI","Maria S. LeMay-Bey, Owner","2026-08-20T00:39:30.007+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2023-08-01",16,{"510k":339,"classification":340,"enforcement":341,"event":342,"event_backfill":343,"pma":344,"warning_letter":345},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]